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1. INTRODUCTION 
Drugs for systemic delivery are administered traditionally and consistently by 
oral and parenteral routes. Even though convenient, both routes have a number of 
disadvantages, especially for the delivery of peptides and proteins, a class of drugs 
that has been rapidly emerging over the last decades.1 Oral administration of drugs 
results in exposure to harsh environment of the gastrointestinal tract and thus to 
potential chemical and enzymatic degradations. Subsequent to gastrointestinal 
absorption, the drug has to pass the liver, where, based on the nature of the drug, 
extensive first pass metabolism occurs which causes rapid clearance from the blood 
circulation. Macromolecular drugs also encounter low permeability across the 
gastrointestinal mucosa. Pain or discomfort during injection, poor patient compliance, 
particularly for multiple daily injections, side effects like tissue necrosis and 
thrombophlebitis leads to low patient acceptability of parenteral administration inspite 
of extreme bioavailability.2   
Over the last few decades several mucosal routes have been investigated as 
alternatives to oral and parenteral drug administration including nasal, buccal, rectal, 
ocular, pulmonary and vaginal mucosa.3 Easy accessibility and circumvention of the 
hepatic first pass metabolism are their advantages. Mucosal bioavailability can vary 
between almost 100% for low molecular weight hydrophobic drugs and below 1% for 
polar macromolecules depending on the physicochemical nature of the delivered 
drug.4 
1.1. NASAL DRUG DELIVERY 
Transmucosal nasal delivery arises as a promising drug delivery option where 
common drug administration (e.g. intravenous, intramuscular and oral) is 
inapplicable. Though the physiology of the nose presents obstacles, it offers a 
promising route for non-invasive systemic delivery of numerous therapies and 
debatable drug delivery route to the brain.5-6 Nasal route becomes easily accessible for 
self-administration without the help of health professionals and no needle stick 
hazards are associated with nasal administration. 
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Intranasal administration of drugs offers an interesting alternative for 
achieving systemic therapeutic effects of drugs compared to parenteral route, which 
can be inconvenient at times or oral administration which results in unacceptable low 
drug bioavailability.7 The nasal epithelium is appropriate for the transmucosal drug 
delivery though it is less permeable for hydrophilic and high molecular weight drugs.8 
Ciliary movement and the resulting clearance of the delivered drug in addition to a 
considerable enzyme activity are the challenges for developing a prolonged release 
dosage form across nasal mucosa. Since nasal mucosa offer several benefits for target 
delivery, a wide variety of therapeutic compounds may be administered intranasally 
for topical, systemic and central nervous system action.9 Since ancient times, drugs 
have been administered via nasal route for therapeutic and recreational purposes.  
Several factors that synergistically enhance the permeation of nasally administered 
drugs are, relatively large surface area due to presence of a large number of microvilli, 
a porous endothelial membrane and a highly vascularized epithelium.10 
Nevertheless, various approaches have been utilized to combat these 
limitations such as the use of in-situ formulations which increases the nasal residence 
time of dosage forms, 11 addition of absorption enhancers to increase the membrane 
permeability and the use of protease or peptidase inhibitors to avoid enzymatic 
degradation of peptide and protein drugs in the nasal cavity. Numerous nasal dosage 
forms are under investigation including solutions (drops, sprays), gels, suspensions 
and emulsions, liposomal preparations, powders and microspheres, as well as 
inserts.12 
Ayurveda has gained importance to deliver medicines through nasal route for 
upper clavicular diseases. Ayurveda chariyas utilise this route of administration as a 
common,  day  to  day  affair.  Nasal  route  of  drug  delivery  is  known as  Nasya karma. 
Nasya (nasal route of drug delivery) is one of the chief part of panchakarma treatment 
and route of choice for almost all diseases of head, ear, nose and mouth 
(urdhwajaturgata roga or diseases occurring in upper part of clavicle). Nasyam  is the 
method which eliminates the vitiated Doshas of the Urdhvanga ensuring the smooth 
functioning of the brain and eventually whole body. Liquid dosage forms like 
swarasa (herbal juices), taila (medicated oil) etc are mostly used for nasya, though 
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fine powders are also administered through nasal route in several acute conditions like 
apasmara (epilepsies), sanyasa (syncope and senseless) etc for anticipating quick 
motor response in order to recover the senses of the patient. Nasal drug delivery in 
ayurveda in relation to the type of dosage form, nature of diseases and style of 
application includes 5 types like navana (instil oil or juice or decoctions like materials 
with finger), avapidana (administration of drug materials by squeezing it to its juices), 
dhmapana (fine powder drug substances are carefully administered through nasal 
route), dhuma (nasal inhalers) and pratimarsha or marsha (oil preparation).13 
Nasyaaushadhi reaches brain via nasal route and acts on higher centers of 
brain controlling various neurological, endocrinal and circulatory functions and thus 
possess local as well as systemic effects. Nasyaaushadhi in the course of neurological 
pathway works, since perception of smell is received through olfactory pathway and 
thus controls various nervous and endocrinal diseases. Nasya used for the treatment of 
diseases like Pakshaghata, Avabahuka, Manyastambha, Ardita, Sangyanash, 
Murchha, Galganda, Aruchi, sleep disorders etc supports to be an indication of it.14  
Nasal drug delivery is used to treat local conditions of the nasal cavity like 
congestion, rhinitis, sinusitis and related allergic conditions with the use of drugs like 
corticosteroids, antihistamines, anticholinergic and vasoconstrictors. In recent years, 
achieving a systemic drug action via nose as the access portal into the body has 
received more attention. Pharmaceutical dosage forms including solutions, gels, 
suspensions, emulsions, liposomes and microparticles are being used to achieve 
systemic  drug  actions  and  are  designed  to  utilize  the  advantage  of  a  rapid  onset  of  
action when administered via nasal route. Intranasal therapy is currently employed for 
migraine, smoking cessation, osteoporosis, rheumatoid arthritis, cancer, insulin-
dependent diabetes, epilepsy, antiemetics and vitamin B12 deficiency. For example, 
morphine and ketamine can be delivered intranasally to achieve rapid analgesic 
effects. FluMist, an intranasal vaccine was first marketed vaccine in 1999 providing 
potential route for vaccine delivery.15-16 
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1.2 Delivery Systems17  
1.2.1 Nasal drops  
Nasal drops are one of the most simple and convenient systems developed.  
Lack of dose precision is the main disadvantage of this type. 
1.2.2 Nasal sprays  
Nasal sprays comprise both solution and suspension formulated as sprays.    
Use of metered dose pumps and actuators aids to deliver precise dose of drugs 
compared to drops. Since powder sprays cause mucosal irritation solution and 
suspension sprays are ideal for use. 
1.2.3 Nasal Emulsions, Microemulsions and Nanoparticles  
Intranasal emulsions and nanoparticles having higher viscosities than drops 
provide higher residence time in the nasal cavity. Poor patient acceptability due to 
nasal dripping and loss of stability are the major disadvantages. 
1.2.4 Nasal gels  
Nasal gels are thickened solutions or suspensions and liquid systems with 
polymers which gel at a particular pH or temperature of high viscosity. Reduction of 
post-nasal dripping due to its high viscosity, decreased taste impact due to reduced 
swallowing, reduced anterior leakage of the formulation, low mucosal irritation with 
the use of excipient as emollient and targeting the drug to the mucosa for better 
absorption are the advantages of gels. 
1.2.5 Nasal powders  
Solution and suspension nasal dosage forms possessing lack of drug stability 
drived way for the development of nasal powders. They are spray dried or freeze 
dried powder mixture of drug and excipients. Though having good stability, the 
suitability of powder formulations is dependent on the aerodynamic properties and 
nasal irritancy of the active drug and/or its excipients. 
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1.3 Anatomy and Physiology of nasal cavity  
The nose as drug delivery site has a number of unique features related to its 
anatomy and physiology. These features have to be taken into consideration while 
developing a nasal drug delivery system. The following sections will therefore give an 
introduction to the anatomy and physiology of the human nose. 
1.3.1 Nasal Anatomy and air passage 
The  nose  is  part  of  the  upper  respiratory  system  and  is  the  main  route  by  
which ambient air enters the body. The apparent external nose surrounds the nostrils 
and one third of the nasal cavity. The nasal cavity is divided by the nasal septum into 
2 halves of approximately equal size, beginning anteriorly at the nares and extending 
posteriorly to the nasopharynx where the two halves of the airway join together. 
Located approximately 1.5 cm from the nares is the narrowest portion of the entire 
airway, the internal ostium (nasal valve) with a cross-sectional area of about 30 mm2 
on each side. 
Nasal cavity of human comprises of a total volume of about 16 to 19 ml with 
an overall surface region of about 180 cm2 which is separated into 2 nasal cavities by 
the septum. The capacity of each cavity is roughly 7.5 ml, having a surface area 
approximately 75 cm2. On administration of drugs into the nasal cavity, a solute gets 
deposited at one or more of anatomically distinctive areas as the vestibular, 
respiratory and olfactory regions.18 
According to their function the nasal cavity can be divided into 3 regions. 
(Lisbeth Illum.2002)19 
 
Figure 1. Anatomy of nose  
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1.3.2 Nasal vestibule 
The frontal part of the nasal cavity is nasal vestibule just inside the nostrils, 
having an area of about 0.6 cm2. Nasal hairs present in this area called as vibrissae 
filters the inhaled particles.  Basically this nasal segment is covered by stratified 
squamous and keratinized epithelium with sebaceous glands.20  
1.3.3 Atrium 
Atrium is intermediate area between nasal vestibule and respiratory region. 
Anterior section constitutes stratified squamous epithelium and the posterior region by 
pseudo-stratified columnar cells thus presenting microvilli.21, 22 
1.3.4 Respiratory region  
Respiratory region is the largest part of the nasal cavity also called conchae 
and is divided into superior, middle and inferior turbinates projecting from the lateral 
wall. Nasal mucosa, being considered the most important sector for systemic drug 
delivery has epithelium, basement membrane and lamina propria. Epithelium consists 
of pseudo-stratified columnar epithelial cells, goblet cells, basal cells, mucous and 
serous glands.23 Epithelial cells are also covered apically with microvilli along with 
fine projections, called cilia. Cilia are up to 7mm in length and beat with a frequency 
of 1000 strokes per min. However, the mucus moves only in one direction from the 
anterior to the posterior part of the nasal cavity to the nasopharynx. 
1.3.5 Respiratory surface epithelium24 
The respiratory epithelium has a thickness of approximately 100ȝm. It consists 
of 4 major cell types. (Fig .2)  
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Figure 2. Cell types of the nasal respiratory epithelium. 
(Cornaz A L Buri et al., 1994). 10 
I  –  Non ciliated columnar cells with microvilli 
II  –  Goblet cell with mucous granules and Golgi apparatus 
III  –  Basal cells  
IV  –  Ciliated columnar cell with many mitochondria in the apical part,  
DM – double membrane, CTM – connective tissue membrane 
1. Basal cells, which are progenitors of the other cell types, lie on the basement 
membrane and do not reach the airway lumen. 
2. Columnar cells are related to neighbouring cells by tight junctions.  
The cytoplasm contains numerous mitochondria in the apical part, as a sign of 
an active metabolism. All columnar cells are covered by about 300 microvilli, 
uniformly distributed to the entire apical surface. These short and slender 
finger-like cytoplasmic expansions increase the surface area of the epithelial 
cells, thus promoting exchange processes across the epithelium. The microvilli 
also prevent drying of the surface by retaining moisture essential for ciliary 
function. Columnar cells can be divided into non-ciliated and ciliated cells. 
Cilia are finger-like protrusions (0.2-0.3ȝm wide and 5ȝm in length) on the 
apical surface of cells, which have a typical ultra structure and are larger than 
microvilli. Each ciliated cell contains about 100 - 300 cilia. The anterior side 
8 
of the nasal cavity is non-ciliated. Cilia start occurring just behind the front 
edge of the inferior turbinate. The posterior part of the nasal cavity as well as 
the paranasal sinuses are densely covered with cilia. 
3.   Goblet cells are mucous secreting cells typical for a respiratory epithelium. 
Their number is slightly larger in the posterior than in anterior part of the nasal 
cavity with a mean concentration of goblet cells of about (4,000-7,000/mm2) 
similar to the trachea and the main bronchi. The contribution of goblet cells to 
the volume of nasal secretion is probably small compared to that of the sub-
mucosal glands. Little is known about the release mechanism from goblet 
cells, which in contrast to sub-mucosal glands are not under parasympathetic 
control. Goblet cells probably respond to physical and chemical irritants in the 
microenvironments. 
1.3.6 Olfactory region  
Olfactory region present at the roof of the nasal cavity extends a short way 
down the septum and lateral wall. It is also pseudo-stratified but has specific olfactory 
receptor cells responsible for smell perception.  
1.3.7 Mucus membrane of nose and its composition  
A thin, clear and continuous layer of fluid, called mucus covers the entire 
nasal epithelial surface. Approximately 20-40 ml of mucus is produced from the 
normal ‘resting’ nose each day.  This mucus is composed of water (95-97%), mucus 
glycoprotein (2.5-3%), electrolytes (1%), proteins (1%), and other macromolecules. 
The baseline pH in the human nasal cavity is approximately 6.3, ranging from 5.2-8.1. 
The mucus glycoprotein (mucins) consist of a protein core (20%) with 
oligosaccharide side chains (80%), cross-linked by disulfide and hydrogen bond. 
These glycoproteins are responsible for the characteristic viscoelastic properties of the 
mucus, which are related to its function of providing a protective coating to the nasal 
epithelium and mucociliary clearance. Mucus consists of 2 fluid layers, each 
approximately 5ȝm thick (mucus or epiphase) floats on a less viscous sol-layer 
(periciliary fluid or hypophase) immediately adjacent to the epithelial surface.25   
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Figure 3. Nasal mucosa (Pires A et al, 2009).18 
1.3.8 Blood supply to nasal cavity  
Design of the nasal vascular bed is such that it rapidly exchanges fluid and 
dissolved excipients between blood vessels and nasal tissues. The capillary flow in the 
nasal mucosa is being reported as 0.5ml/g/min. Sphenopalatine artery, anterior 
ethmoidal artery and branches of the facial artery supplying the vestibule of the nasal 
cavity are the major blood vessels.26 
1.4 Mucociliary clearance 
The cilia of the columnar cells travel with normal, symmetric beats at a 
frequency of about 10 Hz in the lower sol phase where the ciliary tips make contact 
with and propel the gel layer whilst the sol layer resides relatively stationary. During 
the recovery stroke the cilia move backward exclusively through the sol layer during 
which the upper mucus layer together with deposited particles is transported towards 
the nasopharynx from where it is swallowed. The velocity of mucous transport is 
approximately 5- 8 mm/min, hence renews the nasal mucus layer every 10-20 min. 
The combined action of mucus layer and cilia is termed mucociliary clearance. It is an 
essential vague physiological defence mechanism of the respiratory tract for 
protection of body against noxious inhaled substances. Inhibition of the mucociliary 
clearance by drugs and drug delivery systems results in longer contact times of the 
nasal mucosa with inhaled bacteria, viruses, carcinogens etc. On the other hand, the 
mucociliary clearance is responsible for the generally observed rapid clearance of 
nasally administered drugs from the nasal cavity to the nasopharynx. Bioadhesion can 
be useful to overcome the rapid removal of nasally administered drugs.27 
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Figure 4. Effect of mucociliary clearance on nasal drug absorption 
 (Swatantra K.S et al 2011)27 
1.4.1 Periciliary fluid 
Periciliary fluid is a dilute, ionic solution regulated by trans-epithelial ion-
transport providing cilia the capacity to beat and also acts as a fluid reservoir for the 
humidification of the inspired air. 
1.4.2 Mucus 
The mucus performs a variety of physiological roles as 
x Entrapment of substances entering the nasal cavity and removal of them via 
mucociliary clearance thus protecting the mucosa. 
x Humidification of the inspired air which aids heat transfer. 
x Secretion of about 1.5-2L of mucus by goblet cells and serous glands. 
1.4.3 Cilia 
Cilia appear as hair like structures on the epithelial cell surface. Roughly 300 
cilia per cell are present with each cilia measuring about 5-10µm long and 0.1-0.3µm 
wide. The beat cycle of respiratory tract cilium is composed of 3 phases as effective 
stroke, rest phase and recovery stroke with a rate of about 20Hz. Despite the fact that 
there are a lot of inter-individual differences in mucociliary clearance rate, it has been 
estimated at 6mm/min.28 
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1.5 Mechanism of drug absorption from nose 
Absorption of drugs from the nasal cavity is by passage through the mucus. 
Large/charged particles may find it more difficult to cross, while small unchanged 
particles easily pass this layer. 2 mechanisms like paracellular transport via movement 
between cells and transcellular or simple diffusion across the membrane are involved. 
1.  Aqueous  route  of  transport  also  called  as  the  paracellular  route  is  slow  and  
passive. Bioavailability of drugs with a molecular weight greater than 1000 
Daltons is low indicating converse relationship between molecular weight and 
absorption.29 
2.  Transcellular route occurs through a lipoidal route useful for transport of 
lipophilic drugs. Active transport route via carrier mediated means or transport 
through the opening of tight junctions also occurs.   
 
Figure 5. Mechanism of drug absorption from nose (Dodane et al, 1999).30 
(A1) Intercellular spaces, (A2) Tight junctions, (B1) Passive diffusion, (B2) Active transport,  
(C) Transcytosis 
1.6. Different factors affecting nasal drug absorption 
Diverse factors that affect bioavailability of nasally administered drugs are: 
1.6.1  Biological Factors 
1.6..1.1  Structural features  
5 different features of nasal cavity are nasal vestibule, atrium, respiratory area, 
olfactory region and the nasopharynx whose structures, kind of cells, thickness and 
number of cells present in that area controls the permeability.  Combination of drugs 
with absorption enhancers increases the permeation of compounds.31 
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1.6.1.2  Biochemical changes  
Nasal mucosa present with a large number of enzymes as oxidative and 
conjugative enzymes, peptidases and proteases acts as a barrier to the delivery of 
drugs. They cause the degradation of drugs and result in pseudo-first-pass effect. 
Various approaches such as the use of protease and peptidase inhibitors as bacitracin, 
amastatin, boroleucin and puromycin overcome these degradations. 10  
1.6.2.2  Physiological Factors  
1.6.2.1 Blood supply and neuronal regulation 
Nasal mucosa is an extremely porous site. High vasculature owing to 
parasympathetic stimulus gives congestion and low blood supply due to sympathetic 
stimulus causes relaxation which controls the augment and drop in the amounts of 
drug permeability respectively. Thus improved permeability of a compound occurs 
due to parasympathetic stimulus. 
1.6.2.2 Nasal secretions 
Nasal secretions produced by anterior serous and seromucus glands affect the 
permeability of drugs through the nasal mucosa. Characteristics of nasal secretions 
influencing permeability are viscosity of nasal secretions, drug solubility in 
secretions, diurnal variation and pH of nasal cavity.  
1.6.2.3 Mucociliary clearance (MCC) and Ciliary beating 
MCC of the nasal cavity causes clearance of the nasally administered drugs 
adhering to nasal mucosa within 21min since it is the normal defense mechanism and 
then cleared in GIT by draining into nasopharynx. Increasing contact time between 
drug and mucus membrane enhances the drug permeation because of reduced MCC 
while, increased MCC decreases drug permeation. 
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1.6.2.4 Pathological conditions 
Pathophysiological conditions of the nasal cavity as mucociliary 
disfunctioning, hypo or hyper secretions, irritation of the mucosa occurs due to 
diseases  such  as  the  common  cold,  rhinitis,  atrophic  rhinitis  and  nasal  polyposis  
affects drug permeation. 
1.6.2.4 Environmental conditions 
Rate of MCC undergoes moderate reduction at the temperature of 24oC 
predicting a linear increase in ciliary beat frequency with raise in temperature. 
1.6.2.6 Membrane permeability 
Membrane permeability affects the drug absorption throughout the nasal route. 
Since drugs with large molecular weight and water solubility like proteins and 
peptides have low membrane permeability, gets absorbed using endocytosis in smaller 
amounts.32  
1.7 Physicochemical Properties of Drug 
1.7.1 Molecular weight and size 
Permeation of drugs is correlated inversely with molecular weight, size, 
hydrophilicity and lipophilicity. Generally, the bioavailability of larger molecules 
ranges from 0.5 to 5%. Drugs less than 300 Da have higher permeability along 
aqueous channels of the membrane than drugs with molecular weight greater than  
300 Da whose permeation rate is highly sensitive. 
1.7.2 Solubility  
Drug absorption through the biological membranes depends on their solubility. 
Drugs having adequate aqueous solubility show increased dissolution in nasal 
secretions. Drugs with less aqueous solubility are absorbed by active transport and 
water soluble drugs gets absorbed using passive diffusion.33 
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1.7.3 Polymorphism 
Polymorphism is found to influence the dissolution rate, solubility and 
absorption of drugs through biological membranes. This factor should be taken into 
consideration in the design of dosage form for nasal delivery.34 
1.7.4 Chemical form of drug  
Chemical form of drugs influences their absorption across nasal mucosa.     
Prodrugs undergo biotransformation at the target site before exhibiting their 
pharmacological effect. They overcome bad taste, poor solubility, insufficient 
stability, incomplete absorption across biological barriers etc of drugs. Hydrophobic 
and hydrophilic drugs are being administered as prodrugs to enhance their water and 
lipid solubilities. Addition of co-solvents such as ethanol, glycerol, polyethylene 
glycol and propylene glycol also increases solubility of drugs.35 
1.7.5 Physical state of drug 
Particulate nasal drug products are based upon 2 parameters like particle size 
and morphology. Control of these parameters is ideal for drug dissolution properties 
in the nostrils. Particles too fine below 5µ must be avoided since it may get inhaled in 
lungs while particles in 5–10µ range are deposited in the nostrils.  
1.8  Physicochemical Properties of Formulation 
1.8.1 Physical form of formulation 
Nasal drops are the simplest and the most convenient formulation, but often 
results in overdose and quick nasal drainage. Nasal sprays of solution and suspension 
are ideal than powder sprays due to development of nasal mucosal irritation. 
Currently, nasal gels have been developed which reduce postnasal drip and anterior 
leakage, fixing the drug in nasal mucosa. This enhances the drug residence time and 
diminishes MCC, thereby, potentially increases the nasal absorption. Recently 
specialized systems such as lipid emulsions, microspheres, liposomes and films have 
also been developed to improve nasal drug delivery.36 
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1.8.2 pH 
Nasal formulations must be adjusted to suitable pH to circumvent irritation, 
for efficient absorption and prevent augmentation of pathogenic bacteria. Optimum 
pH for the formulation is ought to be adjusted between 4.5 and 6.5. The pH of the 
nasal surface is 7.5 and that of nasal secretions in adults is 5.5–6.5 and in infants and 
children is 5.0–6.7. 
1.8.3 Osmolarity  
Drug absorption can be affected significantly by tonicity of formulation. 
Shrinkage  of  epithelial  cells  occurs  in  the  presence  of  hypertonic  solutions.  For  
example, hypertonic saline inhibit or cease ciliary activity. Low pH also has an 
analogous effect as that of a hypertonic solution.37 
1.8.4 Pharmaceutical Excipients   
Pharmaceutical excipients used in nasal formulations are selected based on 
their functions. Generally used excipients are solubilizers, buffering agents, 
antioxidants, preservatives, humectants and gelling agents or viscosity modifiers.38 
1.8.5 Viscosity 
Formulations with higher viscosities increase the time of contact between the 
drug and the nasal mucosa thus expanding the time for permeation. However, 
extremely thick formulations obstruct regular functions like ciliary beating or 
mucociliary clearance thus altering the drug permeability. 
1.8.6 Partition coefficient and pKa 
A quantitative relationship between the partition coefficient and nasal 
absorption is constant. As per the pH partition theory, unionized species are absorbed 
better compared with ionized species and same holds true in case of nasal absorption. 
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1.8.7 Drug concentration, dose and dose volume 
Drug concentration, dose and dose volume of administration are 3 interrelated 
parameters that impact the performance of the nasal delivery system. Increasing the 
drug concentration by increase in formulation volume limits the nasal absorption as it 
will drain out of the nasal cavity. The ideal dose volume range is 0.05-0.15ml with an 
upper limit of 0.2ml.39 
1.9. Advantages and disadvantages of nasal drug delivery 
1. Rapid absorption and onset of action. 
2. It avoids the hepatic first-pass metabolism; hence useful for the drugs those 
are affected by this process and useful for the drugs that are degraded in GI. 
3. The administration is simple and hence self-medication is possible. 
4. It is a painless mechanism of the drug administration as no needle is involved. 
5. The route can be used for both local and systemic delivery of drugs. 
6. Low dose is required. 
7. Can be administered to the unconscious patient. 
8. The permeability is more compared to skin. 
9. Intranasal delivery provides a practical, non-invasive method for bypassing the 
blood brain barrier (BBB) to deliver the therapeutic agents to the brain and 
spinal cord  
10. Improved patient compliance. 
1.9.1 Disadvantages of nasal drug delivery 
1. Only a limited amount of drug can be administered by intranasal route. The 
effective nasal delivery volume in human is 200µL per nostril. 
2. The dosing regimen as a result of drainage of the solution or expulsion of the 
dose due to sneezing. 
3. The potential toxicology or irritancy of the drug product across nasal mucosa. 
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1.10. In situ forming hydrogels  
In situ is a Latin word which means “in position”. In situ gel drug delivery 
systems are defined as liquid formulation generating a solid or semisolid depot after 
administration. These systems when exposed to physiological conditions will shift to 
a gel phase producing a gel in situ. Conformational changes of polymer in response to 
physiological environment causes phase transition of low viscosity solution to form 
visco elastic gel. Gelation occurs via the cross-linking of polymer chains by covalent 
bond formation (chemical cross-linking) or non-covalent bond formation (physical 
cross-linking).The influence of external stimuli such as temperature, pH and ionic 
strength, on the cross-linking of polymer chains have been studied to improve the gel 
strength or to induce in situ gelation. Both natural and synthetic polymers can be used 
for the production of in situ gels which are capable of releasing drug in a sustained 
manner maintaining relatively constant plasma profiles.40 
1.10.1 Importance of In situ Gelling System40, 41  
x The importance is the possibility of administering accurate and reproducible 
quantities compared to already formed gel.  
x In-situ forming polymeric delivery system offers ease of administration and 
reduced frequency of administration improved patient compliance and 
comfort.  
x Poor bioavailability and therapeutic response exhibited by conventional nasal 
solution due to rapid elimination of drug may be overcome by use of gel 
system that are instilled as drops into nasal cavity and undergoes a sol-gel 
transition from instilled dose.  
x Liquid dosage form that can sustain drug release and remain in contact with 
nasal mucosa for extended period of time is ideal.  
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1.11.  Approaches for In situ Gel42 
1.11.1 In situ Gel Formation Based on Physiological Stimuli 
1.11.1.1 Temperature Induced In situ Gel Systems 
Temperature is the generally used stimulus in environmentally responsive 
polymer systems. Temperature change is quite easy to control and also easily 
applicable both in vitro and in vivo which is useful for sustaining the drug release by 
effective gelling of the solution. Such hydrogels are liquid at room temperature (20–
25 °C) and endure gelation when in contact with body fluids (35– 37 °C) owing to an 
increase in temperature.41  
1.11.1.2 pH Triggered Systems 
In situ gel formation based on physiologic stimuli can be induced by pH 
changes. pH-sensitive polymers have acidic or basic groups that respond to changes in 
environmental pH by releasing or accepting protons. At pH range 4 to 6 the 
formulation behaves as a sol which undergoes gelation when the pH is raised by the 
body fluid to pH > 5. Swelling increases as the environmental pH increases if the 
polymer contains anionic groups, but decreases if polymer contains cationic groups. 
Most of anionic pH-sensitive polymers are based on carbomer or its derivatives.  
1.11.2 In situ gel formation based on Physical Mechanism 
1.11.2.1 Swelling 
In situ gel formation also occurs once material absorbs water from adjacent 
environment and expands to occupy the required space. One such material is myverol 
(glycerol mono-oleate), a polar lipid which swells in water acquiring lyotropic liquid 
crystalline phase structures. It has some bioadhesive properties and is degraded in 
vivo by enzymatic action.42  
1.11.2.2 Diffusion 
Diffusion of solvent from polymer solution into surrounding tissue, results in 
precipitation or solidification of polymer matrix in this method. For example,           
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N-methyl pyrrolidone (NMP) has been revealed to be valuable solvent for such 
system. 
1.11.3 In situ gel formation based on Chemical Reactions 
1.11.3.1 Ionic Cross Linking 
Presence of various ions such as potassium, calcium , magnesium  and sodium 
cause phase transition of polysaccharides such as carrageenan, gellan gum (Gelrite), 
pectin, sodium alginate as they are ion-sensitive polysaccharides. For example, alginic 
acid undergoes gelation in the presence of divalent/polyvalent cations. 
1.11.4 Enzymatic Cross Linking 
Development of in situ gels by natural enzymes induced catalytic effects have 
not been investigated extensively but seems to have some advantages compared to 
chemical and photochemical approaches. For example, an enzymatic process operates 
well under influence of physiologic conditions without need for potentially harmful 
chemicals such as monomers and initiators. 
1.11.5  Photo-Polymerization 
Photo-polymerization is a technique generally used for in situ gel development 
of biomaterials. Injection of a solution of monomers or reactive macromer along with 
an initiator into a tissue site with the application of electromagnetic radiation forms a 
gel. Acrylates or other similar polymerizable functional groups are usually used as the 
polymerizable groups on the individual monomers and macromers because they 
rapidly undergo photopolymerization along with a suitable photo initiator. Such 
systems are being designed for long term persistence in vivo while providing rapid 
polymerization rates at physiological temperature. 
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Figure 6. Hydrogel formation mechanism 
1.12. Mucoadhesive drug delivery system 
Mucoadhesive drug delivery systems are the systems which make use of the 
property of mucoadhesion of certain polymers which are adhesive on hydration and 
are targeted to a particular region of the body for extended period of time. 
Bioadhesion is the process of attachment of synthetic or biological macromolecules to 
a biological tissue and if the adhesion is to a mucous coat the phenomenon is 
mucoadhesion.43 
Numerous theories have been put forward to describe the mechanism of 
polymer-mucus interactions causing mucoadhesion. They include,    
1.12.1 Theories of Mucoadhesion44 
1.12.1.1 Electronic Theory  
The adhesive polymer and mucus in general comprise different electronic 
characteristics. When these two surfaces come in contact, a double layer of electrical 
charge forms at the interface causes adhesion due to the attractive force from electron 
transfer across the electrical double layer. 
1.12.1.2 Adsorption Theory 
The adsorption theory proposes that adhesion of a polymer to a biological 
tissue results from primary chemical bonds and van der Waals, hydrogen, 
hydrophobic or electrostatic forces which form secondary chemical bonds between 
the polymer and mucosal tissue. 
In situ forming 
hydrogels
1. Temptarure 
induced gelation
2. pH induced 
gelation
3. Ion induced 
gelation
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1.12.1.3 Wetting Theory 
Liquid bioadhesive systems primarily works on the basis of wetting theory 
which emphasizes intimate contact between the adhesive and mucus. Thus a wetting 
surface is controlled by structural similarity, degree of cross linking of the adhesive 
polymer or use of a surfactant. 
1.12.1.4 Diffusion Theory 
Interpenetration created between the chains of the adhesive and the substrate 
to a sufficient depth to form a semi permanent adhesive bond is the basis of diffusion 
theory. The penetration rate depends on the diffusion coefficient of both interacting 
polymers and the diffusion co-efficient which depends on molecular weight and 
cross-linking density. 
1.13. Polymers used in in situ gel45 
1.13.1 Ideal Polymers 
1.  The polymers and its degradation products must be nontoxic and non-
absorbable from the gastrointestinal tract. 
2.  It should adhere quickly to moist tissue and possess some site specificity. 
3.  It should be a non-irritant to the mucous membranes. 
4.  It should possess a wide margin of safety both locally and systemically. 
5.  The cost of the polymer should be not too high, so that prepared dosage form 
remains competitive. 
1.13.1.1 Cellulose Derivative 
The intranasal absorption of drugs are enhanced using various soluble 
cellulose derivatives such as hydroxypropyl methylcellulose (HPMC), hydroxypropyl 
cellulose (HPC), methylcellulose (MC), carboxymethyl cellulose (CMC) and 
insoluble cellulose derivatives such as ethyl cellulose and microcrystalline cellulose 
(MCC). Celluloses act as absorption enhancer which leads to improved intranasal 
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absorption and increased bioavailability of various small hydrophobic as well as 
hydrophilic macromolecular drugs. 
1.13.1.2 Xyloglucan 
Xyloglucan a polysaccharide derived from tamarind seed, forms 
thermoresponsive gels in water, under certain condition. Tamarind seed xyloglucan is 
composed of three units of xyloglucan oligomers with heptasaccharide, 
octasaccharide and nonasaccharide, which differ in the number of galactose side 
chains. Xyloglucan formulation were assessed for ocular delivery of pilocarpine, 1.5 
wt% xyloglucan formulation enhanced the miotic response to a degree similar to that 
of a 25 wt% poloxamer 407 gel. 
1.13.1.3 Pluronic F-127 
Poloxamers or Pluronic are commercially available triblock copolymers of 
non-ionic nature. They contain a central block of relatively hydrophobic 
polypropylene oxide enclosed on both sides by the blocks of relatively hydrophilic 
polyethylene oxide. Pluronics or Poloxamers undergo in situ gelation by temperature 
change. A 25-40% aqueous solution of this polymer gels at about body temperature 
and release of drug from such a gel occurs for a period of one week. 
1.13.1.4 Carbomer (Carbopol) 
Cross-linked polyacrylic acid of high molecular weight, commercially 
available as Carbopol. Carbopol is a polyacrylic acid (PAA) polymer, which shows a 
sol to gel transition in aqueous solution as the pH is raised above its pKa of about 5.5. 
1.13.1.5 Sodium Alginate 
Alginic acid is a linear block copolymer polysaccharide consisting of ȕ-D-
mannuronic acid and Į-L-guluronic acid residues joined by 1, 4-glycosidic linkage. 
Addition  of di and trivalent metal ions to dilute aqueous solutions of alginates form 
firm gels by a cooperative process involving consecutive glucuronic residues in the Į-
Lglucuronic acid blocks of the alginate chain. 
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1.13.1.6 Polyacrylates 
Polyacrylates are used in nasal drug delivery systems due to their excellent 
mucoadhesive and gel forming potential. Polyacrylates can temporarily open the tight 
junctions  between  the  epithelial  cells  at  some  point  in  the  swelling  progress  in  the  
nasal cavity for the improvement of the paracellular absorption of drugs. 
1.13.1.7 Chitosan 
Chitosan being a biodegradable, thermosensitive, polycationic polymer is 
obtained by alkaline deacetylation of chitin. Chitosan and its derivatives enhance the 
intranasal drug absorption due to their excellent mucoadhesive properties. Protonated, 
soluble chitosan have the ability to trigger the opening of tight junctions by 
facilitating the paracellular transport of hydrophilic mannitol. 
1.13.1.8 Xanthum Gum 
Xanthan gum is a high molecular weight extra cellular polysaccharide formed 
by the fermentation of the Gram negative bacterium Xanthomonas campestris. The 
anionic character of this polymer due to the presence of both glucuronic and pyruvic 
acid groups in the side chain makes its use as a pH sensitive polymer in the 
formulation of in situ gels.  
1.14. Disease profile 
1.14.1.Insomnia  
Insomnia is defined as dissatisfaction with sleep quantity or quality that results 
in clinically significant distress or impairment in social, occupational or other 
important  areas  of  functioning.  Insomnia  is  associated  with  one  or  more  of  the  
symptoms as difficulty in initiating sleep (sleep-onset insomnia or initial insomnia); 
difficulty in maintaining sleep (sleep-maintenance insomnia or middle insomnia) and 
early-morning awakening with the inability to return to sleep (late insomnia)46 
(American  Psychiatric  Association).  It  is  a  common  sleep  disorder  and  can  have  
serious consequences such as increased risk of depression and hypertension. 
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Insomnia is a sleep disorder with a stringent diagnostic criterion and often 
relate with symptoms. Sleep disorders are present with various co-morbid conditions 
such as medical, psychiatric and neurologic disorders. The epidemiological, cross-
sectional and prospective studies propose that insomnia, chronic pain and depression 
are mutually interacting and each one increases the risk for emergence and/or 
exacerbation of the other. Chronic pain including migraine is the most common co-
morbidity that has been linked to insomnia from the findings of epidemiological 
surveys.47-49  
Clinically insomnia is of 3 types. Transient insomnia causes sleep difficulties 
which last for few days with little or no evidence of impairment of functioning during 
the  day.  Short  term  or  moderate  insomnia  lasts  for  less  than  a  month  which  mildly  
affects functioning during the day together with feelings of irritability and fatigue. 
Chronic or severe insomnia lasts  for  less  than  a  month  which  severely  impairs  
functioning during the day and cause strong feelings of irritability, restlessness, 
anxiety and fatigue. Acute insomnia is triggered by precipitating events as ill health, 
change of medication or circumstances or stress after which sleep settles back to its 
normal sequence. So treatment for acute insomnia is based on avoiding or 
withdrawing precipitating symptoms if possible and if symptoms are significant, 
supported with use of hypnotics. Acute and chronic insomnia requires different 
approaches of treatment.50 
Chronic insomnia is unlikely to remit spontaneously and is characterized by 
cycles of relapse and remission or persistent symptoms. Co-morbid medical disorders, 
psychiatric disorders and working night or rotating shifts all indicates predominant 
risks for insomnia.51 Patients with repeated episodes of acute insomnia or ongoing co-
morbidities have persistent symptoms of insomnia which leads to chronic insomnia. It 
lasts for more than one month, occurs more frequently in women, older adults and 
patients with chronic medical and psychiatric disorders. Effects of it include fatigue, 
mood disturbances and problems with interpersonal relationships, occupational 
difficulties with reduced quality of life. 
Globally, it is estimated 10 to 15% of the general population suffer insomnia 
regularly and about 25 to 35% presenting transient or occasional insomnia.52    In a 
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study from India, the prevalence of insomnia was reported in 18.6% of the patients 
with 18% for initiation of sleep, 18% for maintenance and 7.9% with early morning 
awakening.53 
Insomnia is generally classified as Primary and Secondary types. Pathogenesis 
of primary insomnia is being unknown, evidences state hyper arousal as its condition. 
Insomnia patients show increased cerebral glucose metabolism on positron-emission 
tomography while awake and asleep, increased beta activity and decreased theta and 
delta activity on electroencephalography during sleep, increased metabolic rate and 
higher levels of secretion of adrenocorticotropic  and cortisol hormones.54    
Primary insomnia includes idiopathic insomnia (infancy/childhood), 
psychophysiologic insomnia (maladaptive conditioned response), paradoxical 
insomnia        (sleep- state misperception). Secondary insomnia includes adjustment 
insomnia (due to psychological stresses), inadequate sleep hygiene (impaired lifestyle 
habits), insomnia of psychiatric disorder (anxiety/depression), insomnia due to 
medical condition (as chronic pain, nocturnal cough or dyspnea, restless legs 
syndrome), drug induced insomnia (drug abuse, consumption or discontinuation of 
medication, alcohol or caffeine).55 
 
Figure 7. Complications of Insomnia56  
 
Symptoms of insomnia are sleepiness during day, general tiredness and 
irritability, problems with concentration or memory. The most commonly reported 
symptoms of insomnia includes waking up feeling unfreshed (38%), waking up 
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frequently during  night (32%) and others are difficulty in falling asleep (21%), 
waking up too early and not being able to fall back asleep (21%).57 
Sleep stages were first defined in mid 1960s using various telemetric 
techniques developed for monitoring the physiologic functions of astronauts for sleep 
monitoring. Polysomnographic readings as electro-oculogram (EOG), 
electromyogram (EMG) and electroencephalogram (EEG) can be used for dividing 
sleep into stages. Researches reveal that physiologic and behavioral correlates are 
clinically important for sleep stages. 
Rapid eye movement (REM) sleep occurs every 90min followed by short 
periods of waking. REM sleep shows low voltage, fast EEG activity associated with 
rapid movements of eyes and low EMG tone of most anti-gravity muscles. Non – 
REM (NREM) sleep is divided into 4 stages. Stage 1 sleep is the transition from 
drowsy wake to sleep which is characterized by slow rolling eye movements and 
disappearance of EEG alpha rhythm. Stage 2 dominates much of the night sleep 
possessed by sleep spindles and K complexes on EEG. Stages 3 and 4 known as deep 
sleep includes large amounts of slow delta rhythm on EEG. These sleep stages occur 
throughout the night in cycles.58 
Sleep disorders are basically of three kinds as (1) trouble staying awake 
(hypersomnia), (2) trouble sleeping (insomnia) and (3) abnormal sensations or 
behavior during sleep (parasomnias). Trouble staying awake and trouble sleeping are 
together referred as “dyssomnias”. Sleep disorders are usually diagnosed using two 
types of studies as polysomnogram which records eye movements, EEG, EKG, EMG, 
ear oximetry, airflow of nose and mouth and multiple sleep latency tests (MSLT) 
measures daytime sleepiness.59 
1.14.2. Migraine  
 Migraine is an irregular often intolerable headache related health problem that 
causes significant destruction to the quality of life of the patients and it is a common 
problem among the primary complaints of both childhood and adults. The 
etiopathogenesis of migraine is not clearly established although it has been reported 
that psychosocial, physiological, genetic factors or socio-psychological parameters 
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seem to have influence on migraine. Migraine is also believed to be due to a genetic 
predisposition, environmental and systemic triggers.60-62  
 Prevalence rates of migraine in childhood and adult population have increased 
worldwide. Different diagnostic criteria attribute to higher prevalence rates; however 
migraine remains generally under diagnosed or misdiagnosed. Migraine is often 
attributed to sinus disease. Headache management should identify and treat sleep 
disorders that may improve or resolve headache.   
WHO had estimated that incidence of current headache disorder is about 50%. 
Half to three quarters of adult population aged between 18–65 years in the world have 
had headache and among those population, 30% or more have suffered with migraine. 
Due to differences in study methodology the incidence of migraine vary. Population 
based studies are not available in India. Epidemiologic studies from around the world, 
the incidence of migraine was about 18% in females and 6% in males.63-65 
 International Headache Society classifies migraine into two major clinical 
subtypes as migraine with aura (MA) and migraine without aura (MO). Migraine is 
best described as a neuronal event that may be caused by a hereditary susceptibility of 
the brain and various environmental triggers. A most recently and widely studied 
theory explains that the trigeminovascular system, which under the influence of a 
variety of external and internal triggers result in the release of various inflammatory 
peptides, including calcitonin gene- related peptide (CGRP), substance P, neurokinin 
A and nitric oxide. The resultant perivascular inflammatory response influences the 
trigeminal nucleus caudalis in the brain stem and cervical cord area transferring pain 
data to the upper areas of the brain including the thalamus and cortex. This leads to a 
state of hyperexcitability or cortical sensitization resulting in the pain of migraine and 
associated features including gastrointestinal and visual changes. Migraine in adults 
may represent a progressive disorder whereas in children the progressive nature is 
uncertain and childhood headaches may be attributed to longitudinal outcome and 
phenotypic changes.66  
Migraine is a recurrent incapacitating neurovascular disorder characterized by 
unilateral and throbbing headaches related with photophobia, phonophobia, nausea 
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and vomiting.67 Researches show that the activation and sensitization of 
trigeminovascular pain pathway as the basis for migraine headache.68 As generally 
recognized migraine attacks start in the brain related with premonitory symptoms of 
difficulty in speech and reading, increased emotionality, sensory hypersensitivity 
etc.64 Some triggering effects of migraine are stress, sleep deprivation, oversleeping, 
hunger and prolonged sensory stimulation.69-70 
Earlier, migraine was regarded as a disease of blood vessels and neurological 
symptoms  were  found  to  be  as  a  result  of  vascular  problems,  but  at  present  some  
pathological changes of the nervous system which triggers migraine attacks and 
dilation of meningeal arteries lies as the basis for migraine.71 
International Headache Society categorizes migraine to be with repeated 
attacks of headache lasting for 4-72h. With normal physical activities along with 
symptoms as unilateral pain, throbbing pain, moderate or severe intensity, aggravation 
on movement followed by nausea or vomiting, photophobia and phonophobia.72 
 
Figure 8. Pathophysiology of migraine75 
Typically migraine attack contains 4 phases as the cycle starts with prodormal 
phase associated with clinical signs of sensory hyper excitability as photo and 
phonophobia along with cutaneous allodynia on face. It causes malaise, fatigue, 
changes in mood and apetite followed by headache.73 Headache phase gradually 
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develops over 5 to 20mln and lasts for 4-72h. Usually headache is unilateral, pulsatile 
and exaggerated by coughing or physical activity. The third relief phase of the attack 
is followed by postdromal phase where patients feel and complain about tiredness. 
Time periods in between various attacks are called as interictal phases.74 
Migraineurs experience pain on one side or both sides of head, pain feels 
throbbing or pulsing sensitivity to light, sounds, sometimes even smell and touch, 
nausea, vomiting, blurred vision, light headedness followed by fainting.76 
Insomnia and migraine are interrelated condition. A person with insomnia can 
easily develop migraine and having a migraine often leads to insomnia. The 
combination of two can cause change in mood, serious behavioral and other problems. 
Head and abdominal pain from a migraine may exacerbate the inability to sleep in 
people already inclined to sleep disorders. The American Headache Society had 
reported the links between poor sleep and severe migraines than other migraineurs. 
Poor sleepers chose to sleep or rest because of headache pain or the pain of 
migraineurs forced them to sleep.  
Headache and sleep have long been recognized as interdependent due to 
specific causative factors. Sleep disorders and headache are common in general 
population and usually coexist in a patient. One of the principal factors recognized for 
headache and sleep disorders is stress. Depression and anxiety are associated causes 
for  both  sleep  disorders  and  headache.  Clinically  migraine  and  sleep  are  closely  
related that migraine attacks can be provoked by either too little or prolonged sleep 
time. Poor quality of sleep is frequently reported in patients with chronic headache. 
Good sleep hygiene reduces the frequency and duration of migraine attacks.77 
Migraine, tension-type headache, cluster headache (CH) and rare hypnic 
headache (HH) are primary headaches frequently related to sleep. Insomnia and sleep 
apnoea are common sleep disorders reported to be related with headache.78-79 
1.14.3. Relationship between Headache and Sleep 
Insomnia was reported to be a common symptom in patients with chronic 
daily headache. Onset of headache during nocturnal sleep period indicated presence of 
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a specific sleep disorder in many patients. Researchers have found that both sleep 
problems and migraine are associated and increase in sleep disturbance is associated 
with greater headache severity.80 
Sleep and headache appears to be inter-related in various ways. Different types 
of sleep disruption caused by headache are classified as (1) sleep-related headache 
(during or after sleep); (2) sleep-phase related headaches CH; (3) length of sleep and 
headaches and relief with sleep (migraine); (4) sleep disorders and headaches (sleep 
apnoea, parasomnia); (5) effects of headaches on sleep; (6) dreams and headaches.81 
Clinical association between headache and sleep reveals that headache is the 
cause of sleep disturbance (Ex: morning headache as a symptom of sleep apnea) and 
sleep disturbance is the cause of headache (Ex: sleep disruption induced by CH). 
Headache and sleep disorders may overlap in same subject or have a common cause 
as chronic tension-type headache and insomnia are induced by mood disorders. 
International Classification of Headache disorders reports that there are only 2 types 
of headache being related to sleep as HH and sleep apnea headache.82-83 
1.14.4. Sleep and Primary Headache Disorders 
Migraine is most frequent neurologic disorders common in females which are 
unilateral pulsating of moderate-severe intensity, aggravated by physical activity and 
associated with nausea and/or vomiting, photo and phonophobia. Emergence of 
migraine occurs during nocturnal sleep or following a brief period of daytime sleep. 
Lack of sleep precedes attacks. Principal causes of headache have been identified as 
sleep disturbances followed secondly due to stress. In children sleep has been found to 
relieve migraine. Migraineurs were found to be prevalent to complain about sleep 
with reported difficulty in initiating and maintaining healthy sleep patterns. Also sleep 
was found to be an effective acute treatment for migraineuers. Frequent headaches 
were exhibited by short sleepers than long sleepers besides experiencing morning 
headaches while awakening. 
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1.14.4.1. Tension type Headache 
Prevalence of tension-type headache is large in general population with attacks 
lasting from 30 min to 7 days. Sleep disorders are often associated with tension-type 
headache. Co-morbid conditions as anxiety and depression occur with tension-type 
headache. People with chronic tension-type headache more frequently exhibited 
insomnia while sleep disturbances also caused anxiety and depression.84 
1.14.4.2. Cluster Headache 
Cluster headache is a primary headache characterized by attacks of severe 
unilateral retro or peri-orbital pain lasting for 15 min to 3h. It is more common in 
males and heavy smokers and is found to be related to sleep based on fact that only 3 
of 50 patients with cluster headache reported attacks exclusively during the night.85 
1.14.4.3. Hypnic Headache 
HH is an idiopathic headache syndrome with attacks triggered in close 
relationship to sleep and awakens the patient. It occurs only during sleep and 
represents a good model to explore relationship between headache and sleep. 
Hypothetically HH attacks were related to REM sleep caused due to alteration of 
biological hypothalamic pacemaker.86 
Sleep and headache are recognised to be connected in numerous ways which 
can be divided as (1) sleep-elated headaches (occurring during or after sleep), (2) 
sleep phase-related headaches, (3) length of sleep and headaches (excess, lack and 
disruption), (4) sleep-relieved headaches, (5) sleep disorders and headaches, (6) 
effects of headaches on sleep and (7) dreams and headaches. 
Based on the International Classification of Sleep Disorders87 sleep related 
headaches include chronic paroxysmal hemicranias (CPH), cluster headache (CH) and 
migraine headache. 
Headaches occur in relation with specific sleep stages.88-90 Migraine seems to 
be associated with extreme percentages of stages III, IV and REM.91 Consequences of 
sleep disruption upon headaches are well recognized. Usually people who are sleep 
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deprived might nag of headaches which are often mutual felt in the forehead as a dull 
ache or pressure. It has been established that lack of sleep is a reason of tension 
headache (TH). Though mechanisms are not clearly understood it is known that lack 
of sleep triggers nociceptive receptors in the meninges, blood vessels or 
supplementary superficial structures. In migraine a large amount or too a small sleep 
are responsible for headache. 
Sleep and headaches have apparently complex association. People suffering 
with headache exhibit a chronic prototype of insomnia of reasonable extent along with 
other sleep disorder as impatience, hypnologic startle, pain or uneasiness throughout 
the  night  or  at  arousal  time.  Migraineurs  however  have  not  as  much of  the  foresaid  
complaints than those with chronic substance abuse.92 Exploration of the 
physiological and scientific facts concerned with sleep and headaches using 
polysomnographic studies are still deficient.93 
Association between sleep and headaches are being anticipated by various 
mechanisms indicating that headache is being caused by sleep disturbance or vice 
versa. Also both might have mutual relationship since a particular disorder can cause 
incidence of both.      
1.14.4.4. Sleep Disorders and Headache 
Insomnia, is a repeated difficulty with sleep initiation, duration, consolidation 
or quality that occurs despite adequate time and opportunity for sleep and results in 
daytime impairment. Frequent arousal and fragmentation of sleep related to sleep 
stages are believed to be causative factors of headache in patients with insomnia. 
Tension-type headache resembles to be in close relation with insomnia.94 Somatic and 
psychiatric disorders are frequently co-morbid with insomnia. Complaints of muscle 
tension, anxiety and depression are often related to insomnia. Likewise chronic 
tension-type headache have been reported to be associated with anxiety, depression 
and fibromyalgia.95 Depression could also be an aggravating factor for headache in 
patients with insomnia.  
Headache and sleep have reciprocal relationships. Both sleep disorders as 
insomnia and consequences of sleep disorders are associated with a risk factor as 
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headache. The precise influence of sleep on development of headache remains 
complex and elusive in spite of identification of association between sleep and 
headache. A good sleep hygiene reduces the frequency and duration of migraine. 
Treatment of chronic headache might reduce the incidence of sleep disorders.96  
1.15. Pathophysiology 
1.15.1. Pathophysiology of Insomnia 
Insomnia, a disorder of hyper arousal experienced throughout the day exhibits 
a state of hyper vigilance during day and difficulty in initiating and maintaining sleep 
at night.97-98 Hyper arousal has been explained by both cognitive and physiological 
models of insomnia. As suggested by cognitive model, worry and rumination about 
life stresses disrupt sleep, which causes episodes of insomnia particularly in initiating 
sleep and returning back to sleep after awakening.99 Individuals experiencing shift 
from life events to worries about sleep itself and about daytime consequences due to 
insufficient sleep. 
Physiological model related to neurophysiologic factors causing physiological 
arousal has been evaluated using measurements as whole body metabolic rate, heart 
rate variability, neuroendocrine measures and functional neuroimaging. Oxygen 
consumption (VO2) rate indicates whole body metabolic rate. Higher metabolic rates 
at  intervals  across  24h  were  found  in  insomniacs  than  healthy  controls.  Heart  rate  
variability, regulated by both sympathetic and parasympathetic nervous system 
activation provides a measure of arousal. Followed by a 36h study, it was found that 
average heart rates were increased with decrease in variability at all stages of sleep in 
insomniacs than healthy sleepers.100 
Chronic activation of stress responsive neuroendocrine system provides 
evidence of arousal. High levels of urinary free cortisol excretion have been found in 
poor sleepers after 24h measurement. Stage 1 sleep percentage and wake time after 
sleep onset have been correlated to urinary free cortisol levels and catecholamines. 
Both diagnosis of insomnia and severity of sleep disturbance are found to be related to 
over activation of hypothalamic pituitary-adrenal (HPA) axis and hyper secretion of 
cortisol.101 
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Evaluation of plasma measures of cortisol and adrenocorticotropic hormone 
(ACTH) in insomnia patients has shown higher levels in plasma especially in the 
evening and first half of the night.102 These findings suggest that HPA axis is 
associated with pathology of chronic insomnia. Cerebral glucose metabolism is 
assessed as an indirect measure of whole brain metabolism using Positron Emission 
Tomography (PET) in insomnia patients. Increased cerebral glucose metabolism 
during waking and NREM sleep states occurs in insomniacs. These indicate 
interaction of neural networks during insomnia causing general arousal and a 
cognitive system. 
1.15.2. Pathophysiology of Migraine 
Migraine is a neurovascular disorder, with dilation of blood vessels leading to 
induced pain and nerve activation.103 Generally an aura precedes the migraine 
headache in classical migraine/migraine with aura (MA) characterized by focal 
neurological features. Symptoms of aura are absent in common migraine/migraine 
without aura (MO). Based on vascular theory migraine headache attacks associated 
with changes in brain blood vessels was the immediate cause of headache due to 
vasodilation of meningeal blood vessels.104 
Pathophysiology of migraine involves (i) neuronal hyper excitability during 
interictal phase along with altered function of pain controlling structures in midbrain: 
(ii) cortical spreading depression (CSD) during aura phase or precedes the headache 
phase in MO and sensitization of trigemino-vascular system (TGVS) at peripheral and 
central levels which causes cranial vasodilation.105-106 Trigeminal stimulation involves 
release of nitric oxide (NO) and some neuropeptides as calcitonin gene-related 
peptide (CGRP). Trigeminal activation and vasodilation together are responsible for 
headache. TGVS in both migraine with aura and migraine without aura are indicated 
with CSD.107 
Vascular theory enunciated that dilatation of blood vessels within the head 
was decreased by a compression of the superficial temporal artery. However, in the 
19th century, the vascular origin of migraine was destabilized by an inconsistent 
presumption that the prime event was a neurological dysfunction. So, in 1873, 
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Edward Liveing projected that migraine occurs owing to “nerve storms evolved out of 
the optic thalamus.” 
Based on neurogenic theory, thought provoking studies investigating the 
association between the trigeminal nerve and the cranial vasculature have been 
developed. In 1984, Moskowitz proposed that trigeminovascular axons from blood 
vessels of the piamater and duramater release vasoactive peptides which produces a 
sterile inflammatory reaction with pain. Throughout this neurogenic inflammation, the 
trigeminal ganglion is stimulated and this induces neurogenic protein extravasation; 
then some vasodilator peptides are released, including calcitonin gene-related peptide 
(CGRP), substance P and neurokinin A.  
Admittedly, there is no ideal indication thus distant to definitely rule out the 
vascular or the neurogenic theories of migraine in analysis that all acute antimigraine 
drugs perpetually generate equally cranial (carotid) vasoconstriction inhibition of the 
trigemino-vascular system (centrally and/or peripherally). It is expected that novel 
implements for the exploration of migraine would decide this theoretical standoff and 
agree to an integrated theory of migraine to progress.108 
 
Figure 9. Pathophysiological mechanisms of Migraine headache 
1.15.3. Pathophysiology of Insomnia Related Migraine  
Brain mechanism underlying the association amid sleep and headache has 
been currently described. Anatomy of the central nervous system which generates 
sleep and attentiveness is located in the monoaminergic and cholinergic nuclei of the 
basal forebrain and the brainstem interacting with the thalamus and the hypothalamus. 
Tuberomammillary nucleus, ventrolateral preoptic nucleus of the hypothalamus via       
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g-aminobutyric acid (GABA) and galanin inhibits the arousal-associated locus 
coeruleus, dorsal and median raphe. Adenosine, considered an endogenous somnogen, 
activates ventral lateral preoptic neurons in the hypothalamus, which induces sleep 
also is part of the homeostatic regulation of sleep and wake. Along with the 
homeostatic  drive  for  sleep  and  wake,  a  circadian  system  exists  to  find  out  the  
possibility of sleep at any point in the 24h per day and numerous headache syndromes 
too exhibit circadian tendencies. Headache and head pain organization is still further 
wide, relating cervical inputs to the trigeminal nucleus caudalis, hypothalamus, 
periaqueductal gray (PAG) region, thalamus, cerebral cortex, cranial vessels. 
Numerous  potential  sites  of  interaction  exist  among  the  sleep  and  pain  systems,  
particularly in the hypothalamus and PAG. The ventrolateral portion of the PAG in 
particular is a region with both sleep and pain functions. Stimulation of this region of 
the PAG will affect motor behaviour (quiescence) and the likelihood of REM sleep, 
and is also antinociceptive. Medical aspects of the headache progression in addition 
propose association of the hypothalamus, such as the autonomic activation, yawning, 
and sleepiness associated with migraine. Direct imaging evidence shows 
hypothalamic activation in cluster headache and brainstem activation in migraine 
headache. The scientific association among sleep and headache is being defined by 
the fact that patients vastly recognize sleep as a trigger for migraine. Some reasonable 
mechanisms describe effect of sleep on the probability of headache occurrence and its 
severity. For instance, assessment of pain response in both humans and animals 
generally demonstrates a lower threshold after partial or complete sleep deprivation. 
The nature of this association and its basic mechanisms are yet not clear.109 
Sleep stages influences various primary headaches as migraine, CH and HH 
which indicates that hypothalamus, particularly SCN plays an important role in 
pathogenic relationship between headache and sleep. Researches on neuroendocrine 
system have reported that altered melatonin levels in migraine along with lowered 
melatonin levels in chronic migraine patients with insomnia caused by hypothalamic 
involvements occurs. 
Anatomical structures as noradrenergic locus ceruleus and serotonergic dorsal 
raphe influence the control of sleep-wake cycles as well as pain modulation. 
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Serotonergic system plays a vital role in modulation of pain and sleep regulation 
which thus causes relationship between headache and sleep. In spite of literature data 
relating pathogenic mechanisms for headache and sleep, a clear model relating 
headache and sleep does not exist. 
1.16. Pharmacology of Insomnia associated Migraine 
Brain structures as caudalis trigemini, brain stem nuclei locus coeruleus, 
hypothalamus, thalamus and cortex are those involved in both sleep biology and in 
pain processing. Generators in hypothalamus and thalamus maintain arousal. Two 
types of arousal streams act in coordination but separately. Those two streams are one 
for suppression of sleep-initiating action in thalamus which projects from 
pedunculopontine nucleus and laterodorsal tegmentum and other projects from 
midbrain to hypothalamus as from nucleus raphe, locus coeruleus etc. Excitatory 
neurotransmitters belonging to class of monoamines are responsible for all projections 
in hypothalamus and for homoeostasis of orexin, a central molecule for sleep 
induction and pain processing. Several inhibitory transmitters as gamma-aminobutyric 
acid (GABA) and galanin project from ventrolateral preoptic hypothalamus to nucleus 
raphe and locus coeruleus which suppresses activity of arousal nuclei system. 
Adenosine, the primary sleep-inducing molecule accumulates during the day and 
activates the ventrolateral preoptic hypothalamus by a mechanism called 
homoeostatic drive of sleep.110 
Endogenous circardian sleep drive is another mechanism that originates from 
suprachiasmatic nucleus (SCN) of hypothalamus. This drive has a rhythmic activity of 
slightly more than 24h which is modulated by retinal inputs during day and by 
melatonin production of pineal gland at night that results as a complex system of 
either wake or sleepy state. 
Currently transition from wake to sleep and vice versa is found to be 
interpreted as “flip-flop switch mechanism” which indicates connection between 
arousal generating nuclei of midbrain and ventolateral preoptic nucleus of 
hypothalamus. Neurons localized near locus coeroleus activates REM sleep and 
neurons with off- REM properties localized in ventrolateral PAG and lateral pontine 
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tegmentum are responsible for transition between rapid eye movement (REM) and 
non REM sleep. 
Pain processing structures as glossopharyngeal nerve, vagal nerve and upper 
three cervical roots are involved in experience of headache. The trigeminal nucleus 
caudalis (TNC) of brainstem acts as a major centre for all pain like cervical headache. 
Antinociceptive system (pain control system) includes three different 
structures in lower brainstem and pons level which reduce pain activation on spinal 
and TNC level. They are (i) the rostroventromedical medulla oblongata; (ii) series of 
serotonergic raphe nuclei and (iii) the noradrenergic locus corruleus. PAG matter 
(periaqueductal grey matter) in relation with antinociceptive system has connection 
between headache and sleep. Ventrolateral PAG causes REM sleep off on activation 
by orexin, since it stimulates neurons of ventrolateral part of PAG, thus inhibits 
antinociceptive activity in TNC.111 
Posterior hypothalamus containing orexinergic neurons contributes to both 
altered sleep/wake function and pain processing. Orexin A and B are neuropeptides 
synthesised in hypothalamus. Melatonin, a hormone controlled by SCN synthesized 
from serotonin of pineal gland controls sleep-wake cycle.112 
Mostly all types of primary headaches are found to be frequently associated 
with poor quality of sleep. Clinically researches correlate that specific headache 
diagnosis and sleep disorders with chronobiologic patterns and sleep processes 
governed by same anatomic structures (as brainstem and diencephalon) involves in 
regulation of sleep as well as in headache generation. Hypothalamus plays a central 
role in these processes thus provides common pathophysiological substrates for these 
conditions. Sleep mediators as orexins, adenosine and melatonin are evaluated in 
primary headaches particularly for those related to sleep cycle as CH, HH and 
migraine.      
1.16.1. Therapy for Insomnia 
Earlier in 1960s, clinically insomnia was thought to be a symptom, not a 
disorder  which  would  resolve  either  when precipitating  event  passes  out  or  where  a  
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co-occuring medical or psychiatric disorder was resolved. Later researches recognized 
insomnia  to  be  a  disorder  as  it  was  found to  persist  following  treatment  of  primary  
condition. 
In 1970s in US, 2.6% adults used prescription sedative-hypnotic medications 
and 31% over the counter sleep medications as antihistamines. Historically, chloral 
hydrate was commonly used as sedative/hypnotic. Later in 1990s barbiturates for their 
sedative effects were utilized commonly. Since, they produce drug abuse and have 
danger of overdose barbiturates and barbiturate-like medications (methaqualone, 
glutethimide, ethchorovynol etc) are used rarely. 
Amobarbital, butabarbital, pentobarbital, secobarbital and Phenobarbital were 
used as hypnotics, among which Phenobarbital had longer duration of action. 
Barbiturates induce sleep by increasing the frequency and duration of opening of 
chloride ion channel in GABAA receptors complex using binding site. Due to low 
therapeutic index for sedation and drug addictive effect their recommendations for 
treatment of insomnia have been stopped.113 
Prescription oriented hypnotic agents, the benzodiazepines as trazadone, 
estrazolam, flurazepam, temazepam, triazolam came into use as therapeutics for 
insomnia in 2003. They act similarly as barbiturates by PAM (post allosteric 
modulation) of the GABAA receptors binding to their own sub-site on GABAA 
receptors which increases the frequency of opening of central chloride channels 
caused by increase of activity of GABAA receptor/GABA complex. 
Drugs  of  this  class  with  rapid  onset  of  action  are  preferred  for  those  with  
difficulty in initiating sleep and people with sleep fragmentation, early morning 
awakening prefer long half-life drugs as temazepam. Adverse effects as amnesia, drug 
addiction/dependence, delirium, cognitive impairment etc caused by benzodiazepines 
limits their use. 
Benzodiazepine receptor agonists (BZRA or Z drugs) like zolpidem, zaleplon, 
eszopiclone also act by selective binding to GABAA receptors but to the alpha-1 
subunit. Zaleplon and zolpidem are highly alpha-1selective. Controlled release 
zolpidem with increased half-life has been approved for chronic use. ‘Z’ drugs at 
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recommended doses may cause visual hallucinations, delusions,etc but use of novel 
drug delivery systems of these agents with reduced doses decreases such effects. 
OTC antihistaminic drugs like diphenhydramine and doxylamine act by 
blocking histamine-1 receptors of cortex and ventrolateral preoptic (VLPO) nucleus in 
hypothalamus promoting sedation and sleep. Inspite of lower risk of addiction, abuse 
and respiratory suppression, longer half-lives of these drugs produce morning 
sedation and dizziness. 
Melatonin agonists as ramelteon acting at MT1 and MT2 receptors decrease 
the activity of reticular activating system along with its monoamines like serotonin, 
dopamine and norepinephrine thus inducing sleep. Low bioavailability of this drug 
leads to ineffectiveness. Melatonin as such has high degree of first pass metabolism 
and also has lower penetration through blood-brain barrier.114 
American Academy of Sleep Medicine developed evidence based practice 
measures for nonpharmacologic treatment of chronic insomnia using stimulus-control 
therapy, sleep-restriction therapy, muscle relaxation and cognitive behavioral therapy. 
Lack of sufficient evidence for sleep hygiene education, imagery training or cognitive 
therapy restricts nonpharmacological treatments for insomnia. 
 Development of innovative modified-release formulations of BZRA hypnotics 
as zolpidem extended release approved for treatment of insomnia shows both rapid 
and sustained release of medication with reduced risk of next-day effects.   
1.16.2. Therapy for Migraine 
 Migraine, a vascular headache is most commonly experienced between the 
ages of 15 and 55, and 70 to 80% of sufferers have a family history of migraine. 
Migraine is often misdiagnosed as sinus headache or tension-type headache. Many 
factors trigger migraine attacks, such as alteration of sleep-wake cycle; missing or 
delaying a meal; medications that cause a swelling of the blood vessels; daily or near 
daily use of medications designed for relieving headache attacks; bright lights, 
sunlight, fluorescent lights, certain foods and excessive noise. Stress and/or 
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underlying depression are important trigger factors that can be diagnosed and treated 
adequately.  
Migraine is found to be a general disabling trouble whose exact pathogenesis 
still remains unclear. Origination of trigeminal afferents innervating dural structures is 
involved in headache of migraine. Simultaneous stimulation of dural sites and 
trigeminal neurons activation leads to release of calcitonin gene related peptide 
(CGRP) and dilation of dural blood vessels causing pain in humans. 
Conventionally migraine treatment includes both defensive and discriminating 
therapy which aimed to reduce incidence of attacks, relentlessness and for aborting 
attacks respectively. Drugs used for the treatment of migraine are classified into two 
types as (i) non-specific drugs (NSAIDs and analgesics) and (ii) specific drugs 
(triptans and ergot derivatives). Methysergide was the first agent specifically 
developed for the treatment of migraine but not recommended anymore because of its 
ineffectiveness.115-116 
Incidence of attacks beyond two or more per month utilizes prescription 
oriented prophylactic agents for a period of three months either with the presence or 
absence of headache pain. Prevalently used prophylactic agents include Voltage gated 
sodium channel (VGSC) blockers as lamotrigine, sodium valproate, Voltage gated 
calcium channel (VGCC) blockers as flunarizine, gabapentin, pregabalin, 5-HT2 
receptor antagonists like iprazochrome, pizotifen, ȕ-adrenoreceptor blockers like 
timolol, metoprolol, serotonin uptake inhibitors like paroxetine, fluoxetine and 
antiepileptics all possess different mechanisms of action.  
Acute therapy of migraine is further subdivided as non-specific and migraine 
specific. COX inhibitors like aspirin, ibuprofen, paracetamol, opiates and other 
combinational analgesics like metoclopramide comes under non-specific treatments of 
pain disorders. Diclofenac potassium (PRO-513) an innovative formulation utilizing 
buffering technology which improves pharmacokinetics of the drug has been recently 
used for the treatment of migraine attacks. Since these drugs possibly develop a 
common risk of rebound headache associated with medication overuse limits their 
use.  
In 1926, ergotamine of ergot derivatives was found to be the first drug of 
choice used for migraine treatment. Ergot derivatives have agonist effect on serotonin 
42 
receptors and its longer duration of action along with cost effectiveness makes their 
use as migraine specific drug. Risk of overuse, higher vasoconstriction action and 
adverse effects like nausea, vomiting, muscle pain etc reduces its use as an 
antimigraine agent. Comparatively dihydroergotamine has better tolerance but shown 
to have poor oral bioavailability and slow onset of action. Parenterally DHE is more 
effective against migraine attacks but produces severe side effects.  
Later from early 1990s main acute migraine therapy has been evolved with the 
use of triptans. Triptans are serotonin 5-HTIB/ID receptor agonists which targets 
sensory nerves, constricting dilated intracranial blood vessels with decreased 
inflammation and restoration of corrupted blood supply by closing arteriovenosus 
anastamoses. Currently seven triptans are commercially available differing in their 
efficacy and pharmacokinetics. Sumatriptan represents as the gold standard for the 
treatment of migraine therapy. Lower oral bioavailability (14%) and less lipophilicity, 
shorter plasma half-life are its drawbacks. Later the development of newer second 
generation triptans like zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan 
and frovatriptan which effectively penetrates the blood-brain barrier occurred.117 
Triptans are effective in case of about 60% population, thus recommended for 
the  treatment  of  mild  to  severe  migraines  when  not  responding  to  NSAIDs  or  
combination of analgesics due to contraindications, intolerance or hypersensitivity. 
Though orally administered triptans are available, various other formulations like oral 
dispersible tablets, nasal sprays and subcutaneous injections are existing. However 
oral triptans show recurrence of headache in about 15-40% of patients. Subcutaneous 
route has more marked side effects. Beneficial effects of triptans are more when taken 
during onset of headache with mild or moderate pain. Characteristics of individual 
patients, headache features, convenience for use and cost effectiveness, decides the 
choice of triptan type and its formulation.     
New migraine experimental models have been proposed as no model in 
experimental animals can explain all the features of migraine. The new models 
provide ways to dissect component parts of migraine for better understanding and 
development of new treatment strategies. 
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2. AIM AND OBJECTIVES 
 
In view of the food effect observed for oral dose of Zolpidem tartrate and 
low oral bioavailability of Zolmitriptan , it is perceptible  that there is a clear 
unmet medical need for an improved formulation comprising a short acting 
hypnotic agent and antimigraine agent, which exhibits a fewer residual effects the 
following day. Nasal fixed dose combination of drugs used to treat migraine and 
short acting hypnotic shall be of potential breakthrough to treat insomnia 
associated with migraine. 
Oral pharmaceutical formulations are administered typically before retiring 
and rapidly disintegrate in the gastrointestinal tract to provide systemic absorption 
of drug. Peak plasma concentrations are reached within few hours of oral 
administration using available oral formulations. 
Nasal drug delivery has been considered as a potential administration route 
to achieve faster and increased level of drug absorption. This is due to the large 
surface area, porous endothelial membrane, high total blood flow, the avoidance of 
first-pass metabolism, and ready accessibility. High degree of vascularization and 
permeability of the nasal mucosa augments the use of nasal route for the systemic 
delivery.  Major limitation with nasal route of administration is the poor contact of 
the formulations with the nasal mucosa. This study attempts to increase the 
residence time of drug formulations in the nasal cavity, resulting in improved nasal 
drug absorption.  
The objective of the study is to develop an in situ nasal gel containing 
Zolpidem tartrate and Zolmitriptan which gels in situ at the nasal cavity. The nasal 
in situ gel remains in solution form at room temperature and gels at the site of 
application triggered by physiological conditions. 
This study aims to explore the use of mucoadhesive polymers to prolong the 
dwelling time of the drugs in the nasal cavity by using excipients that are suitable 
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for pharmaceutical use. Most of the drugs and inactive components used in the 
pharmaceutical formulations are prone to have toxic effect and may cause marked 
and irreversible damage on nasal epithelium. Poloxamers and carbopols are proven 
to be safe and should be appropriate for exploitation in nasal formulations. The 
study aims to evaluate toxicological effects of the formulation on the nasal 
epithelium. 
  Insomnia is a common disorder characterized by difficulty in the initiation 
or maintenance of sleep. Insomnia periodically affects 30% of adults. Furthermore, 
more than 90% of the total populations have trouble with sleep at some point 
during their lives. Inadequate sleep impairs quality of life and ability to function 
normally in a general sense. It often results in adverse personal, medical or 
psychiatric consequences, in addition to increasing the risk of accidents. 
 Insomnia and migraine are interconnected. A person with insomnia can easily 
develop migraine and having a migraine often leads to insomnia. The combination 
of two can cause change in mood, serious behavioral and other problems. 
 The research work also aims to conduct formulation development of nasal in 
situ gels using Design of Experiments to arrive at optimized formulation and 
evaluate to provide safe and effective formulation to the community. 
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3. REVIEW OF LITERATURE 
Bastian T et al118 reviewed recent concepts on neurobiological mechanisms 
underlying insomnia including clinical key features, diagnostic criteria and 
therapeutic aspects alleviating the symptoms of insomnia, like non-refreshing sleep or 
excessive daytime sleepiness. Significantly, chronic insomnia has been recognized as 
an important risk factor for the development or exacerbation of psychiatric disorders 
such as depression. Insomnia is a common multi-factorial interaction of biological and 
psychological factors affecting both sleep and wakefulness including genetics, 
biological, cultural factors, personality characteristics, personal history and assorted 
habits. Even though several models of insomnia have been elaborated, no single 
underlying pathophysiological method has been shown to represent a causal factor. 
However, distinct alterations of neuroendocrine, quantitative sleep 
electroencephalography and functional as well as structural neuro-imaging measures 
have been used to give further insights into possible pathophysiological mechanisms.  
Gregory M Asnis et al119 reported the state of the art of pharmacotherapy 
with a reference to cognitive behavioral therapy for insomnia (CBT-I) as well which 
thus provides the clinician with a guide to all the Food and Drug Administration 
(FDA) approved hypnotics as benzodiazepines, nonbenzodiazepines, ramelteon, low 
dose sinequan, and suvorexant including potential side effects. Frequently, chronic 
insomnia lasts longer than 2 years. Cognizant of this and as a result of longer-term 
studies, the FDA has approved all hypnotics since 2005 without restricting the 
duration of use. Off-label hypnotics as sedating antidepressants, atypical 
antipsychotics, anticonvulsants and antihistamines which in reality, are more often 
prescribed than approved hypnotics. The choice of which hypnotic to choose is 
discussed partially being based on which segment of sleep is disturbed and whether 
co-morbid illnesses exist.   
Philip Cheng et al120 performed a study which provides novel information 
regarding the risk of hypertension in insomnia via sleep maintenance difficulties. 
Findings from this study provide preliminary evidence for examining night time 
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fluctuations of blood pressure and concomitant physiological changes like 
(catecholamines, heart rate, and sympathetic activation) due to wake during sleep as a 
mechanism for subsequent hypertension. 
Thomas L Schwartz et al121 explored basic sleep physiology, the mechanism 
of action for each class of hypnotic agents, their clinical application based on 
pharmacodynamic and pharmacokinetic factors, and potential pharmacologic sleep-
inducing mechanisms of future hypnotics. Currently indicated hypnotic agents with 
regard to their mechanism of drug action and clinical application have been discussed. 
Development of newer pharmacological treatments that may become available in the 
future for use in sleep disorders and their comorbid conditions are also reported. 
David W Dodick et al122 studied about the intimate relationship between sleep 
and headache however the relationship remains clinically and nosologically complex. 
Headaches associated with nocturnal sleep have often been apparent as either the 
cause or result of disrupted sleep. An understanding of the anatomy and physiology of 
both conditions allows for a clearer perceptive of this complex relationship and a 
more reasonable clinical and therapeutic approach. Recent biochemical and functional 
imaging studies in patients with primary headache disorders has lead to the 
identification of potential central generators which are also important for the 
regulation of normal sleep architecture. 
Børge Sivertsen et al123 examined the relationship of insomnia symptoms by 
means of demographic, substantial and psychological circumstances in a large 
population-based study.    Insomnia symptoms were found in 13.5% of the people and 
were more common among women, older adults and in persons with less culture. 
Reporting insomnia symptoms significantly increased the associations with a range of 
conditions, especially mental conditions, pain conditions with uncertain etiology and, 
to a lesser extent, chronic pain conditions. The findings suggest that the independent 
contribution of insomnia is strongest on conditions characterized by some level of 
psychological or psychosomatic properties  
BL Uhlig et al124 postulated that principal headaches, including migraine and 
tension-type headache, are considerably correlated to insomnia symptoms with odds 
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ratio estimates ranging from 1.4 to 1.7. The odds were even larger, from 2.0 to 2.6, for 
recurrent, co-morbid or rigorous headache. Recent studies from Norway established a 
bidirectional, probably underlying, relationship connecting headache and insomnia. 
Further research should use well defined and validated diagnostic criteria both for 
insomnia and headache types in order to get better comparison between studies to 
investigate causality and clarify the significance of the results for clinical practice. 
Ahiwale Raj et al125 formulated and evaluated bupropion hydrochloride nasal 
in situ gel for assessment of safety and stability. Excipients with thermosensetive, 
mocoadhesive and antimicrobial properties like Poloxamer 407, Carbopol 940, and 
Methyl paraben were used correspondingly. Formulations were prepared based on 32 
factorial design and were subjected for evaluations such as appearance, pH, drug 
content, gelation time, gelation temperature, gel melting temperature, gel strength, 
mucoadhesion, viscosity, Ex vivo permeability & histopathology. Sustained effect of 
gel and vital safety factor revealed using ex-vivo studies  was  confirmed  by  the  
histopathological studies. Stability studies done over 6 months assessed that the 
formulation was stable. 
Ahmed M Fatouh et al126 formulated AGM solid lipid nanoparticles loaded 
in situ gel to extend the intranasal retention time and consequently to augment the 
absorbed quantity of AGM. The optimized formulation had good sol–gel transition 
temperature, mucociliary transport time, in vitro release also pharmacokinetic study 
revealed a considerable raise in the peak plasma concentration and absolute 
bioavailability compared to that of the oral suspension of Valdoxan. Drug targeting 
efficiency index for successful brain targeting via the intranasal route compared to the 
intravenous route was effective which indicated a major contribution of the direct 
nose to brain pathway for brain drug delivery. 
Shravan Kumar Konda et al127 investigated a mucoadhesive in situ gel with 
reduced nasal mucocilliary clearance of the antiasthamatic drug, montelukast sodium 
for improving the bioavailability. Use of the thermo gelling pluronic flake 127 
conferred in situ gelation upon contact with nasal mucosa while mucoadhesion and 
drug release augmentation were modulated using Hydroxy propyl methyl cellulose, 
methyl cellulose and polyethylene glycol correspondingly. The results showed that 
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the increased gel viscosity with reduced sol-gel transition temperatures and drug 
release was due to mucoadhesive polymer. The addition of polyethylene glycol 
polymer counteracted the effect of mucoadhesive polymer by decrease in gel 
consistency and increase in sol-gel transition as well as in-vitro drug release. Thus 
mucoadhesive in situ nasal gel in provisos of ease of administration, precision of 
dosing, long-lasting nasal residence and enhanced nasal bioavailability points to the 
potential. 
Ana Serralheiro et al128 aimed to estimate the pharmacokinetics of 
carbamazepine administered through intranasal and intravenous routes to mice to 
assess possibility of direct transfer of the drug from nose to brain. Though having 
similar pharmacokinetic profiles following both administration routes, carbamazepine 
rapidly and extensively reaches the bloodstream, targeting the brain only after IN 
delivery. Compared with the homogenous brain distribution pattern after IV injection, 
the irregular biodistribution of carbamazepine throughout the brain regions following 
IN instillation strongly suggests the involvement of direct transfer of carbamazepine 
from nose to brain. So, IN delivery represents a suitable and promising alternative 
route to administer carbamazepine not only for chronic use but also in emergency 
conditions. 
Animesh Kumar et al129 formulated combinational ZT & KT loaded 
thermoreversible in situ mucoadhesive intranasal gel containing a bioadhesive 
polymer, Xyloglucan that lengthens the residence time for enhanced bioavailability of 
the drugs. Box-Behnken design was utilized to develop and optimize the TMISG for 
assessing the factors affecting the crucial quality attributes. Safety of the formulation 
for nasal administration was confirmed using histopathological studies. The statistical 
divergence in absolute bioavailability among oral and intranasal route recommended 
that intranasal route had almost greater increase in bioavailability for ZT and for KT 
compared with oral formulations. Thus formulation would assist diminish migraine 
related symptoms much better over the currently existing formulations. 
Ulrike Bertram et al130 developed intranasal sponge-like, in situ gelling 
inserts with bioadhesive polymers. Various formulations using hydrophilic polymers 
as (carrageenan, Carbopol, chitosan, hydroxypropyl methylcellulose (HPMC) K15M 
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and E5, sodium alginate, sodium carboxy methylcellulose (NaCMC), polyvinyl 
pyrrolidone (PVP) 90, xanthan gum) were prepared with/without the model drug 
oxymetazoline HCl in demineralised water and lyophilized into small inserts and 
characterized. Amorphous polymers gave sponge-like structure of nasal inserts 
compared with crystalline polymers on freeze-drying. Hardness of the inserts 
increased with the glass transition temperature of the polymer (PVP25 < PVP30 < 
PVP90). Low molecular weight polymeric inserts resulted in polymer dissolution and 
fast drug release (HPMC E5, Na-alginate, PVP90) than those prepared from high 
molecular weight polymers (carrageenan, Carbopol, chitosan, HPMC K15M, 
NaCMC, xanthan gum)  due to osmotic forces, water uptake and electrostatic 
interactions between drug and polymer. So drug release decreased with higher 
polymer content and increased drug loading of the inserts. Bioadhesive nasal inserts 
encompass a high potential as novel nasal dosage form for extended drug delivery. 
L  E  Bromberg  et al131 examined enhanced effect of retention in the nasal 
cavity exhibited by in situ gels formulated using Pluronic-poly (acrylic acid) 
copolymers. Comparison of bioadhesive (Carbomer 934P) and thermogelling 
(Pluronic F127) polymers on nasal clearance with Pluronic-poly (acrylic acid) 
copolymers using a rat model revealed that Pluronic-poly(acrylicacid) copolymers 
showed increased residence time of fluorescent labels.    The results obviously show 
the superior retention of the hydrophobically modified polyelectrolytes( HMP) to 
facilitate both bioadhesive and thermogelling properties over either a bioadhesive 
polyelectrolyte or a polymer of a low molecular weight so as to undergo a sol-gel 
transition. 
Shi-lei Cao et al132 prepared a novel in situ gel  system for  nasal  delivery  of  
mometasone furoate (MF) to study its efficiency on allergic rhinitis model. An ion-
activated in situ gel was formulated and characterized using gellan gum as a polymer. 
Stability studies of the system stored at 40±2 ƕC for 6 months, and the micrographic 
results showed that in situ gel was safe without mucosal irritation at a dose of 20g 
once daily for 1 month to rats with allergic rhinitis. MF in gellan gum exhibited 
apparent effect on allergic rhinitis following intranasal administration and the efficacy 
was appreciably higher than the general suspensions. The intranasal delivery of MF as 
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an in situ gel system is a promising approach for the improvement of the therapeutic 
effects. 
Chenxi Li et al133 developed nasal in situ gel system using combination of 
poloxamer 407 and carrageenan as carrageenan–poloxamer 407 hydrogel(CPH) for 
intranasal delivery of ketorolac tromethamine. Deliberate erosion in aqueous 
environment with potassium ion at the physiological level occurred due to potassium 
ion concentration-dependent erosion characteristics exhibited by CPH. Erosion, drug 
release and thermosensitive properties of CPH were influenced by loading of 
ketorolac tromethamine into gel. Optimum gelation temperature and in vitro sustained 
release profiles was shown by CPH formulations with 15% ketorolac tromethamine. 
In comparison with the intranasal solutions pharmacokinetic study of intranasal CPH 
in rats established improved absolute bioavailability and long-lasting mean residence 
time. Preliminary nasal ciliotoxicity study on an in situ toad palate model showed the 
safety  of  CPH  for  intranasal  use.  All  results  recommended  the  prospective  of  CPH  
combined intranasal delivery of ketorolac tromethamine as a new sustained-release 
platform. 
H Nazar et al134 formulated a thermosensitive nasal drug delivery utilising N-
trimethyl chitosan chloride polymers of chitosan as a hydrogel with PEG and 
glycerophosphate. Evaluations in relation with rheological studies have revealed that 
hydrogels derived from N-trimethyl chitosan with high or medium average molecular 
weights exhibited comparatively short sol–gel transition times at physiologically 
relevant temperatures. They also showed fine water-holding power and strong 
mucoadhesive capacity and displayed rheological synergy with mucus. Aqueous 
hydrogel formulations developed from N-trimethyl chitosan of average molecular 
weight and less quaternisation, appears particularly to be potential in favour of 
rheological, mucoadhesive nature and a sol–gel transition that occurs ideally at 32.5ೊC 
within 7 min. 
Hitendra S Mahajan et al135 studied about augmentation in bioadhesive 
potential of thiolated xyloglucan. Esterification with thioglycolic acid gave thiolated 
xyloglucan which was characterized by NMR, DSC, and XRD examinations.     
Estimation of mucoadhesive characteristics of ondansetron loaded in situ gel systems 
51 
of xyloglucan and thiolated xyloglucan as a comparison using sheep nasal mucosa 
explored higher ex vivo bioadhesion time for thiolated xyloglucan than xyloglucan. 
Enhanced mucoadhesive property of thiolated xyloglucan above xyloglucan can be 
credited to the configuration of disulfide bond connecting mucus and thiolated 
xyloglucan. Ex vivo penetration studies performed using sheep nasal mucosa showed 
enhanced drug permeation of formulations with thiolated xyloglucan. Study results 
suggest that thiolation of xyloglucan improves its bioadhesion and drug permeation 
properties without altering the gel properties. 
Inayat Bashir Pathan et al136 designed a nasal delivery system for the 
treatment of allergic rhinitis with improved mucoadhesive properties and prolonged 
retention time. Effects of amount of gellan gum and mucoadhesive polymer, HPMC 
E4M marked as independent variables were investigated using a 32 factorial design. 
Taking viscosity and mucoadhesive strength as dependent variables the formulations 
were tested for gelation, viscosity, gel strength, mucoadhesion, shot weight, drug 
content, histopathological evaluation and stability study. Viscosity of sol and gel 
formulations increased with increase in polymer concentration. Gel strength was 
within the range of 22-55 sec. Increase in the concentration HPMCE4M increased the 
mucoadhesive force as expressed in terms of detachment stress. Nasal toxicity studies 
of sheep nasal mucosa did with control and optimized formulation proved no change 
in the nasal tissue. A stability study of the optimized formulation as per ICH guideline 
for 90 days showed no change in pH, drug content, and viscosity. In situ gelling 
system of azelastine hydrochloride developed using combination of gellan gum with 
HPMC E4M with better mucoadhesive properties might offer prolonged retention 
time for the treatment of allergic rhinitis. 
Bjorn Jansson et al137 utilized fluorescent microscopic technique to explore 
nasal uptake of a 3000Da fluorescein dextran (FD3) in rats. Formulation containing 
deacetylated gellan gum as an in situ gelling agent was compared with mannitol 
solution for uptake and rheological property. Ease of administration and due to its low 
viscosity, gellan gum solution gels upon contact with the mucosa. It also increased the 
epithelial uptake and transfer of FD3 without altering the epithelial FD3 distribution 
or any evident detrimental effects. 
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N Kashyap et al138 developed biodegradable glucose-sensitive in situ gels of 
chitosan for pulsatile delivery of insulin. Swelling properties, rheology, texture 
analysis and water content were characterized. Optimized gels loaded insulin was 
diagnosed to influence the rheological feature of these gels. Insulin release from these 
gels followed a pulsatile mode in relation to the glucose concentration in vitro. In vivo 
evaluation done in streptozotocin-induced diabetic rats at a dose of 3 IU/kg, 
confirmed release of insulin linearly to glucose concentration and be ideal than usual 
subcutaneous insulin formulation used as control.  Hence biosensitive chitosan in situ 
gelling systems encompass significant use as pulsatile delivery systems for insulin. 
Khaled Mohamed Hosny et al139 formulated saquinavir mesylate  (SM) 
having problems of first pass metabolism, poor aqueous solubility, low GIT 
permeability and absorption as a nasal in situ nanosized microemulsion gel (NEG). 
Based on the solubility estimations of (SM), pseudo-ternary phase diagrams were 
developed for preparation of nanosized microemulsions (NE) using gellan gum as in 
situ gelling agent and subjected to characterizations, as stability study and droplet size 
measurements including gel strength, critical ionic concentration, gelation 
characteristics, in vitro release, and ex vivo nasal  permeation  studies.  The  
pharmacokinetic study was carried out in rabbits. NEs with a composition of 17.5% 
Labrafac PG, 33% Labrasol, and 11% Transcutol HP were developed having droplet 
size range of 25–61 nm and provided the utmost in vitro and ex vivo permeation and 
enhanced bioavailability in the rabbits by 12-fold while compared with the marketed 
tablets. Advanced nasal tissue permeability and better systemic bioavailability could 
be achieved using nasal NEG as novel method for (SM) delivery. 
Noha M Zaki et al140 aimed to decrease nasal mucociliary clearance and 
advance the bioavailability of the antiemetic drug, metoclopramide hydrochloride 
(MCP HCl) as a mucoadhesive in situ gel. Thermogelling poloxamer 407 conferred 
gelation while mucoadhesive and drug release was enhanced by use of other polymers 
as  HPC,  carbopol  934P,  chitosan,  PVA,  PEG,  etc.  The  results  revealed  that  the  
various mucoadhesives increased the gel viscosity and reduced their sol–gel transition 
temperatures (Tsol–gel) includind drug release. However PEG counteracted the effect 
of the mucoadhesive polymers by decreasing the gel consistency with increase in the 
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Tsol–gel and drug release. Carbopol containing in situ gels prolonged the mucociliary 
clearance from 10 min (control solution) to 52 min (mucoadhesive gel). 
Bioavailability of MCP HCl was significantly improved from 51.7% of oral drug 
solution to 69.1% of the nasal in situ gel.  Mucoadhesive nasal in situ gels potentiates 
ease of administration, dosing accuracy, extended nasal residence and enhanced drug 
bioavailability 
P R Patil et al141 studied effect of external stimuli like changes in pH, 
temperature  or    ion  concentrations  gives  transition  of  sol  to  gels.  Based  on  this  
principle, zolmitriptan in situ gel formulations were prepared using gellan gum as 
gelling agent and HPMC K100 as sustained release polymer. Parameters like pH, 
viscosity, drug content, gel strength, mucoadhesive strength and drug release were 
evaluated. Gelling agent and HPMC K100 showed in situ gelling with all parameters 
within range along with sustained drug release pattern at optimized concentration 
indicative of higher bioavailability. 
Pradnya P Jadhav et al142 investigated sedative effect of Nardostachys 
jatamansi plant extract developed as a thermoresponsive nasal gel. Gel formulations 
containing pluronic PF 127 with dried ethanolic N. Jatamansi extract, PEG 400, PEG 
4000 as gelling agents and methyl paraben as preservative were prepared by cold 
method. Optimized batches showed gelation point at 340C and 37 0C, pH of 4.1-5.3, 
spreadability between 0.35-0.8cm, mucoadhesive strength of 1524.44 and 1720.44 
dyne/cm2 and improved residence time and stability. Increased bioavailability with 
reduced side effects will enhance patient compliance. 
Santosh Shelke et al143 formulated naratriptan hydrochloride as 
thermoreversible intranasal gel for direct delivery to brain via olfactory lobe using 
poloxamer 407, a thermoreversible and carbopol 934, mucoadhesive polymer for 
treatment of migraine. Characterization studies as gelation temperature, gel strength, 
mucoadhesive strength, viscosity, in vitro drug release and ex-vivo permeation across 
sheep nasal mucosa were done. Results suggested that the release rate was linear to 
carbopol 934 concentrations, but poloxamer 407 decreased the rate of drug release 
provided histopathological study showed no signs of damage to columnar epithelial 
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cells of sheep nasal mucosa, indicative of non-toxicity. Stability of the gels were 
conducted as per ICH guidelines [Q1A (R2)] and found to be stable. 
Shuai Qian et al144 developed an in situ gel using Pluronic F-127 for 
intranasal delivery of tacrine (THA), an anti-alzheimer’s drug. Following 
characterization studies, comparison of the pharmacokinetics and brain dispositions of 
in situ gel with that of THA oral solution in rats was done. Peak plasma concentration 
(Cmax)  and  area  under  the  curve  (AUC) of  THA as  in situ gel in plasma and brain 
tissue, was 2–3 fold times higher than that of oral solution. The ideal behaviour of the 
in situ gel with improved nasal residence time and bioavailability, greater brain 
uptake suggest its effectiveness for intranasal administration of THA. 
Swati Pund et al145 examined transmucosal permeation kinetics of 
venlafaxine in situ gel via sheep nasal mucosa. Diffusion of venlafaxine through 
mucosa was calculated by means of validated RP-HPLC technique. Drug exhibited 
sustained diffusion through sheep nasal mucosa with 66.5% permeation in 7 h during 
ex vivo study. Results of permeability coefficient and steady state flux were found to 
be 21.11 x 10-3 cm  h-1 and 21.118 µg cm-2 h-1 respectively. Cumulative amount 
permeated through mucosa at 7 h was found to be 664.8 g through an area of 3.14 
cm2. Absence of adverse effects confirms that the barrier function of nasal mucosa 
was impervious even after treatment with venlafaxine in situ gel. Venlafaxine in situ 
gel provides a new facet to the treatment of chronic depression with enhanced 
permeation through sheep nasal mucosa. 
Xiaofeng Xu et al146 developed intranasal spray of phenylephrine 
hydrochloride (PE) as hydrogel for treatment of nasal congestion. Thermosensitive 
polymers poloxamer 407 (P407), poloxamer 188 (P188) and mucoadhesive polymers 
as e-polylysine (e-PL), sodium hyaluronate were used for the formulations. The 
results of evaluation parameters revealed that the gelation temperatures and texture 
profiles were significantly influenced by concentration of P407 or P188. In spite of 
lowering the gel strength, mucoadhesives augmented interaction with mucin. 
Optimized formulations were used for further studies as in vitro release behaviour and 
mucosal ciliotoxicity. Sustained release of PE formulations for up to 8 h without 
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ciliotoxicity suggests that PE hydrogels are capable to attain long-lasting 
decongestion in nasal cavity. 
Xin Li et al147 developed a novel nasal thermo and ion-sensitive in situ gel of 
KT using thermosensitive poloxamer 407 (P407) and ion-sensitive deacetylated gellan 
gum (DGG). Sulfobutyl ether-b-cyclodextrin and chlorobutanol were selected as the 
penetration enhancer and bacterial inhibitor, respectively. In vitro investigation 
postulated Fick’s diffusion and dissolution of KT from the dual sensitive in situ gel. 
Pharmacodynamic evaluation of the KT in situ gel utilized two methods as acetic acid 
induced writhing frequencies and tail retracting latency time from hot water on the 
mouse  models.  KT  in situ gel showed significantly decreased writhing frequencies 
and prolonged latency time of tail retracting (p < 0.05) compared to the control. The 
thermo and ion-sensitive KT ISG had suitable gelation temperature, sustained drug 
release, better intranasal absorption, evident pharmacodynamic effect and negligible 
nasal ciliotoxicity which showed it to be potential intranasal analgesic formulation. 
Yanfeng Wang et al148 developed zolpidem mucoadhesive formulation with 
minimal local toxicity, prolonged nasal residence time and enhanced absorption after 
intranasal delivery which showed efficient in vitro permeability across artificial 
membrane and Calu-3 cell culture. Aqueous solubility of zolpidem was found to be 
appreciably enhanced by using hydroxypropyl-b-cyclodextrin. Different 
mucoadhesive formulations were then prepared using hydroxypropyl-b-cyclodextrin, 
and mucoadhesive polymers like hydroxypropyl methylcellulose, sodium 
carboxymethylcellulose and sodium alginate. Pharmacokinetic studies in rats 
established that intranasal administration of zolpidem could achieve significantly 
faster  absorption  rate  and  higher  plasma  concentration  than  that  from  oral  route.   
Compared with nasal solutions the optimized mucoadhesive formulation containing 
hydroxypropyl methylcellulose was found to improve Cmax and AUC with mild 
nasal ciliotoxicity in rats. 
Shuang Wang et al149 formulated a microemulsion based in situ ion-sensitive 
gelling system for intranasal administration of curcumin. After optimization using 
simple lattice design formulations were prepared with capryol 90, solutol HS15, 
transcutol HP and DGG solution. Evaluation parameters include morphology, droplet 
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size distribution, zeta value and the in vitro release along with histological studies. 
The pharmacokinetics results showed increase in the absolute bioavailability of 
curcumin with the use of microemulsion based in situ ion-sensitive gelling system 
after intranasal administration. Brain targeting property of drug following intranasal 
route was higher as revealed by brain targeting index (BTI) and tissue distribution. It 
was concluded that the microemulsion based in situ gelling can be effective and safe 
vehicle for enhanced in vivo absorption and  targeted delivery of curcumin to brain by 
intranasal administration. 
Paul Jennum et al150 studied about relationship between headache and sleep 
disturbances, especially headaches stirring during the night or early morning. The 
mechanism and causes are complex, multifactorial and poorly implicit. Sleep 
disturbances and daytime functioning are affected or directly related to headache 
disorders like migraine, tension-type headache, cluster headache and hypnic 
headache. Headache shows association with sleep fragmentation, insomnia and 
hypersomnia. In addition medical, psychiatric and rheumatic diseases are related with 
sleep disturbances and headache. The present facts about headache and sleep are still 
sparse and further research is to be advocated. 
Swati Jagdale et al151 formulated optimized controlled release in situ nasal 
delivery of timolol maleate using 32 factorial designs. Thermoreversible in situ nasal 
gel formulations were prepared using HPMC and poloxamer 407 as polymers. Study 
revealed that formulations F1 and F4 revealed the highest % drug release of 93.57% 
and 91.66%, respectively. Factorial design study indicated that the drug release and 
viscosity were most significant dependent factors. Ex vivo diffusion study through 
nasal mucosa indicated F1 was the optimized batch and hence be proficient as a 
potential nasal delivery with enhanced bioavailability for the drug. 
Preeti Pandey et al152 formulated thermoreversible in situ gels utilizing 
poloxamer-407, hydroxypropyl methyl cellulose and chitosan to promote greater 
retention at the nasal mucosal surface compared to existing solution or suspensions. 
Desirable gelation temperature with Newtonian fluid behaviour at storage conditions 
of (4–8 °C) and pseudoplastic fluid behaviour at nasal cavity or sinus temperature 
(<34 °C) were shown by optimized soluble gels. Incorporation of HPMC and chitosan 
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into the gels exhibited significant improvement in mechanical properties and 
mucoadhesion. Ex vivo permeation studies displayed extended drug release profiles of 
the gels in conditions mimicking the human nasal cavity thus indicating their 
robustness for treating a variety of conditions affecting the nasal cavity or sinuses 
Piyush Jangam et al153 prepared in situ nasal gel of levodopa to increase its 
bioavailability and onset of action. Carbapol 934, the pH sensitive gelling agent and 
HPMC K4M, mucoadhesive polymer were used to form the gel. As a result various 
formulations were prepared using different combinations of the polymers and 
evaluated in respect of pH, gelation temperature, mucoadhesive force and permeation 
of drug. Results concluded that both the pH sensitive polymer and mucoadhesive 
polymer used had distinct effects. 
Haoyun Wu et al154 reported the anti-inflammatory and anti-cataract effects 
of Baicalin on eye tissues, but has low bioavailability partly due to its poor stability of 
Baicalin, the special anatomic structure and efficient protective mechanism of eyes. 
The correlation between the stability of Baicalin and in situ pH-triggered carbopol 
974P used as the gelling agent combined with hydroxypropylmethylcellulose E4M, a 
viscosity enhancing agent was investigated. Confocal scanning light microscopy 
analysis, rheometry, Gamma scintigraphic technique and microdialysis method were 
used for in vitro and in vivo evaluations.  The  rheological  behaviour  showed  a  
significant enhancement in gel strength under physiological conditions and sustained 
release of the drug over an 8h period. The radioactivity of formulation was constantly 
higher than that of the control solution in elimination studies. In addition, the AUC 
and  Cmax values  were  higher  than  those  of  the  control  solutions.  So  in situ pH-
triggered gelling system comprises better ability to keep baicalin stable and retain 
drug release than marketed baicalin eye drops in order to enhance the ocular 
bioavailability. 
Cetin Tas et al155 prepared nasal dosage forms (solution, gel and lyophilized 
powder) of MTC using mucoadhesive polymer carbopol 981. Subsequent to the ex 
vivo experiments performed with sheep model, the morphological appearances of the 
nasal mucosa were analyzed with the light microscopic studies. The release of MTC 
from solution and powder formulations were found higher than gel formulation (p < 
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0.05) with no severe damage on the integrity of nasal mucosa. The dimethyl-b-
cyclodextrin complex used in powder formulations showed enhanced penetration 
effect following ex vivo and in vivo experiments. Comparatively the nasal 
bioavailability of nasal gel formulation was found higher than those of the solution 
and powder thus representing as a promising novel tool for the systemic delivery of 
MTC. 
Amolkumar Kempwade et al156 formulated and evaluated in situ 
thermoreversible intranasal gel of an antimigraine drug rizatriptan benzoate using 
poloxamer 407 and carbopol 934 as thermoreversible and mucoadhesive polymers 
respectively by cold method. Evaluation studies like phase transition temperature, pH, 
mucoadhesive strength, in vitro release, ex vivo permeation efficiency and 
histopathological examinations were performed. The 18 % w/v poloxamer solution 
presented phase transition at physiologic conditions (34–35ೊC). Increased   percentage 
of carbopol 934 from 0.1 to 0.5 % w/v decreased the gelling temperature. 
Mucoadhesive strength of all formulations were within the range. Drug permeation 
studies  indicated that it could be increased by using carbopol 934 above 0.3 % w/v 
concentration and  the histopathological evaluation of nasal mucosa after drug 
permeation study had no evidence of damage. As a result in situ thermoreversible 
mucoadhesive gel of rizatriptan benzoate appeared to be a promising approach to treat 
migraine 
Bandar  Essa  AL  et al157 designed and evaluated zolpidem nanoparticle 
impregnated buccal films by double emulsion solvent evaporation method to prolong 
its duration of action.  Different concentrations of HPMC K100, Eudragit RL 100 and 
carbopol 974P were used.   Characterization studies for the prepared films like 
physicomechanical properties, mucoadhesion, percent hydration, in vitro drug release, 
in vivo and ex vivo permeation. Film  composition influenced in vitro drug release.  In 
vivo studies of zolpidem nanosphere impregnated film exhibited enhanced absorption 
of the drug (p < 0.0001) with a higher peak plasma concentration (52.54 ± 8.22 
ng/mL) and area under the curve from time 0 to Į (236.00 ± 39.51 ng.h/ml) than oral 
administration. The increase in time taken to reach the maximum drug concentration 
59 
(1.5 h) further signifies the potential of these films to be an alternative route for 
effective zolpidem delivery. 
Cynthia Kirkwood et al158 reported zolpidem modified-release (MR) as the 
first hypnotic agent to be marketed in an extended-release formulation indicated for 
the management of induction of sleep and sleep maintenance. Drug had similar 
pharmacokinetics in comparison to   immediate-release zolpidem. Two double-blind, 
placebo-controlled, parallel-group trials confirmed efficiency in adults and elderly 
patients treated with zolpidem MR for 3 weeks without significant impairment in next 
day psychomotor functioning. The most frequent adverse effects with zolpidem MR 
were dizziness, somnolence and headache. An initial dose of zolpidem MR 12.5 mg is 
suggested for adults and 6.25 mg for elderly patients. 
David N et al159 developed NeubauerZolpiMist oral spray of zolpidem 
approved by the US FDA in 2008 with an indication for the short  term treatment of 
insomnia categorized by difficulty with sleep initiation. NovaDel Pharma developed it 
using their patented NovaMist spray technology. The recommended doses were 10 
mg for adults and 5 mg for elderly and debilitated patients to be taken once daily 
immediately before bedtime. Each metered spray contains 5 mg of zolpidem. 
Compared to zolpidem immediate-release tablets ZolpiMist was approved to possess 
pre-existing efficacy and safety data. Bioequivalence and pharmacokinetic 
characteristics were demonstrated in clinical studies with healthy adult and elderly 
subjects which paved way for investigation of ZolpiMist for use during middle of the 
night awakenings of the patient.  
Monica Rao et al160 aimed to increase bioavailability of ropinirole and avoid 
patient discomfort by formulating thermoreversible in situ nasal gel. 
Thermoreversible nasal gels were prepared by cold method using Pluronic F 127 and 
Hydroxy methyl propyl cellulose as gelling agents. On evaluation formulations 
displayed gelation at nasal temperature and the gelation time was found to be less than 
mucociliary clearance time. Increased mucoadhesion and gel strength enhanced nasal 
residence time. The nasal gel formulations showed ex vivo drug release between 56-
100% in 5h. Histological study of sheep nasal mucosa revealed that the gel had a 
protective effect on the mucosa unlike plain ropinirole which shows evidence of 
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moderate cellular damage. A 5-fold increase in bioavailability in brain was observed 
on  nasal  administration  as  compared  to  IV  route   which  proves  thermoreversible  in 
situ nasal gel as a promising drug delivery for Parkinsonian patients. 
Nirmal H B et al161 explored that controlled and sustained drug delivery has 
become the standard in modern pharmaceutical design for achieving much better drug 
product effectiveness, reliability and safety. Especially the advantages shown by in 
situ forming polymeric delivery systems like ease of administration, reduced 
frequency of administration, improved patient compliance and comfort enlightens its 
use. The development of gels depends on factors like temperature modulation, pH 
change, presence of ions and ultra violet irradiation, from which the drug gets 
released in a sustained and controlled manner. A variety of biodegradable polymers 
are used for the formulation of in situ gels which include gellan gum, alginic acid, 
xyloglucan, pectin, chitosan, poly(DLlactic acid), poly(DL-lactide-co-glycolide) and 
poly-caprolactone. Generally in situ gels  are  administered  by  oral,  ocular,  nasal,  
rectal, vaginal, injectable and intraperitoneal routes. The production of such devices is 
less complex and thus lowers the investment and is cost effective. 
Parmar Viram et al162 attempted to protect metoclopramide hydrochloride 
from first-pass metabolism following oral administration by formulating nasal 
mucoadhesive in situ gels with gellan gum. In situ nasal gels (10% w/w) with gellan 
gum at a concentration of 0.2%, 0.4%, 0.6% and 0.8%w/v , Xanthan gum at 0.1%, 
0.15% and 0.2% w/v as bioadhesive polymer and benzalkonium chloride (0.01%) as 
preservative were prepared. Accelerated stability study was done for the formulation 
with 0.6% gellan gum and 0.15% Xanthan gum. Increasing gum concentration was 
accompanied by slower release rate during the first h with diffusion model release 
kinetics. Microscopic results revealed no mucosal changes after diffusion study of the 
optimized formulation. Mucoadhesive strength of the in situ gels retained in nasal 
mucosal tissue for prolonged time were in the order of 0.8% w/v > 0.6% > 0.4% 
>0.2% of gellan gum. The 0.6 % in situ gel remained stable liquid for 6 months 
without any turbidity or gelation. Therefore this gel combines the advantage of a 
solution and its administration convenience with favourable residence time and 
sustained release and hence expected improved drug absorption. 
61 
R Dubey et al163 studied with the objective that a dual acting subcutaneous 
formulation could provide immediate release of a triptan and slow but sustained 
release of a non steroidal anti-inflammatory drug may afford a longer duration of 
relief. For this purpose an oil-in-water microemulsions of zolmitriptan and diclofenac 
acid using labrafac lipophile, tween 80, capryol 90 and water were prepared. In vitro 
characterization was found to have uniformly dispersed nanosized globules. The 
formulation provided differential release of zolmitriptan and diclofenac acid both in 
vitro as well as in vivo to facilitate beneficial effects to migraine patients. 
Riten A Shah et al164 prepared pH-induced nasal in situ gel of sodium 
cromoglycate for sustained release and improved bioavailability using carbopol 940 
as a key ingredient at various concentrations and different grades of hydroxyl propyl 
methyl cellulose (HPMC K100, HPMC K4M, HPMC K15M). Effect of varying the 
concentration of carbopol 940 (X1) and different grades of HPMC (X2) on the 
dependent variable i.e. viscosity, mucoadhesive strength, cumulative percentage drug 
released in 1 h (Q1), 4 h (Q4) and 8 h (Q8) was checked using a 32 factoria design. 
Kinetics of drug release was ascertained by fitting in vitro release data to various 
models. Regression analysis and analysis of variance were performed for dependent 
variables. Formulation F6 was considered optimum which contained carbopol 940 
(0.75%) and HPMC K4M (0.50%) and was more similar to the theoretical predicted 
dissolution profile (f2=70.99). Hence, the formulation was found to be effective in 
providing in vitro release, in vitro permeation of drug and mucoadhesion for increased 
residence time of drug. 
Upendra C Galgatte et al165 formulated thermoreversible nasal gels of 
sumatriptan succinate for improving bioavailability and patient compliance. Gelation 
and gel melting temperatures under the influence of poloxamer 407 (thermoreversible 
polymer), sorbitol (osmotic agent), carbopol 934 P (mucoadhesive agent), 
benzalkonium chloride (preservative) was observed. Aqueous gels containing 
poloxamer 407 (16, 18, 20, 22 and 24% w/w) were prepared. Gelation temperature 
decreases with increase in poloxamer 407 concentrations while gel melting TೊC 
increased. Sorbitol was significant in decreasing gel melting temperature. Carbopol 
934 P and sodium chloride was shown to decrease both gelation and gel melting TೊC 
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with increase in their concentrations. Benzalkonium chloride had no effects on the 
formulations. However considerable thermodynamic effects of additives on 
thermoreversible gelation were observed which could be used in formulation 
development of thermoreversible gels. 
Pramod K Kolsure et al166 aimed to develop thermoreversible zolmitriptan 
nasal gel utilizing a mixture of pluronic F-127 (Poloxamer 407) and pluronic F-68 
(Poloxamer 188) to confer temperature sensitive gelation property.  Bioadhesive 
polymers like sodium alginate, sodium carboxymethyl cellulose and polyvinyl 
pyrrolidone (PVP K25) were investigated for the modulation of gel strength and 
bioadhesive force. Addition of the bioadhesive polymers showed increase in gelation 
temperature but reinforced the gel strength and bioadhesive force. Sodium alginate 
had more pronounced effect. Increase in the concentration of bioadhesive polymers 
retarded the release of drug from the pluronic gel while PVP had less effect on drug 
release. Histopathological assessment of sheep nasal mucosa with control and 
optimized formulation showed absence of nasal tissue damage. 
Barbara R Conway et  al167 discussed the prospective of various 
pharmaceutical dosage forms which can be used for local or systemic drug 
administration. Intranasal administration of drugs offers fascinating substitute for 
achieving systemic therapeutic effects of drugs that are comparable to parenteral route 
due to inconvenience or oral administration, which results in low drug   
bioavailability. As a result, it is essential to realize the potential and restrictions of a 
variety of nasal drug delivery systems to attain specific therapeutic objectives.  
Nutankumari  et al168 reviewed the uses, disadvantages, drawbacks, methods 
of nasal drug absorption. Various biological, physicochemical and pharmaceutical 
factors affecting nasal absorption, bioavailability barriers and strategies to improve 
nasal absorption of drugs were discussed. Evidence for the innovative developments 
in nasal dosage form design, evaluation parameters and applications of nasal drug 
delivery systems were collectively counter filed. 
Arun Kumar Singh et al169 explored  nasal route as a substitute route for the 
management of vaccines and biomolecules like proteins, peptides and non-peptide 
drugs that are susceptible to enzymatic or acidic degradation and first-pass hepatic 
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metabolism. Anatomical, histological and physiological overview of nose, absorption 
enhancers, barriers to nasal drug delivery, physicochemical, biological and 
formulation related factors affecting nasal drug delivery system along with its 
advantages were reviewed. In addition research approaches on brain targeting through 
nasal cavity are highlighted. 
Ramesh R Putheti et  al170 reviewed about nasal drug delivery in the 
pharmaceutical and biotech industries at present and suggestions for the future.  
Intranasal drug deliveries are nowadays acquiring interest for administration of a 
extensive range of pharmaceuticals. Pharmaceutical industries look nasal drug 
delivery as a viable alternative to traditional routes of administration for systemic 
drugs owing to high permeability of the nasal epithelium, allowing absorption of high 
molecular weight drugs at approximately 1000 Da with plasma drug profiles 
approximately indistinguishable to those from intravenous injections.   
 
Satish Balakrishna Bhise et  al171 discussed in relation to the various 
bioavailability barriers in nasal drug delivery and the strategies to improve the 
bioavailability of nasal dosage forms. 
 Norbert Verbeke et  al172 demonstrated the milieu of nasal mucoadhesive 
drug delivery with unique references to nasal mucoadhesive polymers. These 
polymers are capable to provide increased effects of both absorption enhancement and 
drug retention time in the nasal cavity. Delivery of small organic molecules, 
antibiotics, proteins, vaccines and DNA using nasal mucoadhesives were discussed 
together with the novel types of functionalized mucoadhesive polymers, their 
categorization and wellbeing as nasal drug products. 
SelcanTurker et al173 deliberated the significance and advantages of the drug 
delivery systems applied via the nasal route, which have bioadhesive properties. 
bioavailability and residence time of the drugs that are administered via the nasal 
route which can be increased by bioadhesive drug delivery systems. 
David S Millson et  al174 discussed regarding the migraine pharmacotherapy 
with oral triptans a approach to clinical management.  
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Dirk Deleu et  al175 studied the action of 5-hydroxytryptamine (5-HT1B/1D) 
agonists called triptans on receptors located in meningeal arteries (5-HT1B) and 
trigeminovascular fiber endings(5-HT1D) has an inhibitory effect on this neurogenic 
inflammation. Recently, a series of second-generation 5-HT1B/1D agonists 
(almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, and sumatriptan) have 
been developed. The in vitro pharmacological properties, pharmacokinetics, clinical 
efficacy,  drug  interactions,  and  adverse  effects  of  triptans  were  evaluated  and  
compared to the golden standard, sumatriptan in the treatment of acute migraine. 
Zeinab  M  A et al176 prepared, characterized and evaluated in situ gel 
formulations based on a blend of two hydrophilic polymers like poloxamer 407 
(P407) and poloxamer 188 (P188). Gels that comprised P407 and P188 exhibited a 
pseudo plastic behavior at different concentrations. 
Joana Sousa et al177 studied the pharmacokinetic parameters of ciprofloxacin 
following intranasal and intravenous administrations to rats in plasma, olfactory bulb 
and  nasal  mucosa  of  two  different  nasal  regions.  For  intranasal  administration  a  
thermoreversible in situ gel was used to increase drug residence time in nasal cavity. 
Ciprofloxacin concentration time-profile in nasal mucosa of the studied anterior 
region was markedly higher after intranasal administration (0.24 mg/kg) than that 
following intravenous administration (10 mg/kg), while in nasal mucosa of the more 
posterior region ciprofloxacin concentrations were found to be higher after intranasal 
administration when the different dose administered by both routes is taken into 
account. 
Jian Zhou et  al178 studied the dissipative particle dynamics (DPD) 
simulations by performing self-assembled microstructures and doxorubicin (DOX) 
loading or release properties of pH-sensitive amphiphilic triblock copolymer, poly(İ-
caprolactone)-b-poly (diethylaminoethyl methacrylate) -b-poly (sulfobetaine 
methacrylate)or poly (ethylene glycol methacrylate) (PCL-PDEAPSBMA/PEGMA). 
Our results show that both copolymers can self-assemble into core-shell-corona 
micelles in aqueous environment. pH responsive drug release property, owing to the 
protonation of the PDEA block. The drug release process follows a “swelling-
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demicellization-release” mode. The multi-scale simulations demonstrate an avenue to 
the optimal design of nanomaterials for drug delivery with desired properties. 
Nasal drug delivery has attracted much attention as a promising alternative 
administration  route.  Zolpidem  tartrate  is  used  for  the  short-term  treatment  of  
insomnia.  The drug is rapidly absorbed from gastro intestinal tract but it is subjected 
to first pass metabolism. Previously nasal in situ gel was prepared using carbopol 934 
as gelling agent and HPMC K4M as sustained release polymer which showed 
controlled and sustained drug release pattern. 
The literature survey reveals that nasal in situ gel is beneficial for drugs that 
are poorly bioavailable following oral administration and seems alternative to 
conventional oral dosage forms. Based on the above consideration, the present study 
was directed towards the significance of simultaneous delivery of Zolpidem tartrate 
and Zolmitriptan through nasal in situ gel.  
Sustained-release formulations of the drug also were administered nasally and 
resulted in low initial but prolonged blood levels. The bioavailability of the sustained-
release formulation was identical to that of the intravenous administration. 
The triptans are reported to be effective in 50 to 90% of patients with 
moderate to severe migraine attacks and they are indicated as a first-line agent or as 
an alternative in patients who have not responded to or who are intolerant of simple 
analgesics or NSAIDs. Current treatment option for treatment of migraine includes 
the use of Sumatriptan, Zolmitriptan, Rizatriptan, Elitriptan, etc. Insomnia associated 
migraine are normally treated with short acting hypnotic such as Zolpidem, Zaleplon, 
Ramelteon etc. Recently insomnia associated migraine is treated by the administration 
of specific drugs in different dosage forms such as tablets, nasal drops, sprays, 
microemulsions, nanosuspensions etc. Clinically, Zolpidem tartrate and Zolmitriptan 
are administered as separate dosage form for insomnia and migraine respectively. 
Patient compliance is one of the important factors that influence the 
therapeutic outcome of the administered drug. It is believed that current strategy of 
treatment for insomnia associated migraine includes drugs individually administered 
which attract poor patient compliance owing to their poor therapeutic outcome. 
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Therefore it was considered that simultaneous administration of Zolpidem tartrate and 
Zolmitriptan as a single dosage form may help overcome the aforesaid disadvantages 
and ensure improved bioavailability with better therapeutic effects. 
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4. SCOPE AND PLAN OF WORK 
The scope of the present work is to formulate nasal in situ gel for the 
simultaneous delivery of both zolpidem tartrate and zolmitriptan as a combination. 
The novel drug delivery system may be used to reduce the dosing frequency along 
with a sustained release. 
The work was intended to design, develop and evaluate thermoreversible and 
pH sensitive mucoadhesive in situ nasal drug delivery system comprising Zolpidem 
tartrate, a short acting hypnotic and Zolmitriptan, an antimigraine agent for the 
treatment of insomnia associated migraine. The suitable drug delivery system may be 
identified by optimization of various variables used in the formulation. 
Specifically the plan of work is as follows 
1. To  formulate  a  fixed  dose  combination  of  Zolpidem  tartrate,  short  acting  
hypnotic and Zolmitriptan, an antimigraine agent. 
2. Preformulation studies 
x Differential Scanning Calorimetry  
x Fourier Transform –IR spectrophotometry 
3. Development of analytical method for quantitative estimation of drugs 
4. Formulation of Zolmitriptan thermoreversible mucoadhesive nasal in situ gel  
5. Evaluation of Zolmitriptan thermoreversible mucoadhesive nasal in situ gel  
x Gelation temperature 
x pH of the nasal in situ gel 
x Gel strength  
x In vitro release 
x Statistical analysis 
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6. Formulation of Zolpidem tartrate pH responsive mucoadhesive nasal in situ 
gel 
7. Evaluation of Zolpidem tartrate pH responsive mucoadhesive nasal in situ gel 
x Gelation temperature 
x pH of the nasal in situ gel 
x Gel strength  
x In vitro release  
x Statistical analysis 
8. Formulation of dual acting mucoadhesive nasal in situ gel containing 
Zolpidem tartrate and Zolmitriptan using Design of experiments (Response 
surface methodology) 
9. Evaluation of dual acting mucoadhesive nasal in situ gel containing Zolpidem 
tartrate and Zolmitriptan 
x Gelation temperature 
x pH of the nasal in situ gel 
x Gel strength  
x In vitro release  
x Statistical analysis using Stat Ease DoE Tool 
x Stability studies on optimized formulation 
10. Ex vivo study for the nasal ciliary toxicity in rats. 
11. In vivo antimigraine activity in rats. 
12. In vivo hypnosis activity in mice. 
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5. DRUG PROFILE 
5.1. Zolpidem Tartrate 179 
Zolpidem is a prescription short-acting nonbenzodiazepine hypnotic that 
potentiates gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, by 
binding to benzodiazepine receptors which are located on the gamma-aminobutyric 
acid receptors. 
Chemical Formula: C19H21N3O 
IUPAC name 
Chemically, Zolpidem is N,N,6-trimethyl-2-p-tolylimidazo[1,2-a] pyridine-3-
acetamide L-(+)-tartrate (2:1) 
Chemical Structure 
 
 
Categories  
Benzodiazepine Related Drugs 
Hypnotics and Sedatives 
Central Nervous System Agents 
Neurotransmitter Agents 
Molecular weight: 764.88 
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Physical Properties 
State –Solid 
Colour: White to off-white crystalline powder 
Melting point: 196°C 
Water solubility: 23 mg/mL 
Mechanism of action 
Zolpidem modulates the alpha-subunit, known as the benzodiazepine receptor, 
within  the  GABAA receptor chloride channel macromolecular complex. Unlike the 
benzodiazepines, which non-selectively interact with all three alpha-receptor 
subtypes, Zolpidem preferentially binds to the alpha-1 receptor. 
Absorption: Zolpidem is rapidly absorbed from the GI tract. 
Protein binding: 92.5 ± 0.1% (independent of concentration between 40 and 790 
ng/ml) 
Metabolism: Zolpidem is converted to inactive metabolites that are eliminated 
primarily by renal excretion 
t max: 4 hr 
t 1/2 : 2-3 hr 
Indication: Zolpidem is indicated for the short-term treatment of insomnia 
characterized by difficulties with sleep 
Dosage:  Recommended initial dose is a single dose of 5 mg for women and a single 
dose of 5 to 10 mg for men, immediately before bedtime with at least 7-8 h remaining 
before the planned time of awakening  
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Adverse drug reaction 
x Night eating syndrome (sleep eating) 
x Headaches 
x Nausea 
x Vomiting 
x Dizziness 
Contraindication/precaution 
x Pregnancy category 
x Gastro esophageal reflex disease (GERD). 
USFDA approval date: December 1992 
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5.2. Zolmitriptan 180  
Zolmitriptan is a synthetic tryptamine derivative and appears as a white 
powder that is readily soluble in water 
Chemical Formula: C16H21N3O2 
IUPAC name 
(4S)-4-({3-[2-(dimethylamino) ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-
2-one 
Chemical Structure 
 
 
Categories  
Cytochrome P-450 CYP1A2 Substrates 
Selective Serotonin (5Ht1) Agonists 
Serotonin 5-HT1 Receptor Agonists 
Triptans 
Molecular weight: 287.36 
Physical Properties 
State –Solid 
Colour: White to almost white powder that is readily soluble in water  
Melting point: 136°C-141°C 
Water solubility – readily soluble in water  
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Mechanism of action 
Zolmitriptan binds to human 5-HT1B and 5-HT1D receptors causing cranial 
blood vessel constriction. Different theories explaining the etiology of migraine 
headache suggest that symptoms are caused by local cranial vasodilatation and release 
of sensory neuropeptides through nerve endings in the trigeminal system. Activity of 
zolmitriptan in treating migraine headache can be attributed to the agonist effects at 
the  5HT1B/1D  receptors  on  intracranial  blood  vessels  and  sensory  nerves  of  the  
trigeminal system resulting in cranial vessel constriction and inhibition of pro-
inflammatory neuropeptide release.  
Absorption: Mean absolute oral bioavailability is approximately 40%. Food has no 
affect on the rate and extent of absorption.  
Protein binding: 25 %  
Metabolism : Hepatic. There have been three metabolites identified: indole acetic 
acid, N -oxide, and N-desmethyl metabolites. However, the N-desmethyl is the only 
active metabolite. 
t max : 4 hr 
t1/2: The mean elimination half-life of zolmitriptan and of the active N-desmethyl 
metabolite is 3 h.  
Indication: Zolmitriptan is indicated for the acute treatment of migraine with or 
without aura in adults. 
Dosage:  The recommended starting dose of Zolmitriptan is 1.25 mg or 2.5 mg. The 
maximum recommended single dose of Zolmitriptan is 5 mg. 
Adverse drug reaction 
x Myocardial Ischemia, Myocardial Infarction, and Prinzmetal Angina  
x Arrthymias  
x Chest and or Throat, Neck and Jaw Pain/Tightness/Pressure  
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x Cerebrovascular Events  
x Other Vasospasm Reactions  
x Medication Overuse Headache  
x Serotonin Syndrome  
x Increase in Blood Pressure  
x Risks in Patients with Phenylketonuria 
Contraindication/precaution 
x History of coronary artery disease (CAD) or coronary vasospasm  
x History of stroke, transient ischemic attack, or hemiplegic or basilar migraine 
x Symptomatic Wolff-Parkinson-White syndrome 
x Cardiac accessory conduction pathway disorders  
USFDA approval date: November 1997 
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6. EXCIPIENT PROFILE 
6.1. Carbomer181 
Carbomers are pharmaceutical excipients that vary in their molecular weight, 
degree of crosslinking, polymer structure and residual components. No 
hypersensitivity reactions are reported in humans when carbomers are used topically. 
In humans, carbomer have been used in oral doses up to 3g as a bulk laxative. 
Carbomers are generally regarded as nontoxic and nonirritant materials. Different 
grades of Carbomers are commercially manufactured. Carbomers are listed in the 
USFDA inactive ingredients list. 
Synonym : Acrylic acid polymer, carboxy polymethylene, polyacrylic 
acid, carboxyvinyl polymer. 
Category : Carbomer polymers are formed from repeating monomer units 
of acrylic acid. The polymer chains are crosslinked with allyl 
sucrose or allyl pentaerythritol. 
Structure: 
 
Functional 
category : 
Bioadhesive, emulsifying agent, release-modifying agent, 
suspending agent, tablet binder, viscosity-increasing agent. 
Application : Carbomers finds application in liquid and semisolid 
pharmaceutical formulations as suspending and viscosity-
increasing agents. Various formulations including creams, gels, 
and ointments for use in ophthalmic, rectal and topical 
preparations use carbomers as the component. Oil-in-water 
emulsions are manufactured using Carbomers as emulsifying 
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agents. Emulsion microspheres were prepared using Carbomer 
as a viscosity-increasing agent. 
Description : White colored, ‘fluffy’, acidic, hygroscopic powder. 
Carbomers have a slight characteristic odour. 
Solubility: Carbomers are soluble in water and after neutralization, in 
ethanol (95%) and glycerin. Carbomers are 3-dimensional 
crosslinked microgels that do not dissolve but swell in water. 
Viscosity : Low viscosity acidic colloidal dispersions are formed when 
carbomers are dispersed in water, on neutralizing they form 
high viscosity gels.   
Carbomer 910 (1.0% w/v) – 3000-7000mPas 
Carbomer 940 (0.5% w/v) – 40,000– 60,000mPas 
pH : 2.7-3.5 for a 0.5% w/v aqueous dispersion. 
2.5-3.0 for a 1% w/v aqueous dispersion. 
Melting point : 2600C 
Glass transition 
temperature :  
100 - 105°C 
Loss on drying :  2.0% 
Incompatibility: Incompatible with phenol, cationic polymers, strong acids and 
high concentrations of electrolytes. 
Stability and 
storage condition : 
Stable, hygroscopic material.  It is recommended to store 
carbomers in an airtight, corrosion resistant container in a cool, 
dry place. 
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 6.2. Hydroxy Propyl Methyl Cellulose: (HPMC K4M) 182 
Hypromellose is widely used in oral and topical pharmaceutical formulations 
and they vary in viscosity and extent of substitution. Hypromellose is manufactured 
from cellulose and it contains methoxy and hydroxylpropoxy groups conforming to 
the limits for the types of hypromellose.  Hypromellose are listed in GRAS, USFDA 
inactive ingredients Guide, Canadian List of Acceptable Non-medicinal Ingredients. 
Synonym  : hydroxypropyl methylcellulose, methylcellulose propylene 
glycol ether, methyl hydroxypropylcellulose. 
Category  : Hypromellose is O-methylated and O-(2-hydroxy 
propylated) cellulose. Grades vary in viscosity and extent 
of substitution. Grades are distinguished by difference in 
apparent viscosity, in mPas, of a 2% w/w aqueous solution 
at 20°C. 
Structure: 
 
Functional category : Coating agent, viscosity-increasing agent, film-former,  
stabilizing agent, tablet binder, rate-controlling polymer 
for sustained release, suspending agent.  
Application  : Pharmaceutical formulations use Hypromellose in oral, 
ophthalmic and topical pharmaceutical formulations. 
Based on the viscosity grade, different concentrations are 
used to film-coat tablets. Lower viscosity grades are used 
in aqueous film-coating solutions. Higher-viscosity grades 
are used with organic solvents. Hypromellose is used as a 
suspending and thickening agent in topical pharmaceutical 
formulations. 
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Description : Hydroxy propyl methyl cellulose is an odourless and 
tasteless, white to creamy white granular or fibrous 
powder. 
Solubility : Hypromellose forms a viscous colloidal solution when 
dissolved in cold water, It is practically insoluble in 
chloroform, ethanol (95%), and ether, but soluble in 
mixtures of methanol and dichloromethane, mixtures of 
ethanol and dichloromethane, and mixtures of water and 
alcohol. Various grades of hypromellose are soluble in 
aqueous acetone solutions, mixtures of dichloromethane 
and propan-2-ol, and other organic solvents. 
Viscosity  : Different viscosity types are commercially available. 
Based on th grades of Hypromellose used the viscosity 
varies from 3 -100000 mPaS. 
pH  : pH varies in the range from 5.0 - 8.0 
for a 1% w/v aqueous dispersion. 
Melting point : Hypromellose becomes brown at 190°C –200°C and chars 
at 225°C –230°C  
Glass transition 
temperature :  
170°C -180°C 
Loss on drying  :  10.0% 
Incompatibility : Hypromellose does not complex with metallic salts or 
ionic organic substances to form insoluble precipitates as 
it is non-ionic. Hypromellose is incompatible with 
oxidizing agents. 
Stability and storage 
condition: 
Stable, hygroscopic material.  It is recommended to store 
hypromellose in an airtight well closed container in a cool, 
dry place. Hypromellose solutions are stable across the pH 
range from 3-11. 
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6.3. Poloxamer183  
The poloxamer polyols are a chain of closely related block copolymers of 
ethylene oxide and propylene oxide and have the chemical structural formula           
HO(C2H4O)a(C3H6O)b(C2H4O)aH. The physical and surface-active properties of 
poloxamer vary over a wide range and a number of grades are commercially 
available. 
Synonym  : Ethylene–propylene glycol co-polymer; polyoxyethylene–
polyoxypropylene co-polymer. 
Category  : Poloxamer are water non ionic tri-block copolymer 
consisting of two polyethylene oxide and polypropylene 
oxide core in an ABA configuration. 
Structure: 
 
Functional category : Dispersing agent, lubricant, wetting agent, emulsifying and 
co-emulsifying agent, solubilizing agent etc. 
Application : Poloxamer commercially known as pluronic has good 
thermal setting property and increased drug residence time. 
It is used as gelling agent, and solubilizing agent. Poloxamer 
gives colorless, transparent gel. Depending upon the ratio 
and distribution of hydrophilic and hydrophobic chain 
several molecular weights available, having different gelling 
property. 
Description : Poloxamers occur as white, waxy, free-flowing granules or 
as cast solids. They are practically odorless and tasteless. 
80 
Solubility : Freely soluble in water at 20°C. 
Viscosity  : 1000 mPas. 
pH  : pH varies in the range from 5.0 – 7.5 for aqueous dispersion. 
Melting point: 16°C for poloxamer 124 
52–57°C for poloxamer 188 
49°C for poloxamer 237 
57°C for poloxamer 338 
52–57°C for poloxamer 407 
Moisture content : Less than 0.5 % 
Incompatibility : Poloxamer 188 is incompatible with phenols and parabens. 
Stability and storage 
condition : 
Poloxamers are stable materials. Aqueous solutions are 
stable in the presence of acids, alkalis and metal ions. 
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6.4. Polyethylene glycol184 
Polyethylene glycols are pharmaceutical excipients that are stable, hydrophilic 
substances and are nonirritant to the skin. Polyethylene glycols are water-soluble and 
are easily removed from the skin. Solid grades are used as ointment bases either alone 
or in combination with liquid grades of polyethylene glycol.   
Synonym   : Carbowax, macrogol, PEG, polyoxyethylene glycol. 
Category   : Ointment base, plasticizer, solvent, suppository base, 
tablet and capsule lubricant. 
Structure  : 
 
Functional category  : Ointment base, suppository base, solvent, plasticizer, 
lubricant etc. 
Application : Polyethylene glycols (PEGs) are widely used in a variety 
of pharmaceutical formulations, including parenteral, 
topical, ophthalmic, oral and rectal preparations. 
Polyethylene glycol has been used experimentally in 
biodegradable polymeric matrices used in controlled-
release systems. 
Description : Polyethylene glycol is an addition polymer of ethylene 
oxide and water. Polyethylene glycol grades 200–600 are 
liquids. Grades above 1000 are solids at ambient 
temperatures. 
Solubility   : Available grades of polyethylene glycol are water soluble 
and miscible with other polyethylene glycols. 
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Viscosity  : 15-20 mPas 
pH  : 4.0-70 
Freezing point  : 15–25°C for PEG 600. 
Flash point : 250°C for PEG 600.  
Incompatibility : PEG exhibits oxidizing activity due to the presence of 
peroxide impurities and secondary products resulting from 
autoxidation. Liquid and solid polyethylene glycol grades 
shows incompatibility with some coloring agents. 
Stability and storage 
condition: 
Polyethylene glycols grades with a molecular weight less 
than 2000 are hygroscopic but do not support microbial 
growth. PEG does not become rancid and are chemically 
stable in solution and in air. 
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6.5. Benzolkonium chloride185 
Structure: 
 
Synonym: Alkylbenzyldimethylammonium chloride; alkyl dimethyl 
benzyl ammonium chloride; Hyamine 3500 
Chemical name: Alkyldimethyl (phenylmethyl) ammonium chloride. 
Description: It  occurs  as  a  white  or  yellowish  white  amorphous  
powder, a thick gel or gelatinous flakes. It is hygroscopic, 
soapy to the touch and has a mild aromatic odour and 
very bitter taste. 
Functional category: Preservative, antiseptic, disinfectant, solubilizing agent 
and wetting agent. 
Solubility: Practically insoluble in ether, very soluble in acetone, 
ethanol (95%), methanol, propanol and water.  
Density: 0.98 g/cm3 at 200C. 
pH: 5 – 8 for a 10% w/v aqueous solution. 
Melting point 400C 
Application: Used as preservative, in ophthalmic preparation at a 
concentration of 0.01–0.02% w/v and in nasal 
formulations at a concentration of 0.002 – 0.02% w/v. 
Incompatibility: Incompatible with aluminum, anionic surfactants, 
citrates, hydrogen peroxide, kaolin, permanganates, 
protein, zinc oxide, zinc sulphate and iodides. 
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Stability and storage 
condition: 
It is hygroscopic and may be affected by light, air and 
metals. 
The bulk material should be stored in an airtight 
container in a cool dry place. It should be protected from 
light and from contact with metals. 
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7. MATERIALS AND EQUIPMENTS 
7.1 Materials used 
The materials used for the preparation of nasal in situ gel are detailed below 
Table 1. List of chemicals used in development 
S.No. Material Source 
1 Zolpidem tartrate Micro labs, Chennai 
2 Zolmitriptan Hetero drugs, India 
3 Poloxamer  BASF, Germany 
4 Poly Ethylene Glycol BASF, Germany 
5 Sorbitol Roquette, Mumbai 
6 Carbopol  Lubrizol, Mumbai 
7 Benzalkonium chloride NovoNordisk Pharmatech, India 
8 Phenyl ethyl alcohol Harmony organics, India 
9 Sodium chloride Merck labs science private Ltd, Mumbai 
10 Disodium hydrogen phosphate Merck labs science private Ltd, Mumbai 
11 Potassium dihydrogen 
phosphate 
Merck labs science private Ltd, Mumbai 
12 Hypromellose Colorcon India Ltd, India 
13 Nitroglycerin Qualigens Fine chemicals, India 
14 Sodium Pentobarbital Qualigens Fine chemicals, India 
15 Glutaraldehyde Qualigens Fine chemicals, India 
 
 
86 
7.2  Equipments used 
The equipments used for the preparation and evaluation of nasal in situ gel are 
given below 
Table 2. List of equipments used in development 
S.No. Instuments / Equipments Source / Supplier 
1 Magnetic stirrer Remi instruments,  Mumbai 
2 Ultraprobe sonicator Electrosonic Industries, Mumbai 
3 Ultra centrifuge Remi instruments, Mumbai 
4 FT-IR spectophotometer Shimadzu, Tokyo 
5 Differential Scanning 
calorimeter 
DSC 60 Shimadzu, Mumbai 
6 Electronic weighing balance Sartorious, Germany 
7 Melting point apparatus Campbell Electronics, Mumbai 
8 UV- VIS spectrophotometer UV-1800 Shimadzu, Mumbai 
9 Design expert® software Stat-Ease, Inc., Minneapolis, MN, USA 
10 pH meter Digisun Electronics DI-707. Hyderabad 
11 Scanning electron microscope Carl Zeiss EVO-18, India 
12 Gel strength apparatus Gel strength tester, India 
13 Franz Diffusion cell Orchid scientific, India 
14 Stability chamber Thermolab Scientific Equipments Pvt. Ltd., 
Mumbai 
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8. METHODS 
8.1. Development of analytical method for quantitative estimation of drugs 
 A simple, sensitive, rapid, precise, cost effective and reproducible UV-Vis 
spectrophotometric method has been developed for estimation of Zolpidem tartrate 
and Zolmitriptan. Selection of media was based on solubility and stability of drugs. 
Phosphate buffer pH 6.4 was selected as analytical media for the study.  
8.1.1. Solubility  
The solubility of Zolpidem tartrate and Zolmitriptan were determined by 
adding excess amount of drugs to vials containing 4ml of selected vehicle. Sealed 
vials were shaken at room temperature (25°C) on a nutating mixer for 2 h and 
centrifuged at 3000 rpm for 15min to remove undissolved drug. The supernatants 
were separated, filtered through a membrane filter. The amount of dissolved drug in 
each vehicle was quantified using the UV-Visible spectrophotometer at 283 nm and 
294 nm. The samples were diluted to an appropriate concentration prior to analysis 
and the amount of Zolpidem tartrate and Zolmitriptan was quantified using a 
calibration curve. 
8.1.2. Determination of absorption Maxima 
 pH 6.4 phoshate buffer was prepared by dissolving 1.79 g of disodium 
hydrogen phosphate, 1.36 g of potassium dihydrogen phosphate and 7.02 g of sodium 
chloride in water to produce 1000 ml. The Ȝ max of the drugs was determined by 
running the spectrum of the drug solution in UV-Visible Spectrophotometer. The UV 
spectra of the drugs were carried out using freshly prepared 6.4 phosphate buffer 
Accurately weighed quantity of drug was dissolved in pH 6.4 phosphate  buffer. The 
solution was then diluted using the buffer. The diluted solution was kept in the sample 
cell and the UV spectrum was recorded in the wave length range of 200-400 nm in 
UV-Vis spectrophotometer. 
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8.1.3. Linearity and Precision 
The linearity of the analytical procedure is its ability within a given range to obtain 
test results directly proportional to the concentration of the analyte in the sample. The 
precision of an analytical procedure expresses the closeness of agreement between a 
series of measurements obtained from multiple sampling of the same homogeneous 
sample under the prescribed conditions. Specificity is the ability to assess the analyte 
in the presence of components which may be expected to be present. 
Repeatability is the precision of a method under the same operating conditions over a 
short period of time. A homogenous sample was prepared and multiple measurements 
were  performed  using  the  same  conditions.  Co-efficient  of  variation  or  %  RSD  
expresses the precision of a data set. RSD (%) is SD (100)/Average, where SD is the 
standard  deviation,  N  is  the  number  of  measurements.  Intra  assay  precision  was  
performed at five concentration levels. Each sample was analysed in triplicate and % 
RSD were calculated. 
8.1.4. Solution stability of Zolpidem tartrate and Zolmitriptan in pH 6.4 
phosphate buffer. 
Phoshate buffer pH 6.4 was prepared by dissolving 1.79 g of disodium hydrogen 
phosphate, 1.36 g of potassium dihydrogen phosphate and 7.02 g of sodium chloride 
in water to produce 1000 ml. Zolpidem tartrate and Zolmitriptan were added at a 
concentration of 8 µg and 20 µg to the phosphate buffer and incubated at 37 °C for up 
to 24 h. The absorbances of drugs were determined at predetermined time intervals (1, 
2, 4, 8, 12 and 24 h) by analysis using UV-Vis spectrophotometer. 
8.1.5. Standard curve of Zolpidem tartrate and Zolmitriptan 
 Standard solution of drugs (1000ȝg/ml) were prepared by dissolving 100 mg 
of pure drugs in 100 ml volumetric flask and adjusted the volume up to 100 ml using 
phosphate buffer pH 6.4. From the solution 10 ml was taken and adjusted the volume 
up to 100 ml using phosphate buffer pH 6.4 (100ȝg/ml). Aliquots of 2 to 20 ml 
portions of the standard solution were transferred to a series of calibrated 50 ml 
volumetric flasks and volume were adjusted with phosphate buffer pH 6.4 to give 
concentrations of 4, 8, 16, 24 and 32 µg/ml. Solutions were scanned in the range of 
200-400 nm against blank (phosphate buffer pH 6.4) and the absorbance of solutions 
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was measured and calibration curve was constructed. The absorbances were measured 
at 294 nm and 283 nm for Zolpidem tartrate and Zolmitriptan respectively against a 
blank medium in UV-Visible spectrophotometer. 
8.2. Preformulation Studies 
Preformulation testing is the initial step in the rational development of 
pharmaceutical dosage form of a drug substance. It is defined as an investigation of 
physical and chemical properties of a drug substance. The overall objective of 
preformulation study is to generate information useful to the formulation in 
developing stable, safe and bioavailable dosage forms. 
Preformulation studies were carried out to find out the drug-excipient 
interactions and solubility. As part of initial preformulation work, potential thermo 
sensitive, pH responsive and mucoadhesive polymers were screened for suitability as 
vehicles for drug delivery. In this regard polymers like polyethylene glycol, sorbitol 
hydroxyl propyl methyl cellulose, carbomer, poloxamer 407 and poloxamer 188 were 
screened. 
Each excipient used in the formulations was blended thoroughly with 
Zolpidem tartrate and Zolmitriptan to increase drug-excipient molecular contacts to 
accelerate the reactions if possible. Each drug-excipient blend was taken separately 
into the vials and exposed for a period of one month and 2 months study at 40ºC. 
After completion of study drug mixtures blend were tested for stability by physical 
observation and assay. 
8.2.1. Organoleptic Characterization of Zolpidem tartrate and Zolmitriptan 
Description 
The colour and odour of the two drugs Zolpidem tartrate and Zolmitriptan 
were characterized and their descriptions were recorded. 
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8.2.2. Compatibility studies 
8.2.2.1. FT-IR Spectrophotometry 
Infrared absorption spectra of the drugs were recorded with Potassium 
bromide pellets using dispersion technique. In KBr dispersion technique the dry 
sample of the drug and was mixed uniformly and the mixed powder blend was placed 
in sample holder and an IR spectrum were recorded using Shimadzu FT-IR 
spectrometer and scanned in the range of 4000 to 400 cm-1.  The  procedure  was  
repeated for drug along with thermo sensitive and mucoadhesive polymers selected. 
The obtained IR spectrum of Zolpidem tartrate and Zolmitriptan were 
compared with IR spectrum of Zolpidem tartrate and Zolmitriptan standard. 
8.2.2.2. Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry studies for Zolpidem tartrate and 
Zolmitriptan, excipients and combinations of Zolpidem tartrate and Zolmitriptan with 
excipients were carried out using Schimadzu DSC-60. In this study Zolpidem tartrate 
and Zolmitriptan were mixed with the excipients used in the formulation and thermal 
analysis of each sample was carried out. The study was performed in the temperature 
ranges of 25 to 400º C and at a heating rate of 10ºC/min with nitrogen flow rate of 30 
ml/min. The samples approximately each 5 mg were placed separately in aluminium 
pan, sealed and recording of thermogram were performed. 
8.3. Formulation of nasal in situ gel 
8.3.1. Formulation of Zolpidem tartrate pH responsive mucoadhesive nasal in 
situ gel (PISG) 
Zolpidem tartrate pH responsive mucoadhesive nasal in situ gel was prepared 
by dissolving the drug in distilled water placed in a beaker. Zolpidem tartrate was 
added such that each 140 µL of in situ nasal gel contains 2.5 mg of drug.  Carbopol 
934 was added to the Zolpidem tartrate solution with continuous stirring. To this 
solution HPMC K4M (Methocel) a mucoadhesive polymer was added and stirred 
using a magnetic stirrer until the HPMC K4M completely dispersed. Sodium chloride 
was weighed and transferred to the drug solution with constant stirring. Benzalkonim 
chloride was added by continuous stirring. This resulting solution was then allowed to 
hydrate overnight at 50C± 3°C until clear liquid solution was formed.  
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Table 3. Formulation of Zolpidem Tartrate Nasal In situ Gel  
(PISG–01 to PISG – 04) 
S.No. Ingredients (mg) PISG-01 PISG-02 PISG-03 PISG-04 
1 Zolpidem tartrate 2.5 2.5 2.5 2.5 
2 Carbopol 934 0.2 0.4 0.6 0.8 
3 HPMC(Methocel K4 M) 0 0 0 0 
4 Sodium chloride 0.9 0.9 0.9 0.9 
5 Benzalkonium chloride 0.02 0.02 0.02 0.02 
6 Phenyl ethyl alcohol 0.25 0.25 0.25 0.25 
7 Aqueous vehicle 100 100 100 100 
  
Table 4. Formulation of Zolpidem Tartrate Nasal In situ Gel  
(PISG – 05 to PISG – 08) 
 
S.No. Ingredients (mg) PISG-05 PISG-06 PISG-07 PISG-08 
1 Zolpidem tartrate 2.5 2.5 2.5 2.5 
2 Carbopol 934 0.5 0.5 0.5 0.5 
3 HPMC(Methocel K4 M) 0.3 0.5 1.0 1.5 
4 Sodium chloride 0.9 0.9 0.9 0.9 
5 Benzalkonium chloride 0.02 0.02 0.02 0.02 
6 Phenyl ethyl alcohol 0.25 0.25 0.25 0.25 
7 Aqueous vehicle 100 100 100 100 
 
8.3.2. Formulation of Zolmitriptan Thermoreversible Mucoadhesive Nasal In 
situ Gel (TISG)  
Thermoreversible mucoadhesive nasal in situ gel was prepared by dissolving 
Zolmitriptan in distilled water placed in a beaker. Zolmitriptan was added such that 
each 140 µL of in situ nasal gel contains 1.25 mg of drug. PEG 6000 was added to the 
Zolmitriptan solution with continuous stirring. To this solution poloxamer 188 was 
added and stirred until complete dissolution. Further poloxamer 407 was weighed and 
added to the drug solution with constant stirring. Benzalkonim chloride was added by 
continuous stirring. This resulting formulation was then allowed to hydrate overnight 
at 50C± 3°C until clear liquid solution was formed.  
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Table 5. Formulation of Zolmitriptan Nasal In situ Gel (TISG-01 to TISG-04) 
S.No. Ingredients (mg) TISG -01 TISG -02 TISG -03 TISG -04 
1 Zolmitriptan 1.25 1.25 1.25 1.25 
2 Poloxamer 407 14 18 22 24 
3 Poloxamer 188 0 0 0 0 
4 PEG 6000 1 1 1 1 
5 Benzalkonium chloride 0.02 0.02 0.02 0.02 
6 Phenyl ethyl alcohol 0.25 0.25 0.25 0.25 
7 Aqueous vehicle 100 100 100 100 
 
Table 6. Formulation of Zolmitriptan Nasal In situ Gel (TISG-05 to TISG-08) 
S.No. Ingredients (mg) TISG -05 TISG -06 TISG -07 TISG -08 
1 Zolmitriptan 1.25 1.25 1.25 1.25 
2 Poloxamer 407 18 18 18 18 
3 Poloxamer 188 0.25 0.5 1.5 2.0 
4 PEG 6000 1 1 1 1 
5 Benzalkonium chloride 0.02 0.02 0.02 0.02 
6 Phenyl ethyl alcohol 0.25 0.25 0.25 0.25 
7 Aqueous vehicle 100 100 100 100 
 
8.3.3. Formulation of Zolpidem tartrate and Zolmitriptan dual active nasal in 
situ gel (DISG)  
Thermoreversible mucoadhesive nasal in situ gel was prepared by dissolving 
Zolpidem tartrate and Zolmitriptan in distilled water placed in a beaker. Drugs were 
added such that each 140 µL of in situ nasal gel contains 2.5 mg of Zolpidem tartrate 
and 1.25 mg of Zolmitriptan. Sorbitol was added to the drug solution with continuous 
stirring. To this solution carbopol 934, a mucoadhesive polymer was added and stirred 
until it completely dissolved. Further poloxamer 407 was weighed and added to the 
drug solution with constant stirring. Benzalkonim chloride was added by continuous 
stirring. This resulting formulation was then allowed to hydrate overnight at 50C± 3°C 
until clear liquid solution was formed.  
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8.3.3.1. Optimization of Nasal In situ gel using Design of experiments (Stat Ease® 
software) 
The development and optimization of Zolpidem tartrate and Zolmitriptan dual active 
in situ nasal gel (DISG) was done using response surface methodology (RSM). DISG 
was optimized using 3 variables and 5 levels. 20 formulations were generated by 
Design Expert® placing 8 formulations on factorial, 6 on axial and 6 replicates of 
central points.  
A series of experiments were designed and conducted using Design expert 
software (From Stat Ease®) in order to study the relationship of input variables, 
namely poloxamer concentration, carbopol concentration and sorbitol concentration 
on responses like flow index, drug release, pH, mucoadhesive strength, gelation time, 
gel strength and drug content. 
Above 3 input variables have been selected for the study, based on the domain 
knowledge in the field. Considering the complexity of the dosage form it was planned 
to study effect of 5 levels for each variable including centre point, on the above 
mentioned responses, hence response surface methodology has been chosen over 
regular 3 level factorial designs. The experimental data were compared against the 
predicted response and the model was designed and executed as per run order. 
Table 7. Formulation of Zolpidem tartrate and Zolmitriptan Nasal In situ Gel 
(DISG – 01 to DISG – 05) 
S.No. Ingredients (mg) DISG-01 DISG-02 DISG-03 DISG-04 DISG-05 
1 Zolpidem tartrate 2.5 2.5 2.5 2.5 2.5 
2 Zolmitriptan 1.25 1.25 1.25 1.25 1.25 
3 Poloxamer 407 17 17 16 16 18 
4 Carbopol 934 0.62 0.62 1 0.25 1 
5 Sorbitol 1 1.84 1.5 0.5 1.5 
6 Benzalkonium chloride 0.02 0.02 0.02 0.02 0.02 
7 Phenyl ethyl alcohol 0.25 0.25 0.25 0.25 0.25 
8 Aqueous vehicle 100 100 100 100 100 
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Table 8. Formulation of Zolpidem tartrate and Zolmitriptan Nasal In situ Gel 
(DISG-06 to DISG-10) 
S.No. Ingredients (mg) DISG-06 DISG-07 DISG -08 DISG -09 DISG -10 
1 Zolpidem tartrate 2.5 2.5 2.5 2.5 2.5 
2 Zolmitriptan 1.25 1.25 1.25 1.25 1.25 
3 Poloxamer 407 18 18 17 18.6 17 
4 Carbopol 934 1 0.25 0.62 0.62 0.62 
5 Sorbitol 0.5 0.5 1 1 0.15 
6 Benzalkonium chloride 0.02 0.02 0.02 0.02 0.02 
7 Phenyl ethyl alcohol 0.25 0.25 0.25 0.25 0.25 
8 Aqueous vehicle 100 100 100 100 100 
 
Table 9. Formulation of Zolpidem tartrate and Zolmitriptan Nasal In situ Gel 
(DISG-11 to DISG-15) 
S.No. Ingredients (mg) DISG -11 DISG -12 DISG -13 DISG -14 DISG -15 
1 Zolpidem tartrate 2.5 2.5 2.5 2.5 2.5 
2 Zolmitriptan 1.25 1.25 1.25 1.25 1.25 
3 Poloxamer 407 17 17 17 15.3 16 
4 Carbopol 934 0.62 0.62 0.62 0.62 0.25 
5 Sorbitol 1 1 1 1 1.5 
6 Benzalkonium chloride 0.02 0.02 0.02 0.02 0.02 
7 Phenyl ethyl alcohol 0.25 0.25 0.25 0.25 0.25 
8 Aqueous vehicle 100 100 100 100 100 
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Table 10. Formulation of Zolpidem tartrate and Zolmitriptan Nasal In situ Gel 
(DISG-16 to DISG-20) 
S.No. Ingredients (mg) DISG -16 DISG -17 DISG -18 DISG -19 DISG -20 
1 Zolpidem tartrate 2.5 2.5 2.5 2.5 2.5 
2 Zolmitriptan 1.25 1.25 1.25 1.25 1.25 
3 Poloxamer 407 17 18 17 16 17 
4 Carbopol 934 0 0.25 0.625 1 1.25 
5 Sorbitol 1 1.5 1 0.5 1 
6 Benzalkonium chloride 0.02 0.02 0.02 0.02 0.02 
7 Phenyl ethyl alcohol 0.25 0.25 0.25 0.25 0.25 
8 Aqueous vehicle 100 100 100 100 100 
 
8.4. Evaluation of Nasal in situ gel  
8.4.1. Gelation Temperature186 
 Gelation temperature, defined as the temperature at which the liquid phase 
makes the transition to a gel and was determined by using the method described by 
Miller and Donovan technique. A 2 ml aliquot of sample was transferred to a test 
tube, immersed in a water bath. The temperature of water bath was increased slowly 
and left to equilibrate for 5 min at each new setting. The sample was then examined 
for gelation, which was said to have occurred when the meniscus would no longer 
move upon tilting the test tube to 900 angle. 
8.4.2. pH of the nasal in situ gel 
The pH of the nasal in situ gel was determined by using pH meter. 50 ml of 
the formulation was taken in a beaker and the electrodes of the pH meter were 
immersed into the formulation and readings recorded after stabilization. 
8.4.3. Gel strength187 
Gel  strength  is  expressed  in  time  (sec)  required  by  a  35  g  piston  for  
penetration  of  5  cm  distance,  through  the  50g  gel  formulation.  Test  was  performed  
using ‘Gel strength apparatus’ designed in laboratory. Nasal in situ gel (50g) was 
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placed in a 100 ml measuring cylinder and gelation was induced by simulated nasal 
fluid (pH 6.5). The apparatus i.e. piston for measuring gel strength (35g) was then 
placed onto the gel. The gel strength was measured as the time (sec) required for 
moving the apparatus 5cm down through the gel. In cases, that take more than 5min to 
drop the apparatus into the gel, suitable weights were placed on top of the apparatus 
and gel strength was described by the minimal weights that pushed the apparatus 5cm 
down through the gel. 
8.4.4. Mucoadhesive strength study188 
Mucoadhesive force of nasal in situ gel was determined using sheep nasal 
mucosa and phosphate buffer pH 6.4 as the moistening fluid. At the time of testing, a 
section of tissue was secured, keeping the mucosal side out, onto each glass vial using 
a rubber band and aluminium cap. The diameter of each exposed mucosal membrane 
was 1.1cm. On glass vials, tissues were fixed in a manner that the mucosal side 
became outer part and properly fixed. A vial with a section of tissue was connected to 
the modified balance and suitable height was maintained. The gel was applied to the 
exposed tissue of lower vial. The height of the vial was adjusted so that the gel could 
adhere to the mucosal tissues of upper vial. After applying constant weight for several 
min, suitable weights were added to the modified balance. Minimum amount of 
weight that detached two vials expressed as mucoadhesive force (dynes /cm2). 
8.4.5. Scanning Electron Microscopy 
The prepared formulations were subjected to SEM analysis to understand the 
morphological character. The results are provided in results and analysis section.  
8.4.6. In vitro release 
In vitro diffusion studies for the formulations were carried out using Franz 
Diffusion cell having 2.4 cm diameter and 13ml capacity. Dialysis membrane having 
cut off molecular weight 12000–14000 kDa was used as diffusion membrane. Pieces 
of dialysis membrane were soaked in phosphate buffer pH 6.4 for 24 h prior to 
experiment. Diffusion cell was filled with phosphate buffer pH 6.4; dialysis 
membrane was mounted on cell. The temperature was maintained at 37 ± 0.5°C. The 
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donor compartment contained 3 ml of artificial nasal fluid. After an equilibration of 
membrane, formulation equivalent to 1mg of the drug was placed in the donor 
compartment. At predetermined time points (0, 60, 120, 180, 240 and up to 480 min),  
one ml samples were withdrawn from the acceptor compartment, replacing the 
sampled volume with phosphate buffer pH 6.4 after each sampling to maintain a 
constant volume. The samples withdrawn were filtered and used for analysis. The 
amount of diffused drug was determined using UV-Visible spectroscopic method. 
8.4.7. Release Kinetics 
To know the mechanism of drug release from various formulations the data 
were treated using mathematical models like zero order model, first order model, 
Higuchi model and Korsemeyer- Peppas model.  
8.5. Pharmacological and Ciliotoxicity studies 
All experimental procedures were conducted in accordance with the guidelines 
towards the protection of laboratory animals used for scienti¿c research purposes. The 
study was conducted after getting appropriate approval from CPCSEA ethical 
clearance (Ref No.: 1629/po/a/CPCSEA/ncp/IAEC/Ph.D/74/12). Healthy adult male 
Wistar rats (290–340 g) and Albino mice (20-25 g) were used in this study and were 
purchased from a professional store breeder. The animals were housed below 
controlled ecological conditions that are 12 h light/dark cycle, temperature 20 ± 2°C, 
relative  humidity  55  ±  5% for  a  least  of  5  days  before  the  experiments.  During  this  
period, animals had free right of entry to a standard rodent go on a diet and water and 
rats were fasted overnight (12h) prior to drug administration and kept on fast during 
the ¿rst 4 h of the study. 
8.5.1. Anti migraine activity189 
Nitroglycerin induced (NTG) migraine activity was performed by using 
Wister  rats  and  these  rats  were  randomly  divided  into  3  groups,  each  group  with  6  
animals in which Group 1 was chosen as a normal, Group 2 was chosen as control and 
Group 3 was used for Zolpidem tartrate and Zolmitriptan dual active in situ nasal gel 
(DISG-05).  For this study intranasal route of administration was used and rats were 
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anesthetized for short term by Ketamine. Intranasally administered 10mg /kg of 
mucoadhesive formulations were carefully administered into both nostrils using 
micro- syringe. One hour after the last treatment, the animals were subcutaneously 
injected with 10 mg/kg of NTG with volume matched saline in their right shoulders, 
exception of control group. Migraines like responses (head-scratching behavior) were 
recorded as the number of episodes of over 2 h after NTG administration. 
8.5.2. Hypnosis activity190 
Thiopental sodium induced hypnosis activity was performed by using Albino 
mice and these mice were randomly divided into two groups, each group with 6 
animals and group 1 chosen as a control and Group 2 was Zolpidem tartrate and 
Zolmitriptan dual active in situ nasal gel (DISG-05) formulation (10mg/kg). After 
induction of sleep by thiopental sodium injection, mice were placed in the inverted 
position and when sedation was over, the mice came to normal posture and time was 
noted. The interval between loss and recovery of wrighting reflex was used as index 
of hypnotic effect. The time interval between injection of thiopental sodium and start 
of sleep was recorded as latency time. 
8.5.3. Nasal Ciliotoxicity Test191 
Nasal ciliotoxicity test was performed by using Wister rats and these rats were 
randomly divided into 3 groups, each group with 6 animals in group 1 chosen as a 
normal  and  other  groups  2  and  3  used  with  different  concentration  of  Zolpidem  
tartrate and Zolmitriptan dual active in situ nasal gel (DISG-05) formulation, 
intranasally dosed with saline and 1% sodium deoxycholate solution treated as 
(normal), 5 mg /kg and 10 mg /kg of Zolpidem tartrate and Zolmitriptan dual active in 
situ nasal  gel  (DISG-05)  formulation  of  drug  treated  as  groups  2  &  3.  50  µl  of  the  
dosing solution was administered to the right lateral nostril once daily for 7 
consecutive days and 24 h after the last dosing, the rats were sacri¿ced with the nasal 
septum mucosa separated. Additional tissue samples were ¿xed with 10 % formalin, 
dehydrated in a graded series of ethanol (50, 70, 80, 90, 95 and 100%), vitri¿cated by 
dimethylbenzene and then embedded in paraf¿n. 5 µm thick tissue sections were 
prepared, stained with hematoxylin-eosin and examined using a light microscope. 
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8.6. Stability studies 
The  formulation  gels  at  body  temperature  of  37°C,  hence  the  stability  is  
studied at intermediate conditions (30°±2°C and 60±5%RH) as recommended by 
ICH. The optimized formulation (DISG-05) was subjected to stability studies as per 
ICH guidelines-Q1A (R2) by loading in cabinet type stability chamber at the 
temperature at 30°±2°C and 60 ±5% RH for a period of 6 months. Samples were 
withdrawn at predetermined time intervals 1, 2, 3 and 6 months and evaluated for gel 
strength, drug content, pH and in vitro release.  
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9. RESULTS AND ANALYSIS 
9.1. Development of analytical method for quantitative estimation of drugs 
9.1.1. Solubility study 
 The  solubility  of  Zolpidem  tartrate  in  buffers  of  various  physiological  range  
was tested and it was found to be in the range of 0.159 to 0.265mg/ml and for 
Zolmitriptan was 3.09 to 12.2.mg/ml in pH 6.4 phosphate buffer. As evident from the 
solubility profile study, Zolpidem tartrate and Zolmitriptan were soluble in pH 1.2, 
pH 6.8 and pH 7.4. 
9.1.2. Determination of absorbance maxima 
 The absorption maxima of the drugs Zolpidem tartrate and Zolmitriptan were 
found to be 283 nm and 294 nm respectively in phosphate buffer pH 6.4. The 
absorbance of the solution was linear within the concentration range of the drugs in 
the range of 4 to 32 µg/ml. The analytical method is specific for the two drugs and no 
drug-drug or drug-placebo interference was observed. The percentage relative 
standard deviation was found to be within limits.  
9.1.3. Linearity and Range 
The  values  for  absorbance  at  different  concentration  of  Zolmitriptan   are  shown  in  
Table 11 and Figure11 .The linear regression equation for the resultant calibration 
curve was y=0.020x+0.003. The calibration curve for the samples analysed  were in 
the concentration range of  4 to 32 µg/ml and was found to be linear  with a linear 
regression coefficient value of 0.999. 
The values for absorbance at different concentration of Zolpidem tartrate  are shown 
in Table 11 and Figure11 .The linear regression equation for the resultant calibration 
curve was y=0.026x+0.014. The calibration curve for the samples analysed  were in 
the concentration range of  4 to 32 µg/ml and was found to be linear  with a linear 
regression coefficient value of 0.997. The results are provided in table 15-16 and 
figures 10-11.  
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9.1.4. Precision 
The intra assay precision data determined are presented in table 12-13. Each 
concentration was determined in triplicate and five different concentration levels were 
studied. The % RSD for the values were found to be less than 2 and hence the method 
was found to be precise. 
9.1.5. Solution stability of Zolpidem tartrate and Zolmitriptan in pH 6.4 
phosphate buffer 
The nasal pH plays a vital role in the delivery of the drugs to the system. Low 
enzymatic activity in the nasal secretions is helpful in targeting the drug delivery 
through nasal route. The stability of the drugs were studied and the results are 
presented in Table 11. Two different concentrations namely 8 µg/ml and 20 µg/ml 
were  studied  for  both  Zolpidem tartrate  and  Zolmitriptan.  The  study  data  shows the  
drugs are stable up to 24 h in the nasal pH and hence suitable for nasal administration. 
The results are provided in table 14   
Table 11. Specificity test for analytical method development 
Test solution 
Absorbance 
Zolpidem tartrate (294 nm) Zolmitriptan (283 nm) 
Placebo 0.002 0.003 
Standard 0.819 0.652 
Standard+ Placebo 0.820 0.654 
    
Table 12. Intra assay precision data of Zolpidem tartrate 
S.No. 
Concentration 
range (µg/ml) 
Average Concentration 
recoverd (µg/ml) S.D. % RSD 
1 4 3.91 0.006 0.148 
2 8 7.84 0.015 0.195 
3 12 11.78 0.139 1.177 
4 20 19.78 0.030 0.152 
5 32 31.68 0.032 0.101 
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Table 13. Intra assay precision data of Zolmitriptan 
S.No. 
Concentration 
range (µg/ml) 
Average Concentration 
recoverd (µg/ml) S.D. % RSD 
1 4 3.94 0.015 0.388 
2 8 7.90 0.021 0.263 
3 12 11.91 0.055 0.463 
4 20 19.83 0.067 0.336 
5 32 31.44 0.352 1.121 
 
Table 14. Solution stability of Zolpidem tartrate and Zolmitriptan 
Time (h) 
Absorbance 
8 µg/ml 20 µg/ml 
Z ZT Z ZT 
Initial 0.173 0.225 0.409 0.539 
1 0.172 0.224 0.408 0.537 
2 0.169 0.226 0.410 0.536 
4 0.170 0.223 0.407 0.535 
8 0.168 0.221 0.406 0.538 
12 0.170 0.221 0.407 0.534 
24 0.168 0.220 0.405 0.534 
Average 0.170 0.223 0.407 0.536 
S.D 0.001 0.002 0.002 0.001 
% RSD 0.817 0.927 0.386 0.278 
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Table 15.  Calibration curve of Zolpidem tartrate 
Concentration 
(µg/ml) 
Absorbance of Zolpidem tartrate (294 nm) 
Average 
Trial 1 Trial 2 Trial 3 
4 0.111 0.107 0.115 0.111 
8 0.224 0.222 0.230 0.225 
12 0.348 0.351 0.354 0.351 
16 0.432 0.444 0.441 0.439 
20 0.536 0.541 0.539 0.539 
32 0.830 0.840 0.835 0.835 
 
 
Figure 10. Standard graph of Zolpidem tartrate 
Table 16. Calibration curve of  Zolmitriptan 
Concentration 
(µg/ml) 
Absorbance of Zolmitriptan (283 nm) 
Average 
Trial 1 Trial 2 Trial 3 
4 0.083 0.085 0.084 0.084 
8 0.169 0.175 0.172 0.172 
12 0.242 0.247 0.241 0.243 
16 0.328 0.339 0.335 0.334 
20 0.406 0.411 0.415 0.411 
32 0.650 0.648 0.654 0.651 
y = 0.0261x + 0.0144
R² = 0.9977
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Figure 11. Standard graph of Zolmitriptan 
 
9.2. Preformulation Studies 
9.2.1. Characterization of Zolpidem tartrate and Zolmitriptan 
The physical appearance of Zolpidem tartrate and Zolmitriptan were found to 
be  white  crystalline  and  off  white  powder  respectively.  The  solubility  results  of  
Zolpidem tartrate and Zolmitriptan in different buffer solutions were given below: 
The preformulation results obtained for the drugs Zolpidem tartrate and 
Zolmitriptan were found to be within the limits and desirable pharmaceutical 
standards for the formulation of Zolpidem tartrate and Zolmitriptan mucoadhesive 
nasal in situ gel. 
9.2.2. Drug - Excipient accelerated compatibility study 
Upon analysis of the drug excipient mixture for their physical characteristics 
no colour change was observed. Based on the chemical evaluation it was found that 
there was no significant change observed indicating that the drug is compatible with 
the chosen excipients. The results of this study were given in table 17-20. 
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Table 17. Physical characteristics of Zolpidem tartrate and Zolmitriptan 
S.No Physical parameters 
Results 
Zolpidem tartarate Zolmitriptan 
1 Description  White crystalline powder Off white powder 
2 Melting  range 190-1960C 136-1400C 
3 Loss on drying 0.04% 0.07% 
4 Assay 99.85% 99.72% 
 
Table 18. Physical characteristics of individual drug and excipients 
S.No Sample  
Description 
Initial  Final  
1 Zolpidem tartrate White crystalline powder No change 
2 Zolmitriptan Off white powder No change 
3 Sorbitol White crystalline powder No change 
4 Carbopol 934 Fine white powder No change 
5 Poloxomer 407 White powder No change 
6 Benzalkonium chloride Off White powder No change 
 
Table 19. Physical characteristics of drug-excipient mixture 
S.No 
 
Sample 
Description 
Initial  Final  
1 Zolpidem tartrate and Zolmitriptan White crystalline powder No change 
2 Zolpidem tartrate + Sorbitol White crystalline powder No change 
3 Zolpidem tartrate + Carbopol 934 White powder No change 
4 Zolpidem tartrate + Poloxomer 407 White powder No change 
5 Zolpidem tartrate+ Benzalkonium 
chloride 
Fine white powder No change 
6 Zolmitriptan + Sorbitol White crystalline powder No change 
7 Zolmitriptan + Carbopol 934 White powder No change 
8 Zolmitriptan + Poloxomer 407 White powder No change 
9 Zolmitriptan + Benzalkonium 
chloride 
Off White powder No change 
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Table 20. Chemical characteristics of drug-excipient mixture 
S.No Sample  
Assay (%) 
Initial  Final  
1 Zolpidem tartrate  99.85±0.15 99.82±0.31 
2 Zolpidem tartrate + Excipients 99.83±0.34 99.82±0.45 
3 Zolmitriptan 99.72±0.25 99.71±0.62 
4 Zolmitriptan+ Excipients 99.71±0.31 99.70±0.84 
 
n = 3; Mean ± S.E.M. 
 
9.2.2.1. Compatibility study using FT-IR and DSC 
In the FT-IR spectrum of Zolpidem tartrate and Zolmitriptan standard consists 
of characteristics band values. These characteristic band values were observed in all 
the recorded IR spectra. The FT-IR absorption spectra of the drug Zolpidem tartrate 
showed respective peaks at 2920.28 for –CH3, 2924 for C=C, 3053 for =C-H group, 
1635 for –C=O, 3348 for –O-H, 1396 for =C-N. The characteristic peaks were 
observed in the mixture and the peaks were not shifted indicating no interaction 
between the drugs and the polymer. 
FT-IR Spectrophotometry was studied to examine any chemical interaction 
within the drug and excipients used in the formulations. The FT-IR absorption spectra 
of the drug Zolmitriptan showed respective peaks at 3341.87 for N-H group, 1726.33 
for C=O, 460.57 for = CH2.  
DSC of Zolpidem tartrate and Zolmitriptan showed a sharp endothermic peak 
at 139.560C and194.860C respectively (melting point). The physical mixture of 
Zolpidem tartrate and Zolmitriptan and other excipients also showed the same thermal 
behavior as the individual component.DSC results also revealed that the physical 
mixture of Zolpidem tartrate and Zolmitriptan with excipients showed 
superimposition of the thermograms. There was no significant change observed in 
melting endotherm of physical mixture of Zolpidem tartrate, Zolmitriptan and 
excipients. 
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From the FT-IR and DSC studies, it was found that there were no interaction 
took place between Zolpidem tartrate, Zolmitriptan and the other ingredients used in 
the formulation of Zolpidem tartrate and Zolmitriptan nasal in situ gels. The FT-IR 
spectra were shown from figures 26-38. and DSC images were shown from figures 
12-25. 
9.2.2.2. DSC thermograms of drug and additives 
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DSC OF ZOLPIDEM TARTARATE
 
Figure 12. DSC thermogram of Zolpidem tartrate 
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DSC OF ZOLPIDEM TARTARATE-CAROPOL 934
 Figure 13. DSC thermogram of Zolpidem tartrate-carbopol mixture 
Figure 14. DSC thermogram of Zolpidem tartrate-poloxamer mixture 
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Figure 15. DSC thermogram of drug Excipient mixture 
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Figure 16. DSC thermogram of Zolmitriptan 
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DSC OF CARBOPOL
 
Figure 17. DSC thermogram of carbopol 
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DSC OF POLOXOMER 
Figure 18. DSC thermogram of poloxamer 
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DSC OF HPMC K4M
 Figure 19. DSC thermogram of Hypromellose 
Figure 20. DSC thermogram of Sorbitol 
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ZOLMITRIPTAN-HPMC K4M
 Figure 21. DSC thermogram of Zolmitriptan -Hypromellose 
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 Figure 22. DSC thermogram of Zolmitriptan -poloxamer 
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ZOLMITRIPTAN-CARBOPOL 934
 Figure 23. DSC thermogram of Zolmitriptan -carbopol 
 
Figure 24. DSC thermogram of Zolmitriptan blend 
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Figure 25. DSC thermogram of Zolmitriptan Excipient mixture 
9.2.2.3. FT-IR Spectra of drug and additives 
 
 
Figure 26. FT-IR spectrum of Carbopol-Zolpidem-Zolmitriptan 
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Figure 27. FT-IR spectrum of Poloxamer  
 
 
Figure 28. FT-IR spectrum of HPMC(K4M)-Zolpidem-Zolmitriptan 
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Figure 29. FT-IR spectrum of HPMC K4M 
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Figure 30. FT-IR spectrum of Sorbitol 
 
Figure 31. FT-IR spectrum of Poloxomer 407 
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Figure 32. FT-IR spectrum of PEG 6000-zolpidem-zolmitriptan 
 
Figure 33. FT-IR spectrum of sodium chloride 
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Figure 34. FT-IR spectrum of sodium chloride-zolpidem-zolmitriptan 
 
Figure 35. FT-IR spectrum of Poloxomer-zolpidem-zolmitriptan 
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Figure 36. FT-IR spectrum of Sorbitol-zolpidem-zolmitriptan 
 
Figure 37. FT-IR spectrum of Poloxomer188-zolpidem-zolmitriptan 
 
 
Figure 38. FT-IR spectrum of zolmitriptan 
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9.3. Formulation of nasal in situ gels 
The formulation of Zolpidem tartrate pH responsive mucoadhesive nasal in 
situ gel (PISG), Zolmitriptan thermoresponsive nasal in situ gel (TISG) and Zolpidem 
tartarate-Zolmitriptan dual acting nasal in situ gel  (DISG)  were  prepared  and  
evaluated. The formulations of the 3 types of nasal in situ gel were clear in 
appearance in sol form.  
The numbers of formulations developed with each strategy were as mentioned below. 
pH responsive mucoadhesive nasal in situ gels (PISG) – 08 formulations 
Thermoresponsive mucoadhesive nasal in situ gels (TISG) – 08 formulations 
Dual acting mucoadhesive nasal in situ gels (DISG) – 20 formulations 
9.4. Evaluation of nasal in situ gels 
9.4.1. Gelation temperature 
The gelation temperature of PISG-01 to PISG-08 was studied. The first 4 
formulations (PISG-01 to PISG-04) were optimized by using 0.2, 0.4, 0.6 and 0.8. 
Further 4 formulations were optimized by using the 0.5 % w/w.  
The gelation temperature of 32- 36°C is one of the ideal requirements for nasal 
in situ gel. The gelation temperature was given weightage while choosing the various 
polymer concentrations. The impact of varying concentrations of poloxamer 407 and 
poloxamer 188 on the gelation temperature of TISG was studied. The gelation 
temperature ranged from 30.5 ±0.2°C to 38.6 ±0.2°C. The major gelation agent 
poloxamer 407 showed a decrease in gelation temperature with increase in polymer 
concentration. Poloxamer has more hydrophobic segments that correspond to gelate at 
lower temperature. The 4 different concentrations namely 14, 18, 22, 24%w/w were 
used and TISG containing 18%w/w polymer concentration was selected for further 
optimization. 
The subsequent set of formulations was assigned the codes TISG-05 to   
TISG-08. The poloxamer 407 concentration was kept constant at 18%w/w and the 
poloxamer 188 was varied from 0.25%w/w to 2.0%w/w. The addition of poloxamer 
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188 to the formulation increased the gelation temperature from 26.3°C±0.2°C to 
34.6°C±0.2°C. This depends on the ratio of hydrophilic to hydrophobic bonds in the 
polymer structure. The mucoadhesive polymer (PEG) concentration was maintained 
constant at 1%w/w. The results of the study suggest optimization of the polymer 
concentration to achieve the desired gelation temperature. 
The experimentation of DISG-01 to DISG-20 consisted of optimization of 
carbopol 934 to poloxamer ratio. The polymer concentration impacted the gelation 
temperature. The gelation temperature observed was in the range of 32.23 ±0.2°C to 
42.67±0.2°C. 
9.4.2. Viscosity 
 The viscosity increased for the formulations PISG-01 to PISG-04 as the 
polymer concentration increased. From the four formulations 0.5 % w/w of the 
carbomer was optimized and further trials were taken with the optimized 
concentration. The quantity of hypromellose was varied from 0.3% w/w to 1.5% w/w 
maintaining the carbomer concentration at 0.5 % w/w. The trials assigned PISG-05 to   
PISG-08 codes exhibited flow index in the range of 9998 to 11700 cps. 
This study was performed on all the three types of gels. The trials TISG-01 to 
TISG-04 consisted of 14-24 % w/w poloxamer 407 and increase in viscosity was 
observed with increase in polymer concentration. The second set of trials were taken 
with 18 % w/w of poloxamer 407 and varying concentrations of poloxamer 188 
ranging from 0.25 % w/w to 2.0 % w/w. The viscosities of the formulations were in 
the range of 9214 to 9956 cps. 
 The minimum and the maximum flow index observed for the formulations 
DISG-01 to DISG-20 was 8296 and 12077 cps respectively. The results show changes 
in the viscosity which appears to be dependent upon the type of polymers and their 
concentration used in the gels. 
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9.4.3. pH 
Nasal delivery systems should have optimum pH of 5.5 to 6.5. The 
formulations PISG-01 to PISG-08 vary in the concentration of the polymers. The pH 
of all the formulations were found to be in the range of 5.4 to 6.4. The varying 
concentration  of  polymers  did  not  affect  the  pH  of  the  formulations  TISG-01  to   
TISG-08. The pH of the formulations was in the range of 5.8 to 6.3. The various 
formulations of DISG-01 to DISG-20 exhibited pH in the range of 5.7 to 6.8. The pH 
of all the formulations were within the acceptable range for nasal application.  
All the formulations irrespective of the approaches used for development 
showed optimum pH range. So the results suggest that the polymers or the additives 
used in the formulations though have changed the pH of the respective formulations it 
provided the optimum pH desirable for nasal delivery. 
9.4.4. Mucoadhesive strength 
Mucoadhesion increases the nasal residence time, facilitates absorption and 
improves bioavailability of the drug. The effects of the polymer concentration on the 
mucoadhesive strength were studied. The mucoadhesive strength observed in the 
formulations coded PISG-01 to PISG-04 were in the range of 5879 to 7495 
dynes/cm2. The increase in the concentration of HPMC K4M from 0% w/w to 1.5 % 
w/w affected the adhesive behavior of the in situ gel. 
The mucoadhesive strength observed with TISGs were in the range of 4212 to 
6325 dynes/cm2. The mucoadhesive strength observed with the formulations     
DISG-01 to DISG-20 varied from 4312 to 5734 dynes/cm2 depending on the ratio of 
poloxamer 407 to carbopol 934 to sorbitol polymer concentration.  
9.4.5. Drug content 
All the formulations showed drug content >95% and therefore the different 
methods of preparation seems to retain the desired drug content in the formulations.  
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9.4.6. Gelation time 
The gelation time shows how rapidly the administered solution turns to gel in 
the nasal cavity. The gelation time of the formulations were studied. The gelation time 
decreased as the polymer concentration increased from 14% w/w to 24% w/w. This 
phenomenon was apparent in the formulations TISG-01 to TISG-04. The gelation 
time was observed to be in the range of 135-148 sec in the formulations TISG-05 to 
TISG-08 containing 18% w/w of poloxamer 407 and poloxamer 188 in the range of 
0.25 to 2 w/w %. 
The gelation time was observed to be in the range of 122-346 sec for the 
formulations coded DISG-01 to DISG-20 manufactured using thermoreversible and 
pH sensitive polymers.  
9.4.7. Gel strength 
Gel strength is the force required to give a predetermined deformation of the 
formulations. All formulations showed varying gel strength and this seems to be 
dependent upon the polymer type or its concentration.  
The gel strength was measured for the formulations containing carbomer 
coded as PISG-01 to PISG-04 and was found to increase with the polymer 
concentration. The gel strength of formulations PISG-05 to PISG-08 manufactured 
with carbopol 934 and HPMC were in the range of 40 to 52 sec. HPMC K4M caused 
change in the gel strength of the formulations. The results of PISG-01 to PISG-08 are 
provided in table 21-22 and figures 39-44. 
The gel strength was measured for the formulations TISG-01 to TISG-04 and 
found to increase with the polymer concentration. The poloxamer 188 concentration 
affects the gel strength of formulations TISG-05 to TISG-08. This was evident from 
the fact that the observed gel strength being in the range of 42 to 48 sec. The results of 
TISG-01 to TISG-08 are provided in table 25-26 and figures 47-54. 
The gel strength was measured for the formulations coded as DISG-01 to 
DISG-20 and was found to increase with the polymer concentration. The gel strength 
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of formulations evaluated was in the range of 26 to 46 sec. The results of DISG-01 to 
DISG-20 are provided in table 29-32 and figures 57-64. 
Table 21. Evaluation of Zolpidem tartrate pH responsive Mucoadhesive In 
situ Nasal gel (PISG) 
Formulation Code Flow Index (cps) Drug release pH 
PISG-01 6530±32 332±18 6.3±0.2 
PISG-02 7865±22 354±4 6.1±0.2 
PISG-03 11235±29 421±7 5.8±0.2 
PISG-04 13564±38 433±9 6.4±0.2 
PISG-05 10523±46 434±3 6.1±0.2 
PISG-06 9998±17 440±12 5.9±0.2 
PISG-07 11568±12 448±9 6.1±0.2 
PISG-08 11700±23 441±6 6±0.2 
 
Table 22. Evaluation of Zolpidem tartrate pH responsive Mucoadhesive In situ 
Nasal gel (PISG) 
Formulation 
Code 
Mucoadhesive 
strength 
(Dynes/cm2) 
Drug content(%) Gel strength (sec) 
PISG-01 5879±32 98.1±1.1 28±5 
PISG-02 6132±23 99.5±1.6 32±7 
PISG-03 7156±17 96.5±2.0 39±4 
PISG-04 7495±41 98.3±0.9 56±6 
PISG-05 6384±7 97.2±1.1 40±4 
PISG-06 6548±23 98.6±0.8 46±6 
PISG-07 7056±12 96.9±0.7 48±4 
PISG-08 7345±6 98.2±1.5 52±2 
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Figure 39. Flow Index of formulations (PISG-01- PISG-08) 
 
 
Figure 40. Drug release of formulations (PISG-01 - PISG-08) 
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Figure 41. pH of formulations (PISG-01 – PISG-08) 
 
 
Figure 42.  Mucoadhesive of formulations (PISG-01 – PISG-08) 
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Figure 43. Drug content of formulations (PISG-01 – PISG-08) 
 
 
Figure 44. Gel strength of formulations (PISG-01 – PISG-08) 
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PISG-04, 0.5 % w/w concentration was taken for further optimization. 4 trials PISG-
05 to PISG-08 were taken with Hypromellose in the concentration range of 0.3% w/w 
to 1.5 % w/w. The times taken for 80% w/w drug release were in the range of 434 – 
448 min. The results are provided in table 23-24 and figures 45-46.  
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Table 23. Release Profiles of Zolpidem tartrate pH responsive Mucoadhesive In 
situ Nasal gel (PISG) 
Time (min) PISG-01 PISG-02 PISG-03 PISG-04 
0 0 0 0 0 
60 16.2 13.1 11.5 9.5 
120 23.6 21.9 20.7 17.9 
180 44.3 42.4 41.0 39.6 
240 57.3 55.7 51.8 51.0 
300 66.3 62.1 59.2 56.4 
360 89.9 86.1 73.1 66.3 
420 96.7 92.5 86.3 80.2 
480 103.3 98.9 90.5 85.0 
 
 
 
Figure 45. Percentage Cumulative Drug Release (PISG-01 – PISG-04) 
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Table 24. Release Profiles of Zolpidem tartrate pH responsive Mucoadhesive In 
situ Nasal gel (PISG) 
Time (min) PISG-05 PISG-06 PISG-07 PISG-08 
0 0 0 0 0 
60 16.2 13.1 11.5 9.5 
120 23.6 21.9 20.7 17.9 
180 44.3 42.4 41.0 39.6 
240 57.3 55.7 51.8 51.0 
300 66.3 62.1 59.2 56.4 
360 89.9 86.1 73.1 66.3 
420 96.7 92.5 86.3 80.2 
480 103.3 98.9 90.5 85.0 
 
 
 
Figure  46. Percentage Cumulative Drug Release ( PISG-05 – PISG-08) 
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Table 25. Evaluation of Zolmitriptan Thermoreversible Mucoadhesive In situ 
Nasal gel (TISG) 
Formulatio
n 
 Code 
Gelation 
Temp(°C) Flow Index (cps) 
Drug release 
(min) pH 
TISG-01 32.0 ± 0.2 7898 ± 50 384± 21 6.1± 0.2 
TISG-02 26.3 ± 0.2 8257 ± 48 420± 19 6.2± 0.2 
TISG-03 24.2 ± 0.2 9406± 39 442± 12 5.9± 0.2 
TISG-04 22.1 ± 0.2 9514± 44 484± 16 6.2± 0.2 
TISG-05 29.3 ± 0.2 9214± 46 414± 13 5.8± 0.2 
TISG-06 30.2 ± 0.2 9465± 46 431± 10 6.1± 0.2 
TISG-07 33.1 ± 0.2 9870± 35 439± 12 6.3± 0.2 
TISG-08 34.6 ± 0.2 9956± 32 444± 8 6.2± 0.2 
 
Table 26. Evaluation of Zolmitriptan Thermoreversible Mucoadhesive In situ 
Nasal gel (TISG) 
Formulation 
 Code 
Mucoadhesive 
strength 
(Dynes/cm2) 
Gelation 
time (sec) 
Drug content 
(%) 
Gel 
strength 
(sec) 
TISG-01 4212 ± 32 248±5 97.9± 1.2 12±5 
TISG-02 5842±47 146±6 98.2±2.1 32±3 
TISG-03 6214±23 121±8 96.5±2.0 140±4 
TISG-04 6521±36 115±4 98.2±1.8 150±3 
TISG-05 5732±16 148±3 98.1±1.2 42±4 
TISG-06 5892±26 142±6 98.5±1.7 45±6 
TISG-07 6134±17 139±4 99.1±1.6 43±3 
TISG-08 6325±33 135±3 99.5±1.3 48±6 
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Figure 47. Gelation temp of formulations (TISG-01 – TISG-08) 
 
Figure 48. Flow Index of formulations (TISG-01 – TISG-08) 
 
Figure 49. Drug release of formulations (TISG-01 – TISG-08) 
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Figure 50. pH of formulations (TISG-01 – TISG-08) 
 
Figure 51. Mucoadhesive strength of formulations (TISG-01 – TISG-08) 
  
Figure 52. Gelation time of formulations (TISG-01 – TISG-08) 
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Figure 53. Drug content of formulations (TISG-01 – TISG-08) 
 
 
Figure 54. Gel Strength of formulations (TISG-01 – TISG-08) 
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release for t80% on addition of poloxamer 188 in varying concentrations. The results 
are provided in table 27-28 and figures 55-56. 
 
Table 27. Release Profiles of Zolmitriptan Thermoreversible Mucoadhesive In 
situ Nasal gel (TISG) 
Time (min) TISG-01 TISG-02 TISG-03 TISG-04 
0 0 0 0 0 
60 15.2 12.3 10.8 8.9 
120 22.1 20.5 19.4 16.8 
180 41.5 39.7 38.4 37.1 
240 53.6 52.1 48.5 47.7 
300 62.1 58.1 55.4 52.8 
360 74.2 70.3 68.4 62.1 
420 84.2 80.8 75.1 72.9 
480 96.7 92.6 84.7 79.6 
 
 
Figure 55. Percentage Cumulative Drug Release (TISG01 – TISG 04) 
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Table 28. Release Profiles of Zolmitriptan Thermoreversible Mucoadhesive In 
situ Nasal gel (TISG) 
Time (min) TISG-05 TISG-06 TISG-07 TISG-08 
0 0 0 0 0 
60 14.1 11.9 10.0 7.9 
120 21.0 19.7 18.8 15.6 
180 40.3 37.3 36.9 35.2 
240 52.0 48.5 45.6 46.3 
300 59.6 54.0 51.5 51.2 
360 69.7 65.4 63.6 59.6 
420 83.5 78.6 75.1 72.1 
480 97.7 92.3 88.9 85.6 
 
 
 
Figure 56. Percentage Cumulative Drug Release (TISG-05 – TISG-08) 
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Table 29. Evaluation of Zolpidem tartrate and Zolmitriptan Dual active In situ 
Nasal gel (DISG-01-DISG-10) 
Formulation 
 Code 
Gelation 
 Temperature 
(ೊC) 
Flow 
 Index (cps) 
Time for 
Drug 
 release(min)  
pH 
DISG-01 37.57±0.2 9990±12 427±15 5.8±0.2 
DISG-02 34.63±0.2 9564±21 436±9 6.1±0.2 
DISG-03 38.23±0.2 8296±32 409±7 6.5±0.2 
DISG-04 40.23±0.2 8494±16 403±10 6.7±0.2 
DISG-05 32.23±0.2 10194±32 417±6 6.1±0.2 
DISG-06 33.02±0.2 10277±41 407±12 5.7±0.2 
DISG-07 35.62±0.2 11999±18 444±9 6.6±0.2 
DISG-08 37.55±0.2 9986±14 430±8 6.4±0.2 
DISG-09 36.28±0.2 12077±16 436±11 6.5±0.2 
DISG-10 33.82±0.2 10989±14 413±9 6.1±0.2 
 
Table 30. Evaluation of Zolpidem tartrate and Zolmitriptan Dually active In situ 
Nasal gel (DISG-01-DISG-10) 
Formulation 
Code 
Mucoadhesive 
strength 
(dynes/cm2) 
Gelation 
time (sec) 
Drug  
content 
(%) 
Gel strength 
(sec) 
DISG-01 4862±22 254±3 98.2±1.2 32±4 
DISG-02 4964±16 243±2 97.5±1.5 34±3 
DISG-03 4762±15 261±9 99.5±1.8 28±7 
DISG-04 4538±22 220±5 98.6±1.6 26±5 
DISG-05 5524±26 162±4 99.1±0.9 34±4 
DISG-06 5342±45 176±7 98.2±0.6 30±9 
DISG-07 5184±47 132±8 98.5±0.2 46±5 
DISG-08 4792±25 212±5 99.6±0.7 36±2 
DISG-09 5734±13 124±9 99±1.3 45±3 
DISG-10 4532±9 202±4 98.5±1.5 31±2 
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Table 31. Evaluation of Zolpidem tartrate and Zolmitriptan Dual acting In situ 
Nasal gel (DISG-11-DISG-20) 
Formulation 
 Code 
Gelation 
 Temperature 
(ೊC) 
Flow 
 Index (cps) 
Time for 
Drug 
 release(min)  
pH 
DISG-11 37.53±0.2 9983±37 436±5 6.3±0.2 
DISG-12 37.56±0.2 9992±9 430±11 6.4±0.2 
DISG-13 37.57±0.2 9990±19 416±14 5.9±0.2 
DISG-14 41.32±0.2 8796±30 390±6 6.5±0.2 
DISG-15 36.13±0.2 9204±45 411±3 6.3±0.2 
DISG-16 42.67±0.2 9355±28 436±8 5.9±0.2 
DISG-17 36.67±0.2 11887±23 433±7 6.6±0.2 
DISG-18 37.58±0.2 9994±15 417±12 6.4±0.2 
DISG-19 35.97±0.2 8693±26 416±9 6.3±0.2 
DISG-20 33.45±0.2 9872±41 440±6 6.8±0.2 
 
Table 32. Evaluation of Zolpidem tartrate and Zolmitriptan Dual acting In situ 
Nasal gel (DISG-01-DISG-10) 
Formulation 
Code 
Mucoadhesive 
strength 
(dynes/cm2) 
Gelation time 
(sec) 
Drug  
content 
(%) 
Gel strength 
(sec) 
DISG-11 4825±16 235±8 99.8±1.2 33±7 
DISG-12 4810±12 230±5 100.1±1.2 36±6 
DISG-13 4802±13 241±3 98.7±1.1 37±3 
DISG-14 4439±12 346±8 97.9±0.3 28±8 
DISG-15 4733±25 239±4 98.3±0.9 30±6 
DISG-16 4312±37 212±6 99.2±1.4 35±4 
DISG-17 5218±33 122±4 98.5±1.6 42±3 
DISG-18 4825±16 235±8 99.8±1.2 33±7 
DISG-19 4810±12 230±5 100.1±1.2 36±6 
DISG-20 4802±13 241±3 98.7±1.1 37±3 
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Figure 57. Gelation temperature of formulations (DISG-01 – DISG-20) 
 
Figure 58. Flow index of formulations (DISG-01 – DISG-20)
 
Figure 59. Drug release of formulations (DISG-01 – DISG-20) 
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Figure 60. pH of formulations (DISG-01 – DISG-20) 
 
Figure 61. Mucoadhesive strength of formulations (DISG-01 – DISG-20) 
 
Figure 62. Gelation time of formulations (DISG-01 – DISG-20) 
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Figure 63. Drug content of formulations (DISG-01 – DISG-20) 
 
Figure 64. Gel strength of formulations (DISG-01 – DISG-20) 
9.4.8.3. In vitro drug release profiles of formulations (DISG-01 – DISG-20)  
The time taken for 80% w/w drug release for the trials DISG-01 to DISG-20 
varied from 390-444 min based on the ratio of poloxamer 407 to carbopol 934 to 
sorbitol and polymer concentrations. DISG-14 showed the minimum time 390 min for 
80% drug release whereas DISG-07 took 444 min for 80% w/w drug release. The 
results indicate optimization of poloxamer 407, carbopol 934 and sorbitol maximize 
the time for 80% drug release. The results are provided in table 33-37 and figures 65-
74. 
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Table 33. Release Profiles of  Zolpidem tartrate and Zolmitriptan Dual active In situ Nasal gel 
(DISG) 
 
Time 
(min) DISG-01 DISG-02 DISG-03 DISG-04 
Drug Z ZT Z ZT Z ZT Z ZT 
0 0 0 0 0 0 0 0 0 
60 10.8 8.5 8.7 6.1 15.8 13.0 19.0 21.8 
120 25.2 28.2 23.1 26.0 30.2 28.3 33.4 36.5 
180 41.4 37.4 39.4 43.2 46.5 49.7 49.6 51.4 
240 52.8 54.8 50.8 48.1 57.9 62.0 61.0 58.6 
300 61.6 59.5 59.6 55.9 66.7 69.5 69.8 66.7 
360 71.4 68.2 69.3 73.4 76.4 73.1 79.6 75.9 
420 80.4 77.6 78.4 81.0 85.5 83.6 88.6 91.3 
480 90.3 92.7 88.3 85.1 95.4 97.4 98.6 97.5 
 
 
 
Figure 65. Percentage Cumulative Drug Release (Z) ( DISG01 – DISG 04) 
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Figure 66. Percentage Cumulative Drug Release (ZT) (DISG-01 – DISG-04) 
 
Table 34.  Release Profiles of Zolpidem tartrate and Zolmitriptan Dual active In situ Nasal gel 
(DISG) 
Time 
(min) DISG-05 DISG-06 DISG-07 DISG-08 
Drug Z ZT Z ZT Z ZT Z ZT 
0 0 0 0 0 0 0 0 0 
60 12.7 15.6 15.3 17.4 7.7 9.5 9.7 11.6 
120 27.1 30.2 29.7 31.6 22.1 25.0 24.2 22.8 
180 43.3 46.3 46.0 41.9 38.4 35.0 40.4 37.9 
240 54.7 58.9 57.3 59.7 49.7 47.4 51.8 48.6 
300 63.5 60.7 66.2 67.9 58.6 54.4 60.6 64.6 
360 73.3 70.3 75.9 74.4 68.3 71.2 70.3 74.8 
420 82.3 84.8 85.0 82.4 77.3 81.0 79.4 82.5 
480 92.3 90.2 94.9 93.1 87.3 85.7 89.3 87.1 
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Figure 67. Percentage Cumulative Drug Release (Z) (DISG-05 – DISG-08) 
 
 
Figure 68. Percentage Cumulative Drug Release (ZT) (DISG-05 – DISG-08) 
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Table 35.  Release Profiles of  Zolpidem tartrate and Zolmitriptan Dual active In situ Nasal 
gel (DISG) 
Time 
(min) DISG-09 DISG-10 DISG-11 DISG-12 
Drug Z ZT Z ZT Z ZT Z ZT 
0 0 0 0 0 0 0 0 0 
60 9.4 11.4 14.5 18.3 9.3 6.8 10.0 8.1 
120 23.9 25.3 28.9 31.4 23.8 20.7 24.5 22.2 
180 40.1 37.9 45.2 47.1 40.0 38.4 40.7 44.0 
240 51.5 48.5 56.5 59.0 51.4 53.4 52.1 55.9 
300 60.3 62.0 65.4 62.6 60.2 63.6 60.9 63.8 
360 70.0 74.7 75.1 71.9 69.9 73.9 70.6 66.9 
420 79.1 74.6 84.1 82.7 79.0 76.8 79.7 77.2 
480 89.0 87.3 94.1 91.7 88.9 87.0 89.6 88.1 
 
 
 
 
Figure 69. Percentage Cumulative Drug Release (Z) (DISG09 – DISG 12) 
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Figure 70. Percentage Cumulative Drug Release (ZT) (DISG09 – DISG 12) 
 
Table 36. Release Profiles of  Zolpidem tartrate and Zolmitriptan Dual active 
In situ Nasal gel (DISG) 
Time 
(min) DISG-13 DISG-14 DISG-15 DISG-16 
Drug Z ZT Z ZT Z ZT Z ZT 
0 0 0 0 0 0 0 0 0 
60 13.5 11.9 19.6 21.0 13.9 15.5 7.8 10.0 
120 27.9 25.2 34.0 36.5 28.3 29.6 22.2 19.7 
180 44.2 41.0 50.2 54.1 44.6 42.4 38.5 36.6 
240 55.5 51.5 61.6 59.7 55.9 53.1 49.8 53.9 
300 64.4 66.0 70.4 67.6 64.8 68.1 58.7 62.4 
360 74.1 75.9 80.2 76.8 74.5 70.0 68.4 64.3 
420 83.1 85.8 89.2 93.3 83.5 87.3 77.4 73.6 
480 93.1 91.1 99.2 97.8 93.5 92.6 87.4 85.1 
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Figure 71. Percentage Cumulative Drug Release (Z) (DISG13 – DISG 16) 
 
 
 
Figure 72. Percentage Cumulative Drug Release (ZT) (DISG13 – DISG 16) 
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Table 37. Release Profiles of  Zolpidem tartrate and Zolmitriptan Dual active 
In situ Nasal gel (DISG) 
Time 
(min) DISG-17 DISG-18 DISG-19 DISG-20 
Drug Z ZT Z ZT Z ZT Z ZT 
0 0 0 0 0 0 0 0 0 
60 8.9 10.4 12.2 14.0 12.8 14.5 9.4 10.6 
120 23.3 26.0 26.6 23.7 27.2 26.0 23.9 22.4 
180 39.6 43.4 42.8 45.4 43.4 45.6 40.1 42.2 
240 51.0 49.8 54.2 51.8 54.8 52.7 51.5 48.9 
300 59.8 57.2 63.0 66.8 63.6 66.8 60.3 63.5 
360 69.5 66.2 72.8 69.1 73.4 70.1 70.0 66.6 
420 78.6 74.4 81.8 86.3 82.4 86.5 79.1 83.1 
480 88.5 87.2 91.8 89.5 92.4 90.0 89.0 87.0 
 
 
 
Figure 73. Percentage Cumulative Drug Release (Z) (DISG17 – DISG 20) 
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Figure 74. Percentage Cumulative Drug Release (ZT) (DISG17 – DISG 20) 
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9.4.9. Scanning Electron Microscopy 
The surface morphology of the prepared formulations TISG, PISG and DISG 
were of smooth surface texture. The particles were found to be in nanometer size 
range.  
  
Figure 75(a). SEM of TISG Figure 75(b). SEM of PISG 
  
Figure 75(c). SEM of DISG 05 – Different magnifications 
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9.4.10. Release kinetics 
The release rate kinetic data for all the equations were shown in graphs. The 
value fitted to zero order plot and its regression value was 0.9886, as its value is close 
to 1, it was confirmed that it followed zero order release. The mechanism of drug 
release was further confirmed by Korsemeyer-Peppas plot. According to this 0.5 is 
Fickian  diffusion,  0.5  <  n  <  1  is  anamalous  transport  or  Non-Fickian  transport,  1  is  
Case  II  transport,  n  >  1  is  Super  case  II  transport.  The  n  value  of  the  formulation  
DISG 05 was 0.6264 and hence it suggests Non-Fickian transport. The results are 
provided in figures 76-79. 
 
Figure 76. Zero Order Plot (DISG05) 
 
Figure 77. First Order Plot (DISG05) 
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Figure 78. Higuchi Plot (DISG05) 
 
 
Figure 79. Korsmeyer-Peppas Plot (DISG-05) 
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9.5. Optimization – Model validation using Response Surface Methodology  
All the 20 experiments were carried out as mentioned in the design layout. 
(Table 38.) Quadratic design model has been used to study the impact of main effects, 
interaction effects and squared effects (if any) of the variables on responses. 
Design analysis revealed a linear model for responses gelation temperature, 
flow index, drug release, mucoadhesive strength, gelation time and gel strength and a 
mean model for responses pH and drug content. The results are provided in table 38-
39 and figures 80. 
 
Table 38. Design Layout using Response surface methodology 
Std Run 
Poloxamer 
407 
Carbopol 
934 
Sorbitol 
Gelation 
Temp 
Flow 
index 
Drug 
release 
pH 
Muco 
adhesive 
strength 
Gelation 
time 
Drug 
content 
Gel 
Strength 
A:A B:B C:C R1 R2 R3 R4 R5 R6 R7 R8 
1 12 16.0 0.3 0.5 40.23 8494 403 6.7 4538 220 98.6 26 
2 18 18.0 0.3 0.5 35.62 11999 444 6.6 5184 132 98.5 46 
3 13 16.0 1.0 0.5 35.97 8693 416 6.3 4639 240 99.3 30 
4 16 18.0 1.0 0.5 33.02 10277 407 5.7 5342 176 98.2 30 
5 6 16.0 0.3 1.5 36.13 9204 411 6.3 4733 239 98.3 30 
6 1 18.0 0.3 1.5 36.67 11887 433 6.6 5218 122 98.5 42 
7 15 16.0 1.0 1.5 38.23 8296 409 6.5 4762 261 99.5 28 
8 8 18.0 1.0 1.5 32.23 10194 417 6.1 5524 162 99.1 34 
9 4 15.3 0.6 1.0 41.32 8796 390 6.5 4439 346 97.9 28 
10 2 18.7 0.6 1.0 36.28 12077 436 6.5 5734 124 99 45 
11 20 17.0 0.0 1.0 42.67 9355 436 5.9 4312 212 99.2 35 
12 5 17.0 1.3 1.0 33.45 9872 440 6.8 4985 228 98.9 37 
13 10 17.0 0.6 0.2 33.82 10989 413 6.1 4532 202 98.5 31 
14 3 17.0 0.6 1.8 34.63 9564 436 6.1 4964 243 97.5 34 
15 17 17.0 0.6 1.0 37.56 9992 430 6.4 4810 230 100.1 36 
16 7 17.0 0.6 1.0 37.57 9990 427 5.8 4826 254 98.2 32 
17 14 17.0 0.6 1.0 37.53 9983 436 6.3 4825 235 99.8 33 
18 9 17.0 0.6 1.0 37.58 9994 417 6.4 4823 220 99.4 36 
19 11 17.0 0.6 1.0 37.57 9990 416 5.9 4802 241 98.7 37 
20 19 17.0 0.6 1.0 37.55 9986 430 6 4792 212 99.6 36 
Targets 32-36 
8500-
10000 
400-
480 
5-
6 
4000-
5000 
average 
averag
e 
average 
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Table 39. Model equations derived using Response surface methodology 
Response 
p Value # 
Model Equation 
Model A B C 
Gelation 
Temperature 0.025 0.0069 0.0026 0.974 R1 =+36.78-1.57 A-1.81 B-0.016 C 
Flow index <0.001 <0.001 0.1161 0.2618 R2 = +9981.60+1112.11A-238.31B-166.84C 
Drug release 0.0341 0.0067 0.4419 0.3999 R3=+422.35+10.20A-2.58 B+2.83 C 
pH 0.9291 0.5286 0.9454 0.8741 p  Value was more than 0.05, model not significant, Equation was generated 
Mucoadhesive 
strength <0.0001 <0.0001 0.0136 0.0599 
R5 =  +4889.20+ 349.56A+ 126.37B + 
92.30 C 
Gelation time <0.0001 <0.0001 0.1200 0.3700 R6 =+214.95-54.28 A+11.2B+6.22C 
Drug content 0.9061 0.8671 0.5308 0.7433 p  Value was more than 0.05, model not significant, Equation was generated 
Gel Strength 0.0008 0.0001 0.1754 0.5994 R8= +34.30 +4.88 * A -1.36  * B +0.52  * C 
# - A–Poloxamer concentration, B-Carbopol concentration, C-Sorbitol 
concentration 
9.5.1. Model Analysis  
In table 39, p values were found to be more than 0.05 in  coloured  cells, hence 
these factors do not have any significant impact on the studied response at 95% 
confidence interval. p values were found to be less than  0.05 in the uncoloured cells, 
hence these factors have a significant impact on the studied response at 95% 
confidence interval, hence considered for optimization. Positive (+) sign indicates 
proportional and negative sign (-) indicates inversely proportional relationship of  the 
factor on the studied response. 
For illustration of model equation deriveed for response 1 - gelation 
temperature, Poloxamer concentration (A) has coefficient 1.57 with negative sign (-) 
indicates, an increase in A results in decrease in response 1.  Carbopol concentration 
(B)  has  coefficient  1.81  with  negative  sign  (-)  indicates,  an  increase  in  B  results  in  
decrease in response 1. Sorbitol concentration(C) has coefficient 0.016 with negative 
sign (-) indicates, an increase in C results in decrease in response 1. 
Coefficient of B> Coefficient of A> Coefficient of C indicate B has more 
negative impact than A and C on the response 1 
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Figure 80. 3-Dimensional response surface analysis for the interaction effect of factor A 
and factor B 
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9.6. Pharmacological and Nasal ciliotoxicity studies 
9.6.1. Antimigraine activity 
Table 40. Antimigraine activity study in wister rats 
Number of head-scratching behaviour 
Groups Doses (mg/kg) 0 – 30 min 
30 – 60 
min 
60 – 90 
min 
90 – 120 
min 
Normal - 1.66 ± 0.51 1.5 ± 0.54 1.33 ± 0.51 1.16 ± 0.41 
Control(NTG) - 22.83 ± 2.41 21.5±1.51 20.16±1.47 19.66±1.75 
Formulation 10mg/kg 8.5 ± 1.64 8.16 ±0.75 7.83 ±0.75 7.16 ± 0.98 
n = 6 for all groups; data are expressed as mean ± SD 
 
The behavior of scratching head with forward limb of rats is similar to that of 
the behavior of human beings with migraine. The symptom of migraine headache and 
its frequency represent the severity of ache to some extent which is a reasonable index 
for the evaluation of antimigraine activity of a drug. 
After intranasal administration of the optimized Zolpidem tatrate and Zolmitriptan 
intranasal in situ gel formulation, the rats were monitored for its head scratching 
behavior for every 30 min.  
During the observation time 30-120 min after in situ gel  administration,  there  were  
only a few head scratching actions in normal rats. 
 In control group head scratching behavior was found to be increased noticeably.  
Compared with the control group, Zolpidem tatrate and Zolmitriptan intra nasal in situ 
gel formulation (10mg/kg) could significantly reduce the frequency of head scratching 
behavior in all the observation times (30-120 min). The above data indicates the 
developed Zolpidem tatrate and Zolmitriptan intranasal in situ gel (10mg/kg) has a 
significant effect in relieving the symptoms of migraine. The results are provided in 
table 40. 
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9.6.2. Hypnosis activity 
Table 41. Thiopental sodium induced sleeping time-Hypnosis study 
Responses (min) 
Groups Doses (mg/kg) 
Onset of 
sleeping 
Sleeping 
duration 
Control  1.3 mg/kg 9.83 ± 1.84 56.66 ± 3.67 
Formulation 10mg/kg 7.66 ± 1.21 128.66 ± 5.68 
         n = 6 for all groups; data are expressed as mean ± SD 
The optimized Zolpidem tatrate and Zolmitriptan intranasal in situ gel 
(10mg/kg) significantly reduced the time for the onset of sleeping and increased the 
duration of sleeping as compared to the control. In this study, the intranasal 
administration of Zolpidem tatrate and Zolmitriptan in situ gel (10mg/kg) 
significantly modified the latency to induce sleep as well as increased duration of 
hypnosis induced by Thiopental sodium. The maximum duration of sleep time was 
observed 128.66 ± 5.68 min at a dose of 10 mg/kg body weight. The results are 
provided in table 41 and figures 81. 
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Figure 81. Intranasal administration of Zolpidem tartrate and Zolmitriptan 
 in situ gel  
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9.6.3. Nasal ciliotoxicity study 
After repeated administration of mucoadhesive formulation for 7 consecutive 
days, rat nasal epithelium was found to be complete with densely arranged cilia as 
shown in histopathological studies.Nasal ciliotoxicity study in Wister rats 
demonstrated that intranasally administered Zolpidem tartrate-Zolmitriptan intranasal 
in situ gel could achieve mild change in the structure of the epithelium and the shape 
of the glandular tissue, basal cell, capillary and nerve bundle in the lamina propria 
were regular and clearly visible. 
No significant changes in the mucosal thickness were seen in nasal mucosal 
section treated with formulations as shown in histopathological studies. These 
findings suggest that the intranasal formulation possess no serious ciliotoxicity and 
irritability to the nasal mucosa. The results are provided in figures 82-84. 
 Histopathology of nasal mucosa 
 
Figure 82. Normal rat (vehicle treated): Hematoxylin & eosin (H&E stained). 
Ciliated respiratory epithelium lining the septum in the anterior nasal cavity of a 
Sprague-Dawley rat. The respiratory epithelium consists of intact tall columnar 
goblet cells and basal cells. Submucosal glands are adjacent to the underlying 
cartilage.  
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Figure 83. Zolpidem tartrate-Zolmitriptan dual acting in situ gel (10mg/kg) 
treated rat: Minimal structural change is present in tall columnar goblet cells. 
Submucosal glands are adjacent to the underlying cartilage and the basal cells 
are present intact. 
 
Figure 84. Zolpidem tartrate-Zolmitriptan dual acting in situ gel (5mg/kg) 
treated rat: Mild punctate is present in tall columnar goblet cells. sub mucosal 
glands  and in basal cells of the luminal epithelium are present intact. 
9.7. Stability studies 
None of the in situ gel formulations showed any abnormalities during the 
period of assessment. However the formulations were subjected to gel strength, pH, 
drug content and in vitro release which are considered to be critical parameters in 
deciding the stability of in situ gel. The successful and optimized formulation    
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DISG-05 stored at 30°±2°C and 60 ±5% RH for a period of 6 months as per the ICH 
guidelines specified. The formulation DISG-05 retained its physicochemical 
properties including in vitro release. Almost the formulation possessed the property 
with mild variation which is considered negligible. The polymers carbopol and 
poloxamer were potential candidates for the formulation as it retains the stability 
constantly. The results are provided in table 42.   
The graphical representation of the parameters of DISG-05 was given in 
figures 85-88 
Table 42. Stability Studies of Zolpidem tartarate-Zolmitriptan dual acting nasal 
in situ gel (DISG-05) 
Stability 
condition Parameters 
Months 
0 1 2 3 6 
30
°±
2°
C
  /
 6
0 
±5
%
R
H
 
Gel strength 34.3±4 34.3±2 34.2±4 33.9±6 33.8±4 
Drug content 99.1±0.9 99.1±0.4 99.0±0.2 98.8±0.1 98.5±0.6 
pH 6.1±0.2 6.1±0.2 6.1±0.1 6.0±0.2 6.0±0.1 
In vitro release 92.3±0.2 92.2±0.1 92.1±0.3 91.9±0.4 91.6±0.3 
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Figure 85. Stability studies – Gel Strength 
 
 
Figure 86. Stability studies – Drug content 
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Figure 87. Stability studies – pH 
 
Figure 88. Stability studies – In vitro release 
From the overall results of stability studies, it was concluded that the 
formulation DISG-05 was found to be stable during the stability period. 
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10. DISCUSSION 
 The present study investigated development of nasal in situ gel for 
simultaneous  delivery  of  Zolpidem  tartrate  and  Zolmitriptan  for  the  treatment  of  
insomnia associated migraine as an alternative to currently administered individual 
dosage forms. The results of the study show that the developed nasal in situ gel is 
promising for effective control of insomnia associated migraine. The limitation of 
the study is that the data cannot be extrapolated for clinical use as further detailed 
toxicity, pharmacokinetic studies and other necessary clicnical data are warranted. 
 Analytical design is a prerequisite for accuracy of the results in the study. The 
analytical method developed should ensure reproducible results and good recovery. 
Absorbance for Zolpidem tartrate and Zolmitriptan both in combination was 
determined  and  also  interference  of  the  absorbance  of  the  drugs  was  also  
investigated. Zolmitriptan showed absorbance at 294 nm and Zolpidem tartrate at 
283 nm in pH 6.4. There was no interference of the absorbance by the additives 
used in the formulations. 
 Before designing any drug delivery system it is necessary to check possible 
interaction between the drug and the excipients used in the development of the 
formulations. FT-IR spectra of both drugs showed their characteristic peaks and 
these peaks were not affected by the presence of additives used in the formulations. 
The results revealed that there is no interaction between the drugs and the polymers 
used in the formulations. 
 DSC thermogram showed no change in the physical characteristics of the 
drugs by the presence of polymers. The endothermic peak of the drug or of the 
polymer did not show any change and therefore the drug was found to be stable in 
the formulation in presence of the polymer. 
 The present study followed 3 directional approaches for the development of 
nasal in situ gel for the treatment of insomnia associated migraine. Currently 
migraine which is a recurring headache associated with sleep is managed by 
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administration of Zolpidem tartrate (Hypnotic agent) and Zolmitriptan 
(Antimigraine agent) as separate dosage forms. The therapeutic outcome of 
administration of these drugs as separate dosage forms may not effectively control 
insomnia associated migraine as the drugs are required to show therapeutic 
concentrations at the same time, so as to relieve the problem effectively. There is 
no clinical evidence supporting the above view but however the said hypothesis 
cannot be completely ruled out. 
 Bioavailability of drugs from the administered dosage form is a critical 
parameter  for  the  best  clinical  results.  To  improve  the  therapeutic  efficacy  of  the  
administered drugs in the treatment of insomnia associated migraine it was 
considered a unique in situ nasal gel containing both Zolpidem tartrate and 
Zolmitriptan would benefit the therapeutic outcome and therefore a better control 
on insomnia associated migraine. 
 The nasal in situ gel formulations developed in the study are pH responsive 
mucoadhesive gel, thermoreversible mucoadhesive gel and dual acting.  
 In the first approach, Zolmitriptan was developed as a thermoreversible in situ 
nasal gel using poloxamer407, poloxamer188 and PEG in varying ratios and these 
ratios were randomly selected. The formulations were coded as TISG-01 to TISG-
08 and investigated for gelation temperature, viscosity, time for 80% drug release 
(t80%), pH, mucoadhesive strength, gelation time, drug content and gel strength.  
 In the second approach Zolpidem tartrate was developed as a pH responsive 
mucoadhesive in situ nasal gel with varying ratios of carbopol 934 and HPMC 
K4M as polymers and sodium chloride (NaCl) as osmotic agent.  The ratios were 
randomly selected and investigated as described above.  
 In the third approach, Zolpidem tartrate and Zolmitriptan in combination was 
developed as dual acting thermoreversible nasal in situ gel and investigated for the 
physicochemical and release characteristics. 
 Nasal in situ gels should have optimum gelation temperature and phase 
transition should be quick. Poloxamer 407 is widely used as thermoreversible 
material, safe and has been approved by FDA in inhalation, oral solutions, 
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suspensions, ophthalmics and topical formulations. Its temperature sensitivity is 
advantageous to prepare in situ gels for various drug delivery systems such as 
ocular, nasal, vaginal, rectal, subcutaneous, topical, intra-tumoural systems and 
also for stem cell therapy or as a regenerative medicine.12 Poloxamer 188 a 
thermoreversible polymer was also used in the study in combination with 
poloxamer 407 and also with PEG in different ratios. Varying gelling temperatures 
were observed and there were differences in the gelling temperature in the 
formulations  of  TISG-01  to  TISG-08  and  these  differences  were  found  to  be  
significant with changes in poloxamer 407 or poloxamer 188 concentrations. 
 The gelation temperature of the formulations TISGs were compared with that 
of  DISGs.  The  formulations  DISGs  contain  carbopol  934  as  pH  responsive  and  
mucoadhesive agent and sorbitol as osmogen. DISG as well as TISG showed 
varying gelation temperatures as observed with TISG- however a comparatively 
higher  gelation  temperature  was  observed  with  the  formulations  DISG.  The  
increase in gelation temperature of DISGs as compared to TISGs may be due to the 
additive effect of Zolpidem tartrate and Zolmitriptan or due to the presence of 
mucoadhesive agent.  
 Viscosity plays an important role in nasal drug delivery systems. High 
viscosity prolongs the residence time on the mucosa of the nasal cavity and favour 
drug absorption. The desirable viscosity for retaining the drug on the nasal 
membrane is about 5.0Pa.s.192 Most formulations showed viscosity >8.0Pa.s 
indicating suitability of formulations for nasal drug delivery. Difference in 
viscosity was observed and was dependent on the polymer, the mucoadhesive 
agent or the osmogen used in the formulations. From overall performance of the 
formulations on viscosity it is understood that the viscosity is affected by changes 
in polymer type or osmogen or mucoadhesive agent, however the desirable 
viscosity could be obtained by optimising the concentration of the polymer, the 
mucoadhesive agent and the osmogen concentration.  
 Prolonged drug release is desirable for effective control of insomnia associated 
migraine. The effect of the polymer, the mucoadhesive agent and the osmogen 
concentration on the drug release profile was examined in all the formulations 
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developed. In the study the time taken for 80% drug release was compared 
between the formulations. It was observed almost all the formulations showed t80% 
at about 400 min and their release pattern appears slow and extended for 8h. The in 
vitro release profile shows that nasal in situ gel would provide extended release of 
Zolpidem tartrate and Zolmitriptan. 
 Nasal delivery systems should have optimum pH of 5.5 to 6.5. All the 
formulations irrespective of the approaches used for developing showed pH fitting 
in the optimum range. So the results suggested that the polymers or the additives 
used in the formulations though has changed the pH of the respective formulations 
it provided the optimum pH desirable for nasal delivery. 
 Mucoadhesion is significant for formulations designed for mucosal delivery of 
drugs. A higher mucoadhesive strength indicates that a greater proportion of 
applied gel would be retained on the mucosal surface over extended periods. 
Excessive mucoadhesion may cause deleterious effect and damage the mucous 
membrane and so affects drug delivery and therefore optimal mucoadhesive 
strength is necessary to prolong the residence time and reduce the potential of 
formulation leakage.  
 The mucoadhesion of carbopol 934 and HPMC K4M were compared. 
Carbopol 934 and HPMC K4M in combination seems to provide higher 
mucoadhesive strength when compared with either carbopol 934 or HPMC K4M 
individually. The mucoadhesive strength of the formulation PISG was found to be 
greater than that observed with TISG or ISG. These findings indicate carbopol 934 
can help increase the mucoadhesive strength of the nasal gel.  
 All the formulations showed drug content > 95% and therefore the different 
methods  of  preparation  seems  to  retain  the  desired  drug  content  in  the  
formulations. 
 Gel strength is the force required to give a predetermined deformation of the 
formulations.  All  formulations  showed varying  gel  strength  and  this  seems to  be  
dependent upon the polymer type or its concentration as poloxamer407 
concentration increases the gel strength as evident in the formulation TISG-03 and 
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the least gelling strength was found when poloxamer 407 decreases as shown in 
TISG-01. The increase or decrease in gel strength which involved orientation, 
arrangement of poloxamer micelles. Poloxamer 407 in higher concentration 
entangles more efficiently to form rigid gel structures because of greater number of 
micelles. This seems to be offset by addition of poloxamer 188 possibly due to 
dehydration of hydrophobic polypropylene oxide block of co-micelles.  
In model analysis p values were found to be more than 0.05 in grey colour 
cells, hence these factors does not have any significant impact on the studied 
response at 95% confidence interval. p values were found to be less than 0.05 in 
the uncoloured cells, hence these factors have a significant impact on the studied 
response at 95% confidence interval, hence considered for optimization. Positive 
(+) sign indicates proportional and negative sign (-) indicates inversely 
proportional relationship of  the factor on the studied response. 
For instance in case of gelation temperature, in Response 1, A has coefficient 1.57 
with negative sign (-) indicates increase in A results in decrease in response 1.  B 
has coefficient 1.81 with negative sign (-) indicates increase in B results in 
decrease in response 1. C has coefficient 0.016 with negative sign (-) indicates 
increase in C results in decrease in response 1.  
Coefficient  of  B  >  Coefficient  of  A  >  Coefficient  of  C  indicates  B  has  more  
negative impact than A and C on the Gelation temperature (response 1). 
 Stability study of the optimized formulations showed that the formulation 
withstands the adverse conditions of temperature, humidity and retained its 
physicochemical properties and drug content. 
 The optimized formulation was found to be free of nasal ciliotoxicity and the 
hypnosis and antimigraine activity were extended as compared to their standards.  
 The above findings conclude that thermoreversible nasal in situ gel seems 
beneficial for simultaneous delivery of Zolpidem tartrate and Zolmitriptan in the 
treatment of insomnia associated migraine. 
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SUMMARY AND CONCLUSION 
 
 The present study examined the feasibility of simultaneous delivery of 
Zolpidem tartrate and Zolmitriptan in the treatment of insomnia associated 
migraine through in situ nasal delivery system. 
 3 approaches were followed for the development of nasal in situ gels. They 
were thermoresponsive, pH responsive and dual acting (both thermoresponsive and 
pH responsive). 
 Preformulation study was performed through DSC and FT-IR spectral 
analysis of the drug and the polymers and it was found there was no interaction of 
the drugs in the presence of polymers.  
 Initially, in situ nasal gels were developed separately for Zolpidem tartrate 
and Zolmitriptan i.e. thermoreversible nasal in situ gel of Zolmitriptan and pH 
responsive nasal in situ gel of Zolpidem tartrate.  
 The pH responsive nasal in situ gel of Zolpidem tartrate included carbopol 
934, HPMC K4M and sodium chloride in various ratios and these formulations 
were screened for viscosity, t80% drug release, pH, mucoadhesive strength and gel 
strength.  
 The thermoreversible nasal in situ gel of Zolmitriptan included 3 polymers 
poloxamer 407, poloxamer 188 and PEG in various ratios. Gelation temperature 
was examined for Zolmitriptan gel. 
 The formulations were coded as TISG-01 to TISG-08 and PISG-01 to  
PISG-08 and the results were compared. Based on the performance of the above 
findings another formulation, thermoreversible and pH responsive nasal in situ gel 
containing both Zolpidem tartrate and Zolmitriptan was developed with different 
ratios of poloxamer 407, carbopol 934, sorbitol, screened for the physicochemical 
and drug release characteristics as described above and the formulations were 
coded as DISG-01 to DISG-20. The physicochemical characteristics and the drug 
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release profile of all the developed formulations were compared and it was found 
that all the formulations provided the results within the pharmaceutically 
acceptable limits. 
 As the aim of the study was to develop the nasal in situ gel for simultaneous 
delivery of Zolpidem tartrate and Zolmitriptan an optimized formulation DISG-05 
was selected as the best fit by applying appropriate experimental mathematical 
design and it was observed that the formulation DISG-05 was found to be the best 
fit.  
Based on the Design of Experiments, the optimized concentration of factor A, 
factor B and factor C (poloxamer concentration, carbopol concentration and 
sorbitol concentration) have been optimized at 16.0 %, 0.3 % and 1.5 % w/w. 
Desired targets for each response was fixed as constraints and the final 
composition of poloxamer concentration (factor A) at 16.15% w/w, carbopol 
concentration (factor B) at 0.32 % w/w  and sorbitol concentration (factor C) at 1.5  
% w/w was suggested by the software with the maximum desirability of 0.66. 
Same concentration with little modifications for practical feasibility was finalized 
as factor A, factor B and factor C (poloxamer concentration, carbopol 
concentration and sorbitol concentration) have been optimized at poloxamer 
concentration at 16.15% w/w, carbopol concentration at 0.32 % w/w, and sorbitol 
concentration at 1.5 % w/w. 
 An in vivo study was performed on the best fit formulation DISG-05. The 
formulation was found to be free of nasal ciliotoxicity and hypnosis and 
antimigraine activity was extended as compared to the standards. 
Stability study was conducted for a period 6 months as per ICH guidelines Q1A 
(R2)  and it can be concluded that the optimized formulation was able to maintain 
the desired critical quality attributes. Stability study ensured the safety and efficacy 
of the finalized formulation. 
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Conclusion 
 The results of the study demonstrates that a thermodynamic in situ  nasal gel 
is beneficial for simultaneous delivery of Zolpidem tartrate and Zolmitriptan in the 
treatment of insomnia associated migraine effectively and also this provides an 
alternative to conventional dosage forms which have more short coming and 
disadvantages. Optimization of poloxamer 407, carbopol 934 and sorbitol yielded 
best  results  in  the  physicochemical  and  release  characteristics  of  the  in situ nasal 
gel. 
 
Impact of the study 
 The present study findings provide scope for the development of a nasal in 
situ gelling system for improved bioavailability and efficacy of Zolpidem tartrate 
and Zolmitriptan in the treatment of insomnia associated migraine and further 
investigation of the developed formulation in clinical trial may help better 
treatment option for insomnia associated migraine. 
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